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Prefácio 
 
 Esta tese de Doutoramento é o resultado do trabalho de investigação 
realizado no Laboratório de Oncobiologia do Departamento de Genética do Instituto 
Nacional de Saúde Dr. Ricardo Jorge, em Lisboa, entre Janeiro de 2005 e Janeiro 
de 2009, sob a orientação do Doutor Peter Jordan. Este trabalho foi ainda co-
orientado pelo Professor Doutor Rui Artur Paiva Loureiro Gomes, membro da 
Faculdade de Ciências da Universidade de Lisboa onde esta tese será submetida. 
 
 O trabalho aqui apresentado teve como objectivo fundamental a análise 
molecular da regulação do splicing alternativo da pequena GTPase Rac1, cuja 
variante de splicing designada Rac1b se encontra sobre-expressa em certos 
tumores colo-rectais podendo por isso ser um bom alvo terapêutico e de 
diagnóstico. 
 
 De acordo com o disposto no Artigo 41º do Regulamento dos Estudos Pós-
Graduados da Universidade de Lisboa, Deliberação nº 1506/2006, publicada no 
Diário da República, 2ª série — Nº 209 — 30 de Outubro de 2006, a presente 
dissertação encontra-se redigida em língua inglesa, contendo um resumo alargado 
(mais de 1200 palavras) em língua portuguesa (Resumo). 
 
 Ainda de acordo com o disposto no mesmo artigo, foram utilizados nesta 
dissertação resultados de trabalhos de colaboração, estando a minha contribuição 
pessoal devidamente indicada, tendo estes permitido a elaboração de dois artigos, 
um dos quais já publicado e o outro já submetido para publicação: 
 
Gonçalves V, Matos P and Jordan P. 2008. The beta-catenin/TCF4 pathway 
modifies alternative splicing through modulation of SRp20 expression. RNA. 14: 
2538-2549 
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Gonçalves V, Matos P and Jordan P. 2009. Antagonistic SR proteins regulate 
alternative splicing of tumour-related Rac1b downstream of the PI3-kinase and Wnt 
pathways. (submetido). 
 
 Ainda de referir que no âmbito do trabalho presente nesta dissertação foi 
ainda publicado um capítulo de um livro e um artigo: 
 
Jordan P, Gonçalves V and Matos P. 2006. Alternative splicing changes regulation 
and signalling properties of the small GTPase Rac1. In: Alternative Splicing in 
Cancer, Editor: Julian P. Venables. Chapter 3. Transworld Research Network, India  
 
Gonçalves V, Theisen P, Antunes O, Medeira A, Ramos JS, Jordan P, Isidro G. 
2009. A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 
splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat Res. 662: 
33-36 
 
 Gostaria ainda de salientar que a realização deste trabalho só foi possível 
graças ao apoio financeiro da Fundação para a Ciência e a Tecnologia (FCT) e do 
Fundo Social Europeu (FSE), através do projecto POCTI/47546/02, do Programa 
de Financiamento Plurianual do CIGMH, e sob a forma de uma Bolsa de 
Doutoramento com a referência BD/18262/2004. 
 
 
 
 
Vânia Marina Cristóvão Gonçalves 
Lisboa, 19 de Junho de 2009 
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Resumo 
 
 A expressão de genes eucarióticos é um processo com várias etapas que 
incluem a transcrição do gene, o splicing e a poliadenilação do transcrito, e ainda o 
transporte do RNA mensageiro para o citoplasma (Singer e Green 1997). 
 Na etapa inicial da formação do spliceossoma são reconhecidas sequências 
consenso nos locais de splicing 5! e 3!, por componentes da maquinaria de splicing. 
Foram identificadas também sequências adicionais que promovem (splice enhancer) 
ou reprimem (splice silencer) o reconhecimento e inclusão de determinado exão, 
podendo estas localizar-se nesse mesmo exão ou nos intrões adjacentes (Cartegni et 
al. 2002). Estes elementos são específicos de cada gene e reconhecidos por 
proteínas adicionais de ligação ao pré-RNA mensageiro, como por exemplo 
membros da família de proteínas SR ou hnRNP, que promovem ou impedem as 
interacções proteína-proteína necessárias à reacção de splicing. A associação 
destas interacções numa dada célula define se, ou em que extensão, um exão é 
reconhecido e processado pela maquinaria de splicing (Black 2003). Neste sentido, 
splicing alternativo significa regulação da escolha dos locais de splicing. 
 Um gene humano alvo do splicing alternativo é o RAC1. A proteína Rac1 é 
um membro da família das pequenas GTPases Rho que estimula as vias de 
sinalização envolvidas no controlo da dinâmica dos filamentos de actina e da 
activação transcricional. Rac1 alterna entre um estado inactivo ligado a GDP e um 
activo ligado a GTP sendo esta transição controlada na célula por três classes de 
proteínas: GEFs, GAPs e GDIs. Uma variante de splicing alternativo, designada 
Rac1b foi identificada em tumores colo-rectais e da mama e contém 19 aminoácidos 
adicionais devido à inclusão do exão 3b, o qual é geralmente excluído. A presença 
destes aminoácidos adicionais altera profundamente a regulação e as propriedades 
de sinalização da GTPase. Apesar da proteína Rac1b ser expressa nas células em 
níveis reduzidos, está maioritariamente no seu estado activo e portanto ligado ao 
GTP. De facto, Rac1b é incapaz de interagir com Rho-GDIs, ficando assim 
comprometido um mecanismo importante de regulação negativa. Adicionalmente, 
diversas vias de sinalização clássicas de Rac1, tais como a formação de 
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lamellipodia ou a activação das cinases PAK ou JNK, não são estimuladas pelo 
Rac1b activo. No entanto, Rac1b estimula a activação do NF!B mediada por 
espécies reactivas de oxigénio e promove mecanismos de transformação celular 
tais como a progressão do ciclo celular, a sobrevivência celular e a transição 
epitelial-mesênquimal. Estes dados demonstram como o splicing alternativo pode 
afectar profundamente a função da proteína. Estudos recentes sugerem que as 
alterações no nível de expressão de Rac1b contribuem para a tumorigénese (Singh 
et al. 2004, Radisky et al. 2005, Matos e Jordan 2006, Esufali et al. 2007, Matos e Jordan 
2008). Por exemplo, Rac1b e B-RafV600E (uma mutação activadora do B-Raf presente 
em alguns tumores do cólon) cooperam funcionalmente para manter a sobrevivência 
de células de tumores colo-rectais (Matos et al. 2008). Assim, a expressão de Rac1b 
promove a sobrevivência de células tumorais do cólon e por isso, compreender o 
mecanismo molecular subjacente a este evento de splicing alternativo é de interesse 
terapêutico. O trabalho apresentado nesta tese descreve estudos com vista a 
elucidar os mecanismos que regulam o splicing alternativo de Rac1. 
 Dados experimentais de linhas celulares e de tecidos normais revelaram que 
o exão 3b geralmente se encontra excluído, sendo apenas incluído numa pequena 
fracção do transcrito total (Jordan et al. 1999, Radisky et al. 2005). Este exão tem 
características típicas de exões alternativos tais como o seu pequeno tamanho, de 
57 nucleótidos, e um polypyrimidine tract pouco conservado. Com estas limitações 
impostas pela sequência genómica quanto à inclusão do exão 3b de RAC1, as 
modificações no splicing alternativo observadas em tumores colo-rectais podem ser 
o resultado de mutações pontuais na sequência consenso dos elementos 
conservados de splicing. Muitas mutações patogénicas que causam doenças 
hereditárias interferem com o splicing normal do pré-RNA mensageiro (Faustino e 
Cooper 2003). As mutações genómicas subjacentes podem afectar os motivos 
conservados de sequências consenso necessárias à formação do complexo 
spliceossomal funcional, ou criar/destruir elementos enhancer ou silencer (Cartegni et 
al. 2002, Pagani et al. 2004). Assim, amplificámos a sequência genómica de RAC1 de 
três linhas celulares colo-rectais com diferentes níveis de expressão de Rac1b e 
sequenciámos a zona flanqueadora do exão 3b, abrangendo desde 286 nucleótidos 
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a montante e 224 nucleótidos a jusante do mesmo. Nenhuma das três linhas 
celulares apresentava alguma mutação neste fragmento do gene que pudesse 
explicar as diferenças observadas no splicing. 
 A ausência de mutações genómicas nas linhas celulares analisadas sugere 
que as diferenças na expressão de Rac1b são baseadas num evento de splicing 
alternativo regulado, como já descrito em numerosos exemplos de alterações no 
splicing alternativo durante o desenvolvimento embrionário, entre diferentes tecidos 
e também em determinados tipos de tumores. 
 Neste trabalho demonstramos que o splicing alternativo de Rac1 é regulado 
pelas proteínas SR ASF/SF2 e SRp20 em células colo-rectais. Para analisar os 
mecanismos que regulam o splicing alternativo de Rac1b, construímos um minigene 
RAC1 que reproduz as decisões de splicing endógenas em linhas celulares colo-
rectais. Assim, testámos vários factores de splicing candidatos quanto ao seu efeito 
no minigene e identificámos um factor que promove a expressão de Rac1b, o 
ASF/SF2, e outro que a suprime, o SRp20. Os seus papéis fisiológicos no splicing 
alternativo de Rac1 em células de tumores colo-rectais foram confirmados ao nível 
endógeno por experiências de interferência de RNA. Adicionalmente, estes factores 
ligam-se a sondas transcritas in vitro a partir do exão 3b, em experiências de 
alterações na mobilidade electroforética (EMSA). Em conjunto, os nossos dados 
levam-nos a propor que o exão 3b contém um enhancer exónico reconhecido pelo 
ASF/SF2 junto a um silencer exónico reconhecido pelo SRp20. Alguns programas 
bioinformáticos prevêem a existência de tais elementos reguladores que servem 
como locais de ligação para aqueles factores de splicing, corroborando os 
resultados obtidos. 
 No nosso sistema experimental de linhas celulares colo-rectais, observámos 
que as concentrações relativas da proteína ASF/SF2 versus SRp20 determinavam a 
proporção de splicing alternativo. Não só os níveis endógenos da proteína de ambos 
os factores se correlacionavam com a quantidade de Rac1b expresso em diferentes 
linhas celulares, como também a manipulação experimental dos níveis de 
expressão de ASF/SF2 e SRp20 através de sobre-expressão e/ou RNAi, modificou o 
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splicing alternativo do exão 3b. Vários estudos documentam que a abundância 
relativa de factores de splicing antagonistas, incluindo o ASF/SF2 e o SRp20, pode 
afectar decisões de splicing (por exemplo, Jumaa e Nielsen 1997, Mayeda et al. 1993, 
Galiana-Arnoux et al. 2003). É portanto reconhecido que os níveis de expressão dos 
factores de splicing são um mecanismo central para despoletar diferenças nos 
padrões de splicing alternativo. 
 Relativamente aos eventos a montante que regulem as concentrações 
relativas das proteínas ASF/SF2 versus SRp20, identificámos duas vias de 
sinalização que afectam a sua expressão promovendo um aumento ou uma 
diminuição correspondente em Rac1b. A via da Wnt activa o complexo transcricional 
"-catenina/TCF4, sendo o gene SFSR3, que codifica o SRp20, um alvo directo 
(Gonçalves et al. 2008). A estimulação da via aumentou os níveis de SRp20 que 
descobrimos actuar como um silencer no exão 3b, conduzindo à expressão reduzida 
de Rac1b. Por outro lado, encontrámos a via da PI3-cinase envolvida na regulação 
do factor antagonístico ASF/SF2. A inibição desta via aumentou a expressão dos 
níveis do transcrito e da proteína ASF/SF2, que age como um enhancer da inclusão 
do exão 3b, levando a uma expressão aumentada de Rac1b. Em conjunto, estes 
dados mostram que diferentes vias de sinalização influenciam simultaneamente 
factores de splicing independentes a fim de controlar o splicing alternativo de Rac1b. 
 É possível que a fosforilação das proteínas ASF/SF2 ou SRp20 esteja 
também envolvida na regulação do splicing alternativo de Rac1b. Sabe-se que as 
funções nucleares e citoplasmáticas do factor ASF/SF2 são moduladas por 
fosforilação (Xiao e Manley 1997, Sanford et al. 2005) e recentemente, a proteína AKT 
foi descrita como capaz de fosforilar in vitro o ASF/SF2 (Blaustein et al. 2005). Neste 
sentido, observámos que a sobre-expressão de PTEN promove um aumento na 
expressão de ASF/SF2 enquanto a de um mutante cinase-inactivo de AKT não, 
apesar de ambas as circunstâncias induzirem um aumento em Rac1b, o que sugere 
a existência de mecanismos de regulação por fosforilação. Adicionalmente, a 
inibição da PI3-cinase foi já implicada na regulação de outros eventos de splicing 
alternativo, como nos genes da fibronectina e do PKC "II (Blaustein et al. 2004, 
Resumo
 
  xi 
Pelisch et al. 2005, Patel et al. 2001), embora os detalhes mecanísticos estejam ainda 
por caracterizar. Serão necessárias experiências adicionais para esclarecer 
exactamente de que modo a via da PI3-cinase e AKT afectam os níveis e/ou a 
fosforilação do ASF/SF2. É possível que a via controle outros reguladores de 
proteínas SR, como a família de proteínas cinase SRPK e Clk/Sty que funcionam no 
citosol (Gui et al. 1994) podendo contrariar o efeito da AKT nas proteínas SR 
(Blaustein et al. 2005). 
 A nossa observação que a sinalização da PI3-cinase e da "-catenina inibem 
a expressão de Rac1b ajuda esclarecer as vias genéticas que levam à 
tumorigénese colo-rectal. Um grupo de tumores que apresenta mutações 
oncogénicas no gene KRAS aumenta a proliferação celular através da sinalização 
de ERK e fornece um estímulo de sobrevivência através da via PI3-cinase/Rac1 (Qiu 
et al. 1995). Este grupo é representado pela linha celular SW480, que não expressa 
Rac1b endógeno, sendo isto compatível com a presença de K-Ras mutante que 
activa fortemente a PI3-cinase, conduzindo assim à diminuição da expressão de 
ASF/SF2. Por outro lado, acumulam-se quantidades consideráveis de "-catenina no 
núcleo das células SW480, causando o aumento da expressão de SRp20 que 
contribui também para a inexistência de Rac1b nesta linha celular. 
 Em contraste, as células HT29 acumulam pequenas quantidades de "-
catenina nuclear, conduzindo assim à diminuição da expressão de SRp20 e a um 
aumento de Rac1b. Além disso, nesta linha celular o gene KRAS é selvagem mas 
existe, em alternativa, uma mutação oncogénica do gene BRAF (Matos et al. 2008). A 
proteína B-Raf funciona a jusante de K-Ras na via da ERK e assim não pode 
estimular a PI3-cinase directamente, o que está de acordo com o facto das células 
HT29 expressarem mais ASF/SF2 e mais Rac1b. Estas células representam um 
outro grupo de tumores colo-rectais em que a mutação oncogénica B-RafV600E 
ocorre associada à sobre-expressão de Rac1b, e onde B-RafV600E estimula a 
proliferação celular, enquanto a sinalização de Rac1b mantém a sobrevivência 
celular (Matos et al. 2008). No entanto, os detalhes moleculares que conduzem à 
sobre-expressão de Rac1b permaneceram imprecisos. Os dados aqui apresentados 
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permitem agora propor um mecanismo molecular para a sobre-expressão de Rac1b: 
lesões genéticas que iniciam a tumorigénese colo-rectal sem activar a sinalização 
da PI3-cinase e da "-catenina, promovem a selecção de contextos celulares com 
níveis mais elevados de ASF/SF2 relativamente a SRp20. Este cenário celular 
favorecerá a sobre-expressão de Rac1b que conduz ao aumento da sobrevivência 
celular e à subsequente progressão tumoral. 
 Outra grande contribuição deste trabalho é a demonstração que diferentes 
vias de sinalização celular actuam em conjunto para regular um evento de splicing 
alternativo específico. No caso estudado, sincronizando a expressão de duas 
proteínas SR com papéis antagónicos, ASF/SF2 e SRp20, as vias da PI3-cinase e 
da Wnt regulam a inclusão ou exclusão do exão alternativo 3b do pré-RNA 
mensageiro de Rac1. 
 Diversas evidências suportam a nossa conclusão que a via de transdução de 
sinal da "-catenina/TCF4 estimula directamente a transcrição génica do factor de 
splicing SRp20. Demonstrámos que os níveis endógenos do transcrito e da proteína 
SRp20 se correlacionam com a actividade transcricional da "-catenina em diferentes 
linhas celulares colo-rectais. Além disso, a estimulação ou inibição experimental da 
sinalização da "-catenina/TCF4 afectam os níveis de SRp20, e o promotor do gene 
SFSR3 (que codifica para o factor SRp20) responde a essa mesma estimulação e 
inibição. Mostrámos ainda que o aumento dos níveis da proteína SRp20, estimulado 
pela "-catenina, é suficiente para promover decisões de splicing alternativo em 
células colo-rectais, quer num minigene repórter quer no RAC1 e ainda num outro 
gene endógeno, o CD44. 
 Em geral, estes resultados demonstram que a via da "-catenina/TCF 
estimula não só a transcrição génica, mas também a formação de um subconjunto 
de transcritos variantes por splicing alternativo. Assim, são afectados dois níveis do 
programa de expressão génica celular pela sinalização da "-catenina/TCF: a 
activação transcricional do factor de splicing SRp20 codificado pelo gene SFSR3, e 
como consequência do aumento dos níveis desta proteína, a produção de variantes 
de splicing alternativas. Estes dados suportam a noção recente de que a transcrição 
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e o splicing alternativo representam dois níveis diferentes de regulação da 
expressão génica e que diversas vias de sinalização agem coordenadamente sobre 
o conjunto de transcritos resultantes.  
 Em conclusão, este trabalho contribui para a compreensão dos mecanismos 
moleculares responsáveis pela expressão alterada de alguns factores de splicing 
observada em vários tipos de tumores (Stickeler et al. 1999, Venables 2004) e 
apresenta uma explicação mecanística de como alguns sinais celulares podem 
regular o splicing alternativo afectando a actividade de um factor de transcrição, o 
qual controla directamente o nível da transcrição de factores de splicing em resposta 
a mudanças nas vias de sinalização respectivas. Elucidámos também parte do 
mecanismo de tumorigénese que ocorre num subtipo de tumores do cólon 
caracterizando a sinalização envolvida na regulação do evento de splicing 
alternativo que origina a variante Rac1b. Isto permitiu-nos propor um mecanismo 
para a sobre-expressão de Rac1b, o qual faz parte de uma via alternativa de 
transformação maligna, para além das mutações oncogénicas clássicas já descritas 
em tumores colo-rectais. Adicionalmente, os nossos dados abrem a possibilidade do 
desenvolvimento de metodologias terapêuticas específicas devido à identificação 
dos factores de splicing envolvidos e das sequências alvo no exão 3b. 
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Summary 
 
 Tumours develop through the stepwise acquisition of genetic changes 
including those affecting signalling pathways that control cell proliferation and 
survival. The small GTPase Rac1 regulates signalling pathways controlling actin 
filament dynamics and transcriptional activation. An alternative splicing variant 
Rac1b contains 19 additional amino acids due to inclusion of a usually skipped exon 
3b and is overexpressed in a subset of colorectal tumours. Rac1b is required to 
sustain colorectal tumour cell survival and understanding the molecular mechanism 
behind this alternative splicing event is of therapeutic interest. Here we describe that 
antagonistic SR proteins ASF/SF2 and SRp20 regulate Rac1 alternative splicing in 
colorectal cells. Using a Rac1 minigene we identified that SRp20 increased skipping 
of alternative exon 3b in HT29 cells, while ASF/SF2 increased its inclusion. Depletion 
of endogenous expression of these splicing factors by specific siRNAs confirmed 
that ASF/SF2 enhances, whereas SRp20 silences endogenous Rac1b splicing. 
Moreover, we found that both splicing factors bound to Rac1 exon 3b sequences and 
were regulated by upstream signalling pathways: inhibition of PI3-kinase pathway 
increased ASF/SF2 expression and promoted Rac1b, whereas activation of "-
catenin/TCF4 increased SRp20 expression and inhibited Rac1b generation. We 
further found that "-catenin/TCF4 directly stimulates gene transcription of SRp20 
and generates a subset of transcript variants through alternative splicing. This 
supports the recent notion that transcription and alternative splicing represent two 
different layers of gene expression and that signalling pathways act upon a 
coordinated network of transcripts in each layer. A major contribution of this work is 
the demonstration that different cellular signalling pathways act in concert to regulate 
a specific alternative splicing event. The results predict that overexpression of Rac1b 
can occur in tumours without enhanced stimulation of PI3-kinase and Wnt pathways, 
which synchronize the expression of two antagonistic SR proteins, ASF/SF2 and 
SRp20, regulating alternative splicing of the Rac1 pre-mRNA. 
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Abbreviations 
 
A   adenosine 
aa   amino acid 
AKT / PKB  protein kinase B  
APC   adenomatous polyposis coli 
AS   alternative splicing 
ATP   adenosine triphosphate 
BAC   bacterial artificial chromosome 
BGHpa  bovine growth hormone polyadenylation signal 
BK   calcium-activated potassium channels 
bp   base pairs 
BPS   branch point sequence 
BSA   bovine serum albumin 
C   cytosine 
CaMK   calcium/calmodulin-dependent kinases 
cAMP   cyclic adenosine monophosphate 
cDNA   mRNA-complementary DNA 
Clk/Sty   Cdc2-like kinase 
CMV   cytomegalovirus 
CRIB   Cdc42/Rac interactive binding 
CTD   C-terminal domain 
C-terminal  carboxyl-terminal 
CTP   cytosine triphosphate 
CV   consensus value 
DAPI   4,6-diamidino-2-phenylindole 
DMD    Duchenne!s muscular dystrophy 
DMEM   Dulbecco's Modified Eagle's Medium 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DTT   dithiothreitol 
ECM   extracellular matrix 
EDTA   Ethylenediamine tetraacetic acid 
EMSA   electrophoretic mobility shit assay 
EMT   epithelial to mesenchymal transition 
ERK   extracellular signal-regulated kinase 
ESE   exonic splicing enhancer  
ESR   exonic splicing regulatory element 
ESS   exonic splicing silencer 
EST   expressed sequence tag 
Flag   epitope tag from the gene-10 product of bacteriophage T7 
G   guanosine 
GAP   GTPase-activating protein 
Abbreviations
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GDI   guanine nucleotide dissociation inhibitor 
GDP   guanosine diphosphate 
GEF   guanine nucleotide exchange factor 
GFP   green fluorescent protein 
GSK3   glycogen synthase kinase 3" 
GTP   guanosine triphosphate 
HA   epitope tag from Hemagglutinin of the influenza virus 
HIV   human immunodeficiency virus 
hnRNP  heterogeneous nuclear RNP 
I#B$   inhibitor of #B$ 
IKK$   I#B$ kinase complex 
IP   immunoprecipitation 
ISE   intronic splicing enhancer 
ISS   intronic splicing silencer 
JNK   c-Jun N-terminal kinase 
kb   kilo base pairs 
kDa   kilodalton 
MAPK   mitogen-activated protein kinase 
MEK   MAPK kinase 
MMP   matrix metalloprotease 
mRNA   messenger RNA 
MW   molecular weight 
Myc   epitope tag derived from the c-myc gene product 
NE   nuclear extracts 
NF#B   nuclear factor kappa-light-chain-enhancer of activated B cells 
nt   nucleotide 
ORF    open reading frame  
N-terminal  amino-terminal 
PAGE    polyacrylamide gel electrophoresis 
PAK   p21 activating kinase 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PI3K   phosphatidylinositol 3 kinase 
PKC   protein kinase C 
Pol II   RNA Polymerase II 
PolyA   poly-adenilate 
PTB   polypyrimidine tract binding protein 
PTEN   phosphatase and tensin homolog 
RNA   ribonucleic acid 
RNAi   ribonucleic acid interference 
RNAsin  ribonuclease inhibitor 
RNP   ribonucleoprotein 
ROS   reactive oxygen species 
RT-PCR  reverse transcription PCR 
Abbreviations
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SCF   Skp, Cullin, F-box containing 
SDS   sodium dodecyl sulphate 
siRNA   small interfering RNA 
SMA    spinal muscular atrophy  
snRNA   small nuclear RNA 
snRNP   small nuclear RNP 
SRPK   SR protein kinase 
SR protein  serine/arginine-rich protein 
ss   splice site 
STREX   stress axis-regulated exon 
T   thimidine 
T7   epitope tag from T7 bacteriophage gene10 
TBE   Tris/Borate/EDTA 
TBP   TATA binding protein 
TCF4   transcription factor 4 
TCF/LEF  T-cell factor/lymphoid enhancer factor 
TIMP   tissue-specific inhibitor of MMP 
Tris   tris(hydroxymethyl)aminomethane 
TRITC   Tetramethyl Rhodamine Iso-Thiocyanate 
tRNA   transfer RNA 
U   uridine 
UTR   untranslated region 
WB   western blot 
Wnt   wingless 
wt   wild type 
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 Cells of a multicellular organism are genetically homogeneous but can 
become structurally and functionally heterogeneous owing to the differential 
expression of genes (Jaenisch and Bird 2003), allowing them to have a selective 
expression in different tissues and at different times according to their needs.  
 Expression of eukaryotic genes is a multistep process that includes 
transcription of the gene, splicing and polyadenylation of the primary transcript, and 
transport of the fully processed mRNA to the cytoplasm (Singer and Green 1997), 
where it can be translated into protein. How the controlled expression of the tens of 
thousands of genes in a genome is orchestrated is a difficult question to answer (van 
Driel et al. 2003). To date, it is known that regulation can occur at any point in this 
pathway; specifically, at the levels of chromatin domains, transcription, post-
transcriptional modification, RNA transport, translation, mRNA degradation and post-
translational modifications. Pre-mRNA splicing is a part of the post-transcriptional 
regulation of gene expression and will be considered in more detail in the following. 
 
 
Pre-mRNA splicing, constitutive and alternative splicing 
 
One critical step in the expression of nearly all eukaryotic genes is pre-mRNA 
splicing, in which intron sequences are removed and exons are joined together to 
generate a mature protein-coding mRNA transcript. The chemistry of the splicing 
reaction is mediated by the “spliceosome”, an RNA-based machine containing five 
snRNAs and numerous associated proteins (Jurica and Moore 2003). Both the snRNA 
and protein components of the spliceosome interact with defined sequences at the 
exon/intron boundaries to direct RNA excision and ligation at these “splice sites” 
(Fig. 1.1). In addition, several of the snRNAs interact with one another to ensure the 
correct juxtaposition of distant regions of the substrate required for splicing catalysis 
(House and Lynch 2008). 
Although the spliceosome catalyzes RNA cleavage and ligation with high 
fidelity, the inherent flexibility of this enzymatic complex allows it to be highly 
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sensitive to regulation. A frequent consequence of spliceosome regulation is the 
differential inclusion or exclusion of exons in the final mRNA product in a process 
known as alternative splicing. Alternative splicing is predicted to occur in the vast 
majority of mammalian genes and is a primary mechanism by which complex 
organisms can regulate protein expression and generate a diverse proteome from a 
relatively limited genome (Black 2003, Ben-Dov et al. 2008). Although initial studies of 
alternative splicing suggested that regulation occurred predominantly at the earliest 
steps of spliceosome assembly, more recent studies have demonstrated regulation 
of splicing patterns at many points throughout the assembly pathway (House and 
Lynch 2008). 
 
 
 
 
Figure 1.1: Consensus sequences that define exon/intron boundaries. Y=U or C; R=G or A. The 
term for the sequences is shown below; ss: splice site, BPS: branch point sequence, PPT: 
polypyrimidine tract. (adapted from House and Lynch 2008)  
 
Dynamic assembly of the spliceosome  
 
Three sites, the 5! splice site (5!ss), the 3! splice site (3!ss), and the branch 
point sequence (BPS), are present in every intron and are known as the core splicing 
signals (Fig. 1.1). These signals are recognized multiple times during spliceosome 
assembly (Wang and Burge 2008). Each of the snRNAs that compose the 
spliceosome (U1, U2, U4, U5, and U6 snRNAs) associates with a large number of 
proteins to form a ribonucleoparticle called an “snRNP.” The catalytic conformation of 
the spliceosome (so-called “C” complex) forms in a highly dynamic process best 
described by a stepwise pathway involving several intermediate complexes (E-A-B) 
that have been identified and characterized in vitro and in vivo (Fig. 1.2) (Black 2003, 
Tardiff and Rosbash 2006). The earliest known complex committed to the splicing 
pathway (E) is defined by U1 snRNP base-paired to a 5!ss, with the 3!ss recognized 
by binding of the U2AF heterodimer (U2AF65/35) to the polypyrimidine tract and 3!-
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terminal AG, respectively, and association of the protein SF1 with the BPS. The E 
complex is chased into the pre-spliceosome A complex by the ATP-dependent 
addition of U2 snRNP at the 3!ss facilitated by base pairing between the U2 snRNA 
and BPS. Recruitment and addition of the U4#U6/U5 tri-snRNP results in formation of 
the B complex. Finally, the C complex forms by extensive remodelling of both the 
snRNA and the protein components that are present in the B complex, including loss 
of both the U4 and U1 snRNPs, to produce an active site that is capable of 
catalyzing the transesterification chemistry required for exon ligation and lariat 
release (Bessonov et al. 2008). The release of U1 and U4 snRNPs, as well as many 
other molecular rearrangements required for assembly, is promoted by the action of 
a series of DEX(D/H) box ATPase proteins (House and Lynch 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Schematic representation of the spliceosomal complexes. See text for details.  
 
Since each molecular rearrangement and transition during spliceosome 
assembly represents a potential point of regulation, a more detailed characterization 
of spliceosome assembly will ultimately lead to a deeper understanding of the 
mechanisms of alternative splicing (House and Lynch 2008). 
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Regulation of splice site recognition 
 
Although the splice sites within the pre-mRNA function to direct the splicing 
machinery, these sequence elements in higher eukaryotes are highly degenerate 
and often imbedded within introns that are significantly longer than exons (Black 
2003). Therefore, it is not surprising that sequence elements outside of the splice 
sites can strongly affect metazoan pre-mRNA splicing. Use of most exons is now 
believed to be under the combinatorial control of multiple regulatory RNA elements 
as well as the inherent strength or weakness of the flanking splice sites (Smith and 
Valcarcel 2000, Singh and Valcarcel 2005, Matlin et al. 2005, Hertel 2008, House and Lynch 
2008).  
 
Splice site strength  
 
A critical step in pre-mRNA splicing is the recognition and pairing of 5!ss and 
3!ss (Fig. 1.1). Whereas the 5!ss junction is defined by a single element of 9 nt, the 
3!ss is defined by three sequence elements usually contained within 40 nt upstream 
of the exon/3!-intron junction (Reed 1996). These elements are the branch point 
sequence, the polypyrimidine tract, and the exon/3!-intron junction. Initial recognition 
of exon/intron junctions is based on direct interactions between U1 snRNP with the 
5!ss, the U2 auxiliary factor with the polypyrimidine tract, and U2 snRNP with the 
branch point sequence. Because the sequence specificity of these interactions is 
driven by pre-mRNA/snRNA interactions and the U2 auxiliary factor binding 
preference for polypyrimidines, splice sites are classified by their complementarity to 
U1 snRNA (5!ss) and the extent of the polypyrimidine tract (3!ss). Greater 
complementarity with U1 snRNA and longer polypyrimidine tracts translate into 
higher affinity binding sites for these spliceosomal components and thus more 
efficient exon recognition (Hertel 2008). Splice site consensus values (CVs) reflects 
the strength of the splice site and are usually calculated using previously described 
matrices (Shapiro and Senapathy 1987), obtained through the analysis of splice sites 
from different organisms. There are several on-line tools for calculating splice sites 
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CVs that have been improving with the increasing knowledge in this specific area 
and the development of bioinformatics. Some examples of these tools are: Splice 
Site Prediction by Neural Network, http://www.fruitfly.org/seq_tools/splice.html (Reese 
et al. 1997); Analyzer Splice Tool, http://ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm 
(Carmel et al. 2004); and Human Splicing Finder, http://www.umd.be/HSF/HSF.html 
(Hubbard et al. 2006). These tools are especially useful when the effect of mutations in 
genetic disorders is analyzed. 
 
Splicing enhancers and silencers  
 
Although the splice sites within the pre-mRNA function to direct the splicing 
machinery, these sequence elements in higher eukaryotes are highly degenerate 
and often imbedded within introns that are significantly longer than exons (Black 
2003). Therefore, it is not surprising that sequence elements outside of the splice 
sites can strongly affect metazoan pre-mRNA splicing. Cis-acting auxiliary 
sequences occur within both exonic and intronic regions and can either promote 
recruitment of the spliceosome and exon inclusion (splicing enhancers) or disrupt 
assembly of the splicing machinery and cause exon skipping (splicing silencers). In 
general, these splicing regulatory elements function by recruiting trans-acting 
splicing factors that activate or suppress splice site recognition or spliceosome 
assembly by various mechanisms (Matlin et al. 2005).  
The best characterized of the regulatory elements, exonic splicing enhancers 
(ESEs), are usually recognized by a family of proteins known as SR proteins, which 
contain an RNA-binding domain and a region rich in arginine-serine dipeptides (RS 
domain). Interestingly, SR protein-binding sites are present not only within 
alternatively spliced exons, but also within the exons of constitutively spliced pre-
mRNAs (Schaal and Maniatis 1999). It is therefore expected that SR proteins bind to 
sequences found in most, if not all, exons.  
However, regulation of pre-mRNA splicing is much more complex than the 
simple ESE recruitment model. Intronic splicing enhancers (ISEs) and splicing 
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silencers, either exonic (ESS) or intronic (ISS), occur frequently and influence splice 
site selection (Fig. 1.3) (Black 2003, Pagani and Baralle 2004). Several mechanisms 
have been proposed for ESS- or ISS-mediated splicing repression. Heterogeneous 
nuclear RNP-bound splicing silencers have been shown to repress spliceosomal 
assembly through multimerization along exons (Zhu et al. 2001), through blocking the 
recruitment of snRNPs (Tange et al. 2001), or by looping out exons (Martinez-Contreras 
et al. 2006).  
Figure 1.3: A schematic of regulated splicing. Dashed lines: Two alternative splicing pathways, 
with the middle exon either included or excluded. Splicing is regulated by cis-elements (ESE, ESS, 
ISS, and ISE) and trans-acting splicing factors (SR proteins, hnRNP, and unknown factors). (adapted 
from Wang and Burge 2008) 
 
Typically, silencers and enhancers are present within the vicinity of potential 
exon/intron junctions, suggesting that the interplay between activating and 
repressing cis-acting elements modulates the probability of exon inclusion (Hertel 
2008). These observations suggest that the recognition of every exon is influenced 
by multiple distinct cis-acting elements, a notion strongly supported by computational 
analyses (Zhang and Chasin 2004, Wang et al. 2004). According to this concept, a large 
number of diseases are now known to result from intronic or exonic mutations that 
disrupt normal splicing patterns. This adds to diseases caused by missense, 
nonsense, and frame-shifts mutations in the open reading frame, which give rise to 
defective proteins (Cooper et al. 2009). Up to 25% of synonymous (in terms of amino 
acid coding) substitutions can disrupt normal splicing, as can nonsynonymous and 
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termination codons (Pagani et al. 2005), emphasizing the importance of considering 
silent mutations as mediators of pathogenic effects. For the studied genes, up to 
50% of point mutations within exons affect splicing, and it has been hypothesized 
that more than half of known disease-causing mutations disrupt splicing (Lopez-Bigas 
et al. 2005).   
Generally, the splicing regulatory elements are relatively short (4-18 
nucleotides) (Cartegni et al. 2002, Fairbrother et al. 2002) and degenerate, so that an 
accurate understanding of their sequence context is still lacking. Some recent 
studies employed computational methods to predict sequence motifs for this 
elements, for example, ESEfinder program (Cartegni et al. 2003, available at 
http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home), PESX: Putative 
Exonic Splicing Enhancers/Silencers (Zhang and Chasin 2004, Zhang et al. 2005, 
available at http://cubweb.biology.columbia.edu/pesx/), ESR search (Goren et al. 2006; 
available at http://ast.bioinfo.tau.ac.il/ESR.htm) and Splicing Rainbow (Stamm et al. 2006, 
available at http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8). Several groups of ESEs are 
known, including purine-rich and AC-rich elements, as well as some with more 
complex composition (Graveley 2000, Zheng 2004). ESS sequences have higher 
content of T (38%) and G (36%) and reduced levels of A (17%) and C (9%) (Wang et 
al. 2004). However, up to now it is not possible to reliably identify these elements and 
predict the effect of a genomic mutation on the splicing process. 
 
Exon/Intron architecture  
 
The exon/intron architecture has been shown to have an influence on splice 
site recognition (Berget 1995). For example, increasing the size of mammalian exons 
results in exon skipping. However, the same enlarged exons were included when the 
flanking introns were small (Sterner et al. 1996). Thus, splice site recognition is more 
efficient when introns or exons are small. These early observations suggested that 
splice sites are recognized across an optimal nucleotide length and predicted that 
intron length significantly influences the efficiency of pre-mRNA splicing and 
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alternative splice site choice. This is an important hypothesis because of the 
divergent distribution of intron length in the human genome and because it had been 
proposed that, the spliceosome uses two modes of recognition to define splice sites: 
intron and exon definition (Berget 1995). These two models are still unproven, and all 
the indications for their existence are circumstantial. However, intron definition is 
presumably the ancient one, in which the splicing machinery recognizes an intronic 
unit and places the basal machinery across introns. Therefore, the size of the intron 
is under selection. Indeed in S. cerevisiae and S. pombe, almost all introns are less 
than 350 nt long, and all the information for accurate splicing is within the intron 
sequences (Guthrie 1991). This suggests that intron definition is the only system that 
directs the splicing machinery in these organisms (Berget 1995). In the second 
mechanism, exon definition, the basal splicing machinery is placed across exons. 
The length of exons must not exceed 300 nt. It was postulated that during evolution 
the enlargement of intronic sequences forced the splicing machinery to shift from the 
recognition of short intronic sequences to the selection of short exonic sequences – 
from intron to exon definition. This could explain the selective pressure to maintain 
short intronic sequences in yeast genes and short internal exons in the human 
genome (and other higher metazoans) (Robberson et al. 1990). Because the 
transesterification step of splicing occurs across the intron, a switch between exon 
and intron definition must exist to assemble the mature spliceosome. Recently, it 
was also demonstrated that disruption of the transition from exon-to-intron definition 
is a mechanism for alternative splicing regulation (Sharma et al. 2008). 
 Exon skipping is more likely to occur when exons are flanked by long introns 
in the human genome. Interestingly, experimental and computational analyses 
showed that the length of the upstream intron is more important in inducing 
alternative splicing than the length of the downstream intron, most likely reflecting 
the influence of RNA transcription on pre-mRNA splicing. These results showed that 
the exon/intron architecture defines baseline mechanisms of splice site recognition 
and influences the frequency of alternative pre-mRNA splicing (Fox-Walsh et al. 2005). 
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RNA secondary structure  
 
 Single-stranded RNA is known to adopt local secondary folds and tertiary 
interactions that may involve up to hundreds of nucleotides. Although pre-mRNAs 
are typically depicted in a linear fashion, we have to assume that higher order 
structures exist that maintains a good portion of the RNA double-stranded. 
Depending on the thermodynamic stability, these structures may persist long enough 
to interfere or modulate splice site recognition. In principle, these local structures can 
be inhibiting or activating spliceosomal assembly. This is because the recognition of 
splice sites, enhancers, and silencers usually depends on interactions between 
protein factors and a single-stranded portion of the pre-mRNA. Local RNA structures 
can interfere with spliceosomal assembly if they conceal splice sites or enhancer-
binding sites within stable helices. On the other hand, local RNA structures can also 
promote spliceosomal assembly by masking splicing repressor-binding sites (Hertel 
2008).  
 The importance of RNA secondary structure in modulating splice site selection 
has been documented frequently. For example, two classes of conserved RNA 
elements have been identified in the Dscam (Down syndrome cell adhesion 
molecule) exon 6 cluster, which contains 48 alternative exons 6. Each exon 6 variant 
contains a unique selector sequence that can base pair with a common upstream 
docking site (located in the intron downstream of constitutive exon 5) to form a 
secondary structure, thereby activating and directing mutually exclusive exon pairing 
(Graveley 2005). An inhibitory role of RNA secondary structure was demonstrated for 
splice site recognition of SMN2 exon 7. The formation of an RNA hairpin close to the 
5! splice site of SMN2 exon 7 interfered with its interaction with U1 snRNP, resulting 
in reduced exon inclusion levels (Singh et al. 2007).  
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Pre-mRNA synthesis by RNA polymerase II  
 
 It is widely accepted that the recognition and differential selection of splice 
sites occurs during transcription (Goldstrohm et al. 2001, Listerman et al. 2006). 
Furthermore, various studies have shown that transcription activators affect 
alternative splicing decisions. Such effects of transcription on splicing can be 
explained by two, non-mutually exclusive models: one model relies on the 
recruitment of splicing factors to the Pol II C-terminal domain (CTD); the second 
model is based on the kinetics of transcriptional elongation (Auboeuf et al. 2007). In 
mammals, the CTD consists of 52 repeats of the motif YS2(P)TS5(P)S, in which S2 
and S5 are phosphorylated dynamically. During initiation, Pol II is phosphorylated 
first on S5 and then on S2, at which point Pol II becomes processive and interacts 
with various splicing factors (Goldstrohm et al. 2001, Howe 2002). The interactions with 
the CTD might enable an increased concentration of specific splicing factors in the 
proximity of the nascent transcript, and thereby influence splicing decisions. Thus, 
any physiological post-translational modification on the CTD that affects its binding 
properties could contribute to modulate the combinatorial regulation of splice-site 
selection (de la Mata and Kornblihtt 2006). 
 The kinetic model is based on the notion that, because of their relative 
weakness, splice sites in the alternative exons might need longer to interact with the 
spliceosome, and their use might be favoured by a low elongation rate of Pol II (de la 
Mata et al. 2003). The recruitment and elongation rate of Pol II are coordinated, 
probably because the recruitment of splicing factors and the elongation rate of Pol II 
also depends on phosphorylation of the CTD (Listerman et al. 2006, de la Mata and 
Kornblihtt 2006).  
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Combinatorial control of exon recognition and alternative splicing 
 
 Over the last few years, it has become increasingly clear that exon selection 
is influenced by a number of activating and inhibitory elements. Given the divergent 
sequence and architecture of genes, every exon has its specific set of identity 
elements that permit its recognition by the spliceosome. Each exon is flanked by a 
unique pair of splice site signals and contains a unique group of splicing enhancers, 
silencers and secondary structures. The sum of contributions from each of these 
identity elements then defines the overall recognition potential of an exon or the 
overall binding affinity for the spliceosome. Considering the variation in splice sites, 
exon/intron architecture, number of enhancers and silencers, and secondary 
structures, the potential for a given exon to become recognized is expected to span a 
wide range. Because the spliceosome assembles around splice sites, the binding 
potential of splice sites is crucial for efficient exon definition. The contributions of the 
other parameters will vary significantly from exon to exon or cell to cell, augmenting 
or reducing the overall affinity of the splicing machinery. As a consequence of the 
observed differences in the concentrations of spliceosomal components and splicing 
activator/repressors between different cell types or between distinct biological 
processes such as the cell cycle and development, it is anticipated that the same 
exon may display variable exon recognition potentials in these scenarios. As a result, 
exons that are alternatively included in one cell type can be alternatively excluded in 
another (Hertel 2008). 
 An implication of this combinatorial interpretation of the splicing code is that 
the precise expression level, activity or subcellular localization of regulatory proteins 
in any given cell can have a profound influence on the ultimate splicing pattern of a 
gene (House and Lynch 2008).  
 In the literature, alternative splicing is attributed mainly to the activities of 
splicing enhancers and repressors that allow transient interactions with splicing 
regulators (Black 2003). In most cases, the presence or absence of splicing 
regulatory proteins modulates the overall exon recognition to significantly tilt the 
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balance between exon inclusion and exclusion. Similarly, protein interactions within 
the pre-mRNA may induce or interfere with the formation of RNA secondary 
structures that modulate efficient spliceosomal assembly (Hertel 2008). Regulation of 
alternative splicing can be achieved through modulating any one of the exon 
recognition components (House and Lynch 2008). However, specific regulation 
requires the selected targeting of splicing activator/repressor combinations unique to 
particular exons. This is often mediated through changes in post-translational 
modifications that are essential for optimal activity of many splicing regulatory 
factors, such as alterations in the phosphorylation state of specific SR proteins 
(Stamm 2008). 
 Invariable elements such as splice site sequences and exon/intron 
architecture have also the potential to mediate differential splicing. Based on the 
principle of mass action, fluctuations in snRNP levels can induce changes in the 
efficiency of splice site recognition, thus altering exon inclusion ratios. Such changes 
in the concentration of the general splicing factors could account for many of the 
alternative splicing events observed between different cell types (Hertel 2008). 
 In the cell, alternative splicing has also been attributed to promoter-dependent 
recruitment of specific splicing regulators or to changes in the kinetics of pre-mRNA 
synthesis (Kornblihtt 2005). Thus, modulating the recruitment of specific splicing 
factors or modulating the relative synthesis of competing splice sites can influence 
the selection of alternative splicing patterns. Alternatively, changes in the kinetics of 
RNA synthesis are able to influence the likelihood that local RNA secondary 
structures form that induces alternative splice site selection (Hertel 2008). 
 
Types of alternative splicing events 
 
 Based on systematic analyses, especially from mammalian species, it is 
apparent that the most common type of alternative splicing, accounting for at least 
one-third of known alternative splicing events, involves cassette-type alternative 
exons. These exons, which are either skipped or included in the final message, are 
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flanked by intron sequences (Figure 1.4). Alternative selection of 5!ss or 3!ss within 
exon sequences are also frequent, together accounting for at least one-quarter of the 
known alternative splicing events (Figure 1.4). This type of alternative splicing is 
capable of introducing subtle changes into coding sequences, differing by as little as 
a single codon (Blencowe 2006). Other types of alternative splicing events include 
retained introns (Ohler et al. 2005) and exons that are spliced in a mutually exclusive 
fashion (Figure 1.4). 
 In addition to the alternative splicing mechanisms mentioned above, the exon 
composition of transcripts is often altered by differential selection of transcription 
initiation and 3! end processing/termination sites (Figure 1.4), and these events can 
impact on adjacent or distal alternative splicing events in the same transcript (Zavolan 
et al. 2003, Kornblihtt 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Alternative Splicing Events in Metazoan Transcripts. Types of alternative splicing that 
are responsible for the generation of functionally distinct transcripts. Dashed lines represent different 
possibilities for splice site joining. Constitutive regions are shown in light gray while alternative ones in 
dark grey. (adapted from Blencowe 2006) 
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 Finally, it should also be kept in mind that each of the types of alternative 
splicing summarized above and shown in Figure 1.4 can occur within both translated 
and untranslated regions (UTRs) of transcripts (Blencowe 2006). Alternative exons 
within 5!-untranslated and 3!-untranslated regions can either add or remove RNA 
regulatory motifs and, thereby, modulate the stability and translation of transcripts. 
Several examples of alternative UTRs have been characterized, including those 
found in AXIN2, FGF1 and BRCA1 (Hughes 2006). 
 
Effects of alternative splicing 
 
 Alternative splicing is considered to be one of the main mechanisms by which 
proteome diversity is encoded by a limited number of genes. As most alternative 
splicing events occur in translated regions of mRNAs, they can affect the sequence 
of the encoded proteins. Changes in the primary structure might influence all aspects 
of protein function and properties, such as stability, intracellular localization, binding 
properties, enzymatic activity and post-translational modification. This yields a wide 
range of effects, from complete loss to subtle modulations of protein function. In 
some cases, protein isoforms that are generated by the same gene might have 
different functions (Kriventseva et al. 2003, Stamm et al. 2005, Blencowe 2006, Yura et al. 
2006).  
 Exon selection also affects the levels of gene expression. For example, 
alternative exons within UTRs can modulate the stability and translation of 
transcripts (Hughes 2006). Furthermore, it has been estimated that about one-third of 
alternatively spliced exons introduce premature translation-termination codons 
(PTCs). The splicing variants that contain such PTCs are degraded through the 
nonsense-mediated mRNA-decay (NMD) pathway and do not produce proteins. It 
has been speculated that alternative splicing-coupled NMD could provide a 
mechanism for the regulation of gene expression (Lewis et al. 2003, Blencowe 2006). 
However, some studies have shown that most PTC-containing splice variants are not 
conserved between human and mouse (Baek and Green 2005, Pan et al 2006). 
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Moreover, a recent microarray analysis of alternative splicing events in mammalian 
cells and tissues suggested that most PTC-containing splice variants are produced 
at low levels independent of the action of NMD and are rarely subject to tissue-
specific regulation (Pan et al. 2006). These results support the view that alternative 
splicing-coupled NMD may not play a widespread role in gene regulation. However, 
this process may serve to fine tune the levels of specific classes of genes, including 
subsets of splicing factors and other RNA binding proteins (Blencowe 2006). For 
example, it was recently found that all human SR protein genes have alternative 
splice forms that are degraded by NMD. Thus, this family of splicing factors might 
couple alternative splicing and NMD to regulate their own protein production, 
possibly by a mechanism of feedback regulation (Lareau et al. 2007).  
 
Signal-mediated alternative splicing control  
 
 Extracellular signals impact eukaryotic gene expression at different levels, 
including pre-mRNA splicing (Wilson and Cerione 2000). A large body of evidence has 
been accumulated indicating that splicing regulation can be induced by various 
extracellular signals such as cell growth/death factors, 
neurotransmitters/electrophysiological conditions, and environmental 
nutrients/stresses. Signal-mediated splicing regulation is primarily operated through 
activation of intricate networks of signal transduction pathway (Figure 1.5; Tarn 2007). 
Several signalling pathways and numerous splicing regulatory factors have now 
been implicated in the modulation of pre-mRNA splicing (Stamm 2002, Shin and 
Manley 2004). 
 Signalling pathways may converge on RNA-binding proteins that function as 
trans-acting splicing regulatory factors (Wilson and Cerione 2000, Stamm 2002, Shin and 
Manley 2004). Signalling, largely through kinase cascades, leads to phosphorylation 
of target splicing factors and subsequently alters their activity or cellular localization 
(Stamm 2002, Shin and Manley 2004). Such alterations may influence splicing 
efficiency or induce alternative splicing. Besides phosphorylation, the possibility that 
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other types of post-translational modifications also affect splicing activity still remains 
(Tarn 2007). For example, dephosphorylation (Chalfant et al. 2001), methylation 
(Bedford and Richard 2005), ubiquitination (Bellare et al. 2006) and sumoylation (Li et al. 
2004) have already been reported to play a role in signal-mediated splicing control. 
However, the mechanistic details of the pathways involved, from cellular signals to 
alternative splicing events, lack comprehensive description and thus need further 
investigation. In addition, evidence begins to emerge recently, indicating that steroid 
hormone receptors or their cofactors may modulate the rate of transcription or 
directly interact with splicing factors and thereby affect splicing through a 
transcription-coupled splicing regulation (Auboeuf et al. 2002, Dowhan et al. 2005). 
 Several cellular signalling pathways have been implicated in splicing 
regulation, including Ras/MEK/ERK, Rac/JNK/p38-MAPK, Ras/PI3-kinase/AKT and 
Ca2+/calmodulin/CaMK IV (Stamm 2002, Shin and Manley 2004). For example, 
activation of the p38-MAP kinase pathway led to phosphorylation of hnRNP A1, 
resulting in its cytoplasmic sequestration and altered splicing of an adenovirus 
reporter gene (van der Houven van Oordt et al., 2000). Depolarisation of secretory 
cells repressed inclusion of the STREX exon in BK potassium channel transcripts 
through the action of Ca2+/calmodulin-dependent protein kinases (CaMKs), thereby 
changing the excitability of the channel (Xie and Black, 2001). Also, inclusion of exon 
v5 into the cell surface tumour marker CD44 was dependent on activation of the 
Ras-ERK pathway (Weg-Remers et al., 2001; Matter et al., 2002) and nucleo-
cytoplasmic transport of the splicing regulator polypyrimidine tract-binding protein 
(PTB) is modulated by the cAMP dependent protein kinase (Xie et al., 2003). Finally, 
phosphorylation of SRp40 by AKT2 has been shown to regulate alternative splicing 
of protein kinase C "II (Patel et al., 2005; Jiang et al., 2008). Although many 
examples of signalling-induced splicing control have been described, their 
mechanistic details still remain largely unclear (Tarn 2007). 
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Figure 1.5: Alternative splicing regulation by cellular signals. Simplified models of signalling-
controlled alternative splicing are depicted. Extracellular signals may activate kinase cascades to 
phosphorylate splicing factors, and whereby change their subcellular localization or activity or alter 
their interaction with other cellular factors. Steroid hormones may modulate splicing through a 
cotranscriptional mechanism. Nuclear receptor coregulators may modulate the transcription rate, or 
directly recruit or post-translationally modify splicing factors, and whereby influence pre-mRNA 
splicing. Signalling pathways may concurrently target several splicing factors (SFs) to achieve an 
optimal control of alternative splicing. (from Tarn 2007) 
 
Global analysis of alternative splicing  
 
 The availability of sequenced genomes and large databases of sequenced 
transcripts, primarily comprising expressed sequence tags (ESTs) and smaller 
numbers of cDNA sequences, has provided a rich source of information for the 
identification and analysis of alternative splicing events (Blencowe 2006). However, a 
major limitation of alternative splicing analyses employing transcript sequence data 
is that EST coverage is typically biased toward the 3! and 5! ends of transcripts, and 
in general there are insufficient numbers of sequenced transcripts to infer the 
frequency with which specific alternative exons are included or skipped in a given 
cell or tissue source or under particular experimental conditions (Johnson et al. 2003, 
Pan et al. 2004).  
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 Some of the limitations inherent in the analysis of EST/cDNA have been 
overcome by the development of custom microarrays and computational tools, as 
well as differential hybridization techniques, which permit the large-scale profiling of 
alternative splicing. %%Exon junction arrays!! represent one early design, with high-
density oligonucleotide probes targeted to the junctions between consecutive exons 
(Johnson et al. 2003). Other designs include the use of probe sets to target bodies and 
junctions of constitutive and alternative exons (Pan et al. 2004, Sugnet et al. 2006), as 
well as the use of bead-based fiberoptic microarray platforms with high detection 
sensitivity (Yeakley et al. 2002). These designs have facilitated analyses of genome-
wide alternative splicing in human, mouse, and chimp (Srinivasan et al. 2005, Calarco 
et al. 2007), as well as detection of the global impact of specific splicing factors or 
environmental stimuli on splicing regulation (Hung et al. 2007, Makeyev et al. 2007, 
Pleiss et al. 2007a). 
 The systematic identification of RNA targets for different trans-factors can also 
be achieved by some new approaches such as a cross-linking/immunoprecipitation 
(CLIP) (Ule et al. 2003), RNP immunoprecipitation (RIP) (Keene et al. 2006), and 
genomic SELEX (Lorenz et al. 2006). These analyses have the potential to identify 
regulatory targets of a factor and can be applied genome-wide when coupled with 
microarray or high-throughput sequencing technologies. Analysis of the target 
sequences will help to define the sequence determinants of binding, and may also 
help to identify cooperative or antagonistic relationships between different factors. 
Since only a subset of binding events confers regulatory activity, it is important to 
also have evidence of regulation. Such evidence can be obtained from 
knockout/knockdown or overexpression of the factor, which can be also applied on a 
genome-wide scale when coupled with high-throughput sequencing (Wang and Burge 
2008). 
 In the post-genomic world, research into the mechanisms of splice site 
selection is leading toward the establishment of rules that will allow splice patterns to 
be predicted based on sequence information. Computational methods combined with 
laboratory experiments have already generated algorithms that predict splicing 
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regulatory sequences (Fairbrother et al. 2002, Wang et al. 2004, Zhang and Chasin 2004). 
This significant progress suggests the exciting possibility of crafting a “splicing code” 
that permits the prediction of exons and the probability of their inclusion in the most 
abundant mRNA isoform. Ideally, a splicing code should be able to differentiate 
between alternative splicing events in different tissues and different biological 
processes (Hertel 2008, Wang and Burge 2008). 
 
Splicing regulatory network as a subnetwork of gene regulation 
 
 Recent analyses of sequence and microarray data on alternative splicing 
revealed that the majority of genes regulated in a tissue-specific manner by 
alternative splicing are different from those regulated in a tissue-specific manner at 
the transcriptional level. Moreover, it is emerging that groups of tissue-specific AS 
events may function in a coordinated manner in specific pathways or interaction 
networks, in much the same way as has been observed for groups of genes 
coregulated at the transcriptional level. This promotes the concept of “layers” of gene 
regulation and raises the interesting question as to the extent and nature of exon 
networks that may serve in parallel with other layers to coordinate gene activities and 
interactions so as to refine and/or expand cell- and tissue-type-specific functions 
(Blencowe 2006).  
 The splicing regulatory network is part of a larger network of gene regulation 
with which it is linked both physically and functionally (Wang and Burge 2008). In 
fact, the abundance of protein isoforms results from regulatory events at various 
stages of gene expression, including chromatin remodelling, transcription initiation 
and elongation, pre-mRNA splicing and polyadenylation, mRNA export, and 
translation (Auboeuf 2007). 
 Although bioinformatics predictions on alternative splicing are evolving, it is 
important to understand they are incomplete. Currently, the determination of the 
splicing regulation of a particular splice form or whether it is actually carrying out an 
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important biological function still require experimental verification. Accordingly, much 
can still be learned from candidate gene analysis. 
 
 
Alternative splicing and cancer 
 
 Cancer is viewed as a genetic disease. According to the established models 
of oncogenesis, several sequential mutations in oncogenes and tumour suppressor 
genes, which regulate fundamental cellular processes like proliferation, 
differentiation, and apoptosis, are necessary for cancer development (Cahill et al. 
1999). To become a malignant cancer cell, several essential alterations in cellular 
physiology have to occur: autonomous proliferation, evasion of apoptosis, resistance 
to growth-inhibitory signals, unlimited replicative potential, angiogenesis, invasion 
and metastasis (Hanahan and Weinberg 2000). 
 Up to now, mRNA is viewed as a “passive” intermediate product between 
DNA (with coding potential) and proteins (with executive potential). However, recent 
evidence suggests that different types of RNA molecules play important roles in gene 
regulation not only at the level of mRNA processing and regulation of mRNA stability 
but also at the level of gene transcription (Scholzová et al. 2007). For example, in the 
nucleus, newly synthesized pre-mRNAs are subjected to “quality control” processes 
including “capping”, polyadenylation, alternative splicing, nonsense-mediated decay 
(NMD), RNA editing or RNA export from the nucleus. All these RNA processing 
mechanisms influence each other and are linked in a “multi-component” machine 
encompassing DNA polymerase II (Orphanides and Reinberg 2002).  
 With regard to alternative splicing, numerous reports have shown that 
patterns are changed in tumours (reviewed in Venables 2006). The expression of 
alternative or even tumour-specific splice variants characterizes many cellular events 
critical for cancer biology (Skotheim and Nees 2007). It is still unclear, however, to 
what extent alternative splicing functionally contributes to the initiation and 
progression of cancers. 
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 Mutations in splicing regulatory elements that change splice site selection 
provide a clear link between pre-mRNA processing and cancer development. The 
mutations ultimately lead to the generation of non-functional tumour suppressor 
genes or the activation of oncogenes, which predisposes to cancer (Tazi et al. 2009). 
 In the absence of mutations, changes in the concentration, localization, 
composition, or activity of trans-acting regulatory factors, such as hnRNP and SR 
proteins, can alter splice site selection. Several studies have demonstrated specific 
alterations in the expression of splicing factors in cancer (Karni et al. 2007, Fischer et 
al. 2004, Zerbe et al. 2004, Stickeler et al. 1999, Ghigna et al. 1998). An increasing 
number of examples describing the control of alternative splicing by signal 
transduction pathways support the notion that the loss of the accurate control of 
alternative splicing may lead to preferential expression of cancer-prone protein 
isoforms without any alteration in their genetic information (Kalnina et al. 2005). 
 While an understanding of the causes of alternative splicing in cancer is still a 
long way off, the full extent of pathogenic alternatively spliced isoforms may soon 
become apparent. Even with our current limited knowledge of the alternative 
transcriptome, it is easier to diagnose cellular states by profiling alternative 
transcripts than protein splicing factors (Relogio et al. 2005). 
 Several extensive and genome-wide bioinformatics searches have been 
performed with the aim to identify cancer-associated splice variants (Roy et al. 2005, 
Wang et al. 2003, Xu and Lee 2003). Hundreds of cancer-specific candidate variants 
have been identified in these studies by purely statistical means. However, very little 
biological validation has been performed to confirm these variants, and it is therefore 
premature to judge the overall usefulness and reliability of the computational 
approaches per se (Skotheim and Nees 2007). 
 In this thesis, the alternative splicing of an isoform of the small GTPase Rac1 
was studied, for which experimental evidence has shown functionally distinct 
properties of the variant protein. 
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Small GTPases (Guanosine TriPhosphatases) and Cancer 
 
 Development of multicellular organisms requires an extraordinary %%sensing!! 
ability of cells to detect and respond adequately to cues expressed by other cells 
(adhesion molecules, extracellular matrix, cytokines, morphogens, growth factors, or 
hormones). Intercellular signalling was extensively studied in dynamic situations 
such as embryonic development, and the use of simple genetic models has allowed 
the identification of pathways highly conserved in most eukaryotes. Cell signalling is 
initiated by the binding of ligands to their receptors at the cell surface and then 
converted into specific responses that mostly affect gene transcription, cell shape, 
adhesion, motility, and endo/exocytosis (Boureux et al. 2007). Since the identification 
of the first member Ha-Ras as a viral 21 kDa protein responsible for tumour 
formation (Andersen et al. 1981), Ras and related members have been found in all 
studied eukaryotic organisms and are probably the most conserved proteins among 
the cellular components involved in cell signalling. Ras-like proteins usually are low 
molecular weight proteins that display a conserved structural backbone of 5 G-boxes 
involved in GTP-binding and GTPase activity (Bourne et al. 1991). Ras-like proteins 
constitute a superfamily of over 150 members in mammals, subdivided into 5 main 
families (Fig. 1.6): Ras, Rho, Rab, Arf, and Ran that control each particular aspect of 
cell metabolism, such as cell proliferation for Ras (Hancock and Parton 2005, 
Wennerberg et al. 2005), cell morphology for Rho (Wennerberg and Der 2004), vesicle 
trafficking for Rab and Arf (Donaldson and Honda 2005, Bucci and Chiariello 2006), and 
nuclear trafficking for Ran (Pemberton and Paschal 2005). 
 
The Rho family of small GTPases  
 
 Rho family members (Madaule and Axel 1985) are defined by the presence of a 
Rho-specific insert located between the G4 and the G5 boxes and involved in the 
binding to effectors and regulators (Freeman et al. 1996). Like other Ras-like, Rho 
proteins are present from lower eukaryotes (Tanaka and Takai 1998; Rivero et al. 2001) 
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up to mammals (Wennerberg and Der 2004). In mammals, the Rho family contains 
about 20 members structured into 8 different subfamilies (Fig. 1.6): Cdc42, Rac, 
RhoUV, Rho, RhoBTB, RhoDF, RhoH and Rnd. Splice variants of Rac1 and Cdc42 
have also been identified. RhoBTB3 and Miro1 and 2 are now considered as outside 
of the Rho family because they lack a proper Rho insert domain and are of distinct 
phylogenetic origin. From a global evolutionary view of the Rho family, data indicate 
that Rac is likely the founder member of the family (Boureux et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Phylogenetic tree of the mammalian Ras GTPase superfamily. The 20 Rho family 
members are grouped into 8 subfamilies. (adapted from Vega and Ridley 2008) 
 
Regulators, effectors and functions 
 
 Most Rho family members act as molecular switches, cycling between a GTP-
bound active form and a GDP-bound inactive form (Jaffe and Hall 2005) (Fig. 1.7). 
Their activity is increased by guanine nucleotide exchange factors (GEFs), which 
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promote the release of bound GDP and subsequent binding of the GTP, and 
downregulated by GTPase-activating proteins (GAPs), which enhance the intrinsic 
ability to hydrolyse GTP (Bos et al. 2007). Rho proteins are also frequently post-
translationally modified at the C-terminus with the addition of a lipidic group by 
prenylation (farnesylation or geranylgeranylation) or palmitoylation, thereby 
enhancing their interaction with membranes and determining their intracellular 
localization. GDI proteins (guanine nucleotide dissociation inhibitors) also regulate 
the activity of Rho GTPases by binding to the C-terminal prenyl group, preventing 
their membrane association and sequestering them in the cytoplasm, and thus 
frequently inhibiting their access to downstream targets (Dovas and Couchman 2005). 
RhoGDIs can bind to either the GTP- or the GDP-loaded forms. To date over 70 
RhoGEFs, 60 RhoGAPs and 3 RhoGDIs have been identified in mammals, reflecting 
the complexity of the regulation of this class of proteins (Vega and Ridley 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Basic Rho GTPase activation cycle. GEFs catalyze the loading of Rho GTPases with 
GTP, leading to their activation and allowing the binding to effectors that perform specific functions. 
GAPs promote the hydrolysis of GTP, inactivating Rho GTPases. GDIs constitute an additional step of 
regulation by sequestering Rho GTPases in the cytoplasm impairing its function. (adapted from Vega 
and Ridley 2008)  
 
 Once activated, Rho GTPases bind different effector molecules and trigger a 
signalling cascade to direct cellular responses. Over 70 effector proteins have been 
described binding to the family of Rho GTPases (Bishop and Hall 2000, Bustelo et al. 
2007). Each Rho GTPase has binding affinity for multiple effector proteins and some 
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effector proteins are recognized by multiple Rho GTPases. Many effector proteins of 
Rho GTPases are serine/threonine kinases that become activated and 
phosphorylate downstream target proteins, which initiate various signalling 
cascades, regulating different cellular processes. Other non-kinase effector proteins 
promote downstream signalling by functioning as scaffold or adaptor proteins, 
transferring signals from Rho GTPases via interactions with other proteins (Ellenbroek 
and Collard 2007). 
 Rho GTPases have been implicated in many cellular processes including 
actin and microtubule cytoskeleton organization (regulating changes in cell shape, 
cell adhesion, cell spreading, cell migration and cell polarity), cell division (regulating 
apoptosis and cell survival), vesicular trafficking (including exocytosis, endocytosis 
and phagocytosis) and transcriptional regulation (Jaffe and Hall 2005, Ellenbroek and 
Collard 2007). 
 As well as contributing to physiological processes, Rho GTPases have been 
found to contribute to pathological processes including cancer cell migration, 
invasion and metastasis, inflammation, and wound repair (Jaffe and Hall 2005, 
Aspenstrom et al. 2007).  
 
Association with cancer 
 
 Rho GTPases have been reported to contribute to most steps of cancer 
initiation and progression including the acquisition of unlimited proliferation potential, 
survival and evasion from apoptosis, tissue invasion and the establishment of 
metastases (Sahai and Marshall 2002, Vega and Ridley 2008).  
 Activating mutations in the Ras proteins are found in 30% of all human 
tumours (Schubbert et al. 2007). In contrast, Rho proteins are only rarely mutated in 
tumours, whereas their expression and/or activity are frequently altered (Gomez del 
Pulgar et al. 2005). 
 Some Rho GTPases stimulate cell cycle progression and regulate gene 
transcription, and this could in part explain their pro-oncogenic properties, for 
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example in promoting Ras-induced transformation (Benitah et al. 2004). The induction 
of tumour vascularisation is essential for tumours to grow beyond a certain size and 
malignant cells release factors that promote angiogenesis from nearby pre-existing 
blood vessels. Some Rho GTPases are thought to be able to regulate the release of 
pro-angiogenic factors to promote neovascularisation (Merajver and Usmani 2005). 
 Invasion of epithelial cancers is initiated when the integrity of the epithelium is 
disrupted and malignant cells disrupt the basement membrane and enter the 
underlying stroma. This normally implies loosening of epithelial cell–cell contacts and 
acquisition of a more motile phenotype in a process frequently referred as epithelial 
to mesenchymal transition (EMT) (Lozano et al. 2003, Watanabe et al. 2005, Vega and 
Ridley 2008). Rho and Rac have an antagonistic function to control actin 
microfilament dynamics. They affect polymerization of new filaments as well as their 
contractility via phosphorylation of the myosin light chain (Sanders et al. 1999). RhoA 
promotes actin-myosin contractility and, thereby, the formation of stress fibres and 
focal adhesions (Amano et al. 1997), regulating cell shape, attachment and motility. 
Rac1 promotes actin polymerization and the formation of lamellipodia (Ridley et al. 
1992), which are curtain-like extensions that consist of thin protrusive actin sheets at 
the leading edge of migrating cells (Wennerberg and Der 2004). 
 Cancer cells can invade into tissues either as single cells or as cell groups 
(collective cell migration). Single cells have been described to use two alternative 
migratory mechanisms: mesenchymal and amoeboid migration. Cells using 
mesenchymal migration have an elongated morphology and extend long protrusions 
at the front (via Rac1). Integrin-based adhesions and strong traction are the driving 
forces for movement in addition to extracellular matrix (ECM) degradation by 
secreted and/or transmembrane proteases (Sahai and Marshall 2003, Friedl and Wolf 
2003). In contrast, amoeboid migration is generally independent of extracellular 
protease activity and is driven by actomyosin-based cortical contraction (via RhoA), 
and cells have a more rounded shape. In collective cell invasion, cells move in 
groups through the extracellular matrix and maintain cell–cell adhesions. A leading 
cell at the tip of the group generates the migratory traction necessary for movement 
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and the cells at the back and middle of the group are mostly dragged passively. 
Degradation of the ECM by matrix metalloproteases (MMPs) is essential for this kind 
of collective migration (Wolf et al. 2007).  
 To establish metastases in distant tissues, tumour cells have to enter the 
vascular or lymphatic system, then exit it and proliferate in the new tissue. The ability 
of Rho GTPase family members to regulate cytoskeletal dynamics, cell adhesion and 
cell migration points to a central role in cancer cell invasion and metastasis (Vega and 
Ridley 2008).  
 
The small GTPase Rac1 
 
 Rac1 small GTPase is a member of the Rac subfamily of Rho GTPases, 
which also includes Rac2, Rac3 and RhoG (Fig. 1.6) (Boureux et al. 2007). Rac1 is 
ubiquitously expressed and was initially discovered as Ras-related C3 botulinum 
toxin substrate 1 in 1989 (Didsbury et al. 1989). As a small GTPase, Rac1 protein acts 
as a binary switch, cycling between two conformational states, an inactive GDP-
bound form and an active GTP-bound form (Jaffe and Hall 2005). GTP binding induces 
conformational changes that allow it to activate specific signalling pathways. The 
conformational changes are particularly evident in two short and flexible loop 
structures designated as the switch I and switch II regions (Vetter and Wittinghofer 
2001). These regions not only serve as binding domains for both regulatory and 
effector proteins but also contain amino acid residues required to catalyze the 
hydrolysis of GTP. In vivo, the transition between the active and inactive states of 
Rac1 occurs at the plasma membrane following appropriate cellular signals and is 
tightly controlled and spatially regulated by GEFs (which promote exchange of GDP 
for GTP), GAPs (which enhance the intrinsic GTPase activity) and Rho-GDIs (which 
bind to and remove Rac1 from the plasma membrane, keeping it inactive in the 
cytoplasm and blocking its activation by GEFs). External stimuli, such as activation 
of growth factor receptors or engagement of cell adhesion molecules, determine the 
activity of GEFs, GAPs and GDIs and thus the activation of Rac1 (Buchsbaum 2007). 
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Functions and contributions to cancer 
 
 Once in the active state, Rac1 interacts with specific effector proteins that 
coordinate activation of a multitude of signalling cascades that influence diverse 
physiological outcomes, such as actin cytoskeletal reorganization, cell 
transformation, the induction of DNA synthesis, superoxide production, axonal 
guidance, and cell migration (Fig. 1.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Rac1 signalling model. Rac1 acts as a signal transducer by receiving information via 
activated GEFs from a variety of extracellular stimuli such as receptor kinases, G-protein-coupled 
receptors or integrins. The GTP-bound Rac1 adopts an active conformation capable of binding 
effector molecules that regulate diverse cellular functions such as cytoskeleton remodelling, 
microtubule stability, gene transcription and superoxide production. (adapted from Bosco et al. 2009) 
 
 Activated Rac1 initiates signalling pathways, which regulate actin cytoskeletal 
dynamics and gene transcription. For example, active Rac1 binds to PAK (p21 
activating kinase) and stimulates its protein kinase activity (Manser et al. 1994). 
Activated PAK inhibits myosin light chain kinase (MLCK) and the consequent 
dephosphorylation of myosin light chain leads to the disassembly of stress fibres and 
focal adhesion complexes (Manser et al. 1997). Also, via its effector LIM kinase, PAK 
can lead to the phosphorylation of actin-regulatory protein cofilin (Edwards et al. 1999), 
which polymerizes actin, generates protrusions, and determines the direction of cell 
migration (Ghosh et al. 2004). Furthermore, active Rac1 induces the activation of 
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WAVE-2 and -1 proteins, which stimulate the Arp2/3 complex leading to the 
polymerization of new actin filament branches and lamellipodium formation (Miki et al. 
2000, Eden et al. 2002).  
 The effect of Rac1 on actin polymerization is involved in several processes. 
First, it regulates the integrin-mediated turnover of focal complexes that is required 
for cell spreading and migration (Nobes and Hall 1999, Kiosses et al. 2001, Small et al. 
2002). Second, it is involved in the assembly and stability of E-cadherin based 
adherens junctions (Braga et al. 1997, Nakagawa et al. 2001) thereby inhibiting the 
migration of epithelial cells (Hordijk et al. 1997, Fukata and Kaibuchi 2001). Third, as key 
regulator of cell migration during wound healing, early development and tumour cell 
invasion (Ridley 2001). 
 Activated Rac1 also stimulates transcription factors and gene expression, for 
example following its activation of the Jun NH2-terminal kinase (JNK) cascade (Coso 
et al. 1995), or of the transcription factor NF!B (Perona et al. 1997). The pathway that 
links Rac1 to NF!B involves the production of reactive oxygen species (ROS) and 
occurs in epithelial cells via NOX1 during Rac1-induced mitogenesis (Sulciner et al. 
1996, Joneson and Bar-Sagi 1998, Park et al. 2004). Rac1-stimulated ROS formation 
activates NF!B leading to increased cyclin D1 expression and subsequent cell cycle 
progression (Joyce et al. 1999, Hinz et al. 1999, Guttridge et al. 1999), independent of the 
ERK or JNK kinase cascade (Lamarche et al. 1996). 
 So far little is known about the role of Rac1 in cancer progression in vivo. 
Rac1 knockout in mice is embryonic lethal (Sugihara et al. 1998) but conditional 
knockout mice have been studied extensively (Walmsley et al. 2003, Benninger et al. 
2007). In a conditional lung cancer mouse model Rac1 function was required for K-
Ras-driven proliferation and tumorigenicity (Kissil et al. 2007). Similarly, mice lacking 
the Rac-specific GEF Tiam1 are protected from Ras-induced skin cancer, developing 
fewer tumours, although the tumours that do form are more aggressive (Malliri et al. 
2002). 
 Rac1 could contribute to cancer cell proliferation via modulation of anti-
apoptotic and cell cycle machineries. Rac1 positively regulates transcription at NF!B 
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transcription factor-dependent promoters (Perona et al. 1997) and facilitates 
phosphatidylinositol-3 kinase (PI3K)-dependent activation of AKT serine/threonine 
kinase (Keely et al. 1997, Rul et al. 2002), thereby permitting the survival of 
transformed cells. Rac 1 also stimulates cell cycle progression by increasing cyclin 
D1 expression, and inducing cell transformation in vitro (Benitah et al. 2004, Jaffe and 
Hall 2005). It is likely to inhibit cancer invasion through its ability to enhance epithelial 
cell-cell adhesion. However, active Rac1 can also mediate the loss of adherens 
junction, promoting a more migratory phenotype, and thus could promote or inhibit 
tumour cell invasion depending on the cell background (Sander et al. 1998, Engers et 
al. 2001, Mertens et al. 2005, Espina et al. 2008). Rac1 is necessary for the generation 
of lamellipodial protrusions during mesenchymal migration, as well as for the 
amoeboid migration of Ras-transformed cells (Friedl and Wolf 2003). Rac1 can also 
contribute to cancer cell invasion by regulating the production of MMPs and their 
natural inhibitors, the tissue-specific inhibitors of MMP (TIMPs) (Engers et al. 2001, 
Lozano et al. 2003). 
 Recently, the alternative splice variant Rac1b has been identified in normal 
tissues and tumours (Jordan et al. 1999, Schnelzer et al. 2000). Interestingly, Rac1b 
differs significantly in both regulation and downstream signalling from Rac1. Below, I 
will focus on the characteristics of Rac1b and its possible function in tumorigenesis. 
 
Rac1b, the alternative splice variant of Rac1 
 
 When the expression of the small GTPase Rac1 was studied by RT-PCR in 
colorectal tumour samples, an unknown second Rac1-specific transcript was found 
and termed Rac1b (Jordan et al. 1999, Schnelzer et al. 2000; Genbank Accession 
numbers AJ132694 and NM_018890).  
 Human Rac1b transcripts can be amplified from a variety of normal epithelial 
tissues but are usually less abundant than the Rac1 transcripts. Most notably, 
increased expression of Rac1b was observed in colorectal tumours (Fig. 1.9A) 
(Jordan et al. 1999). This splice variant was found exclusively in amniotes and its 
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conservation indicates that Rac1b was positively selected and calls for specific 
physiological function (Boureux et al. 2007). 
 Rac1b differs from Rac1 in 57 nucleotides that were shown to correspond to 
an additional exon 3b located between exons 3 and 4 of the human RAC1 gene (Fig. 
1.9B). When exon 3b becomes included through alternative splicing into the Rac1 
messenger RNA, the resulting Rac1b protein contains 19 additional amino acids in 
frame between codons 75 and 76 of Rac1 (Fig. 1.9C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: (A) Detection of Rac1 and Rac1b by RT-PCR in various normal human tissues (left 
panel) and its increased expression in colorectal tumours (right panel); Tum: tumour, Muc: 
adjacent normal mucosa, Meta: colorectal tumour metastasis in the liver, Liv: adjacent normal liver, 
HT29: colorectal cell line. (B) Schematic representation of the human RAC1 gene on 
chromosome 7p22. Bars represent the 7 coding exons, including the alternative spliced exon 3b; utr: 
untranslated region, pA: polyadenylation sites. (C) Schematic representation of the Rac1 protein. 
The best characterised domains are represented as dark boxes. The position and sequence of the 
additional 19 amino acids, which are included in Rac1b, is indicated. 
 
Altered regulation and downstream signalling  
 
 Rac1b endogenous levels of protein are quite low compared to Rac1 (Fig. 
1.10). By densitometric analysis of Western blots stained with anti-Rac1, it was 
estimated that HT29 colorectal cells express over 20 times more Rac1 than Rac1b 
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protein. However, the total GTPase amounts expressed in a cell do not necessarily 
reflect how much of it exists in the active, GTP-bound conformation. When the 
corresponding pools of active Rac1 and Rac1b molecules in colorectal tumour cells 
were compared using CRIB-domain pull-down assays as described (Price et al. 2003, 
Matos et al. 2003, Matos and Jordan 2006), the proportion of active Rac1b was found to 
be very high (Fig. 1.10). For example, in the Rac1b-expressing cell line HT29, active 
Rac1b actually exceeded the amount of active Rac1 by up to 3-fold. This disparity 
between the absolute and the activated amounts of Rac1b in these cells promptly 
suggested that the inclusion of the alternative exon 3b during splicing somehow 
affected GTPase regulation and generated a highly activated variant.   
 
 
 
 
 
 
 
 
 
Figure 1.10: Expression of endogenous Rac1b in human cell lines. The endogenous expression 
of Rac1b from breast (T47D, ZR75.1, MCF7), colon (HT29, SW480) and cervix (HeLa) as well as in 
NIH 3T3 mouse fibroblasts was detected as indicated on the left by RT-PCR or by Western blot using 
a Rac1b-specific anti-peptide serum ($-Rac1b) or a commercial monoclonal anti-Rac1 antibody ($-
Rac1) that recognizes both Rac1 and Rac1b. In addition, CRIB-domain pull-down assays are shown 
to demonstrate the amount of active GTP-bound Rac1 and Rac1b in these cell lines. 
 
 Concerning the regulation of Rac1b, it was found that the activation of this 
splice variant was still downregulated by the presence of GAP proteins both in vivo 
(Matos et al. 2003) and in vitro (Fiegen et al. 2004, Singh et al. 2004). Published data 
differ concerning the requirement of GEF proteins for Rac1b activation. In vitro data 
suggest that Rac1b is activated independent of GEFs and acts like a constitutively 
active Rac1 mutant. However, cells cultivated in the absence of serum or treated 
with inhibitors that block GEF-activating pathways, such as PI3-kinase or tyrosine 
phosphorylation, led to loss of active Rac1b (Matos et al., 2003; Matos and Jordan, 
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2005). In cell lysates, an interaction between Rac1b and a constitutively active form 
of Tiam1 (C1199) was detected by co-immunoprecipitation (Matos et al. 2003) or pull-
down assays (Singh et al. 2004). Interestingly, Rac1 only associates with Tiam1 in a 
nucleotide-free (NF) intermediate form whereas both NF and GTP-bound forms of 
Rac1b associate with Tiam1 (Singh et al. 2004). It is possible that in vivo Rac1b does 
not require GEFs for the GDP/GTP exchange, but rather to stabilize the active GTP-
bound conformation. Clearly, Rac1b differs from Rac1 in the activation step involving 
GTP binding. Whether this is a matter of different kinetics of activation in vivo or a 
lack of requirement for GEF activity remains to be clarified. Interestingly, another 
important difference in Rac1b regulation was found at the level of binding to Rho-
GDI. The 19 additional amino acids following the switch II region disturb the binding 
to the C-terminal sandwich domain of Rho-GDI (Scheffzek et al. 2000), and thus 
Rac1b cannot be removed from the plasma membrane by Rho-GDI, leaving it in a 
continuously favourable position to interact with membrane recruited GEFs. 
Consequently, minimal growth stimulation with 0.25% serum was found sufficient to 
elicit a significant activation of Rac1b but not of Rac1 (Matos and Jordan 2005). 
 Structure analysis of crystallized Rac1b showed that the overall nucleotide-
bound structures of Rac1 and Rac1b are very similar. However, the 19 amino acid 
insertion induces a drastic displacement of the switch I region into an open 
conformation and away from the nucleotide binding site. In addition, the switch II 
loop with the adjacent 19 extra amino acids had a high structural mobility that made 
it impossible to determine the exact folding. In biochemical terms, these 
conformational changes in Rac1b translate into a much higher rate of nucleotide 
dissociation and a decreased rate of GTP hydrolysis, consistent with the biochemical 
data on recombinant Rac1b and with the predominant activation detected in vivo 
(Fiegen et al. 2004). 
 Not only the Rac1b regulation is altered but also its downstream signalling. Its 
signal transduction pathways linked to actin re-arrangement, a well-known effect of 
Rac1 activation, is impaired. Furthermore, Rac1b was found impaired in the ability to 
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bind and activate PAK1, or to stimulate the activation of JNK, two other well-
established Rac1 signalling pathways (Matos et al. 2003).  
 In contrast, Rac1b retained the ability to stimulate the NF!B pathway by 
inducing I!B$ phosphorylation and nuclear translocation of RelA (Matos et al. 2003). 
The expression of active Rac1b in colorectal cells stimulated transcription from a 
luciferase reporter promoter containing consensus NF!B binding sites and this 
activity was dependent on the formation of reactive oxygen species (ROS). 
Interestingly, Rac1b only stimulates the classical RelA-dependent NF!B activity, 
whereas Rac1 stimulates also a second RelB-dependent NF!B pathway, which may 
interact in a potential negative feedback regulation (Matos and Jordan 2005, Matos and 
Jordan 2006). Expression of wild type Rac1b was also found to activate the 
serine/threonine kinase AKT in fibroblasts (Singh et al. 2004) (although these results 
could not be confirmed in our lab). 
 Overall, these data indicate that Rac1b is not just a hyperactive form of Rac1, 
but is also selective in downstream signalling. The signalling activities detected so 
far for Rac1b correspond to a subset of Rac1-regulated pathways. Whether Rac1b-
specific effectors exist that do not interact with Rac1, or whether GEFs can 
discriminate between Rac1 and Rac1b remains to be determined. An important 
question is whether and how the subset of signalling pathways activated by Rac1b 
can contribute to tumorigenesis.   
 
Role of Rac1b in tumorigenesis 
 
 Consistent with the previously described role of Rac1 in NF!B-stimulated 
cyclin D1 expression (Perona et al. 1997, Joyce et al. 1999), the over-expression of wild 
type Rac1b in NIH 3T3 fibroblasts stimulated transcription from a cyclin D1-promoter 
construct and accumulation of endogenous cyclin D1 protein as well as increased 
cell cycle progression (Matos and Jordan 2005, Matos and Jordan 2006). Furthermore, 
minimal serum stimulation with 0.25% serum was sufficient to activate wild-type 
Rac1b and protect expressing cells from starvation-induced apoptosis. In agreement 
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with these data, Rac1b was shown to promote the transformation of NIH 3T3 cells 
when co-expressed with activated Raf-1(Y340D), leading to loss of density- and 
anchorage-dependent growth inhibition that causes focus formation in monolayer 
cultures and colony formation in soft agar (Singh et al. 2004). Recently, it was also 
found in colorectal cells that depletion of Rac1b by small interfering RNAs inhibited 
endogenous NF!B activation and reduced cell viability to 50% within 48 hours. This 
reduction was due to increased apoptosis, although a reduced G1-S progression rate 
was also observed. These data show, for the first time, that colorectal cells 
expressing alternative spliced Rac1b also depend on Rac1b signalling to sustain 
their survival (Matos and Jordan 2008). 
 In addition, it was found that Rac1b and B-RafV600E (an activating mutation of 
B-Raf present in some colon tumours) functionally cooperate to sustain colorectal 
cancer cell survival and suggest they constitute an alternative survival pathway to 
oncogenic K-Ras (Matos et al. 2008). The presence of mutation in either B-Raf or K-
Ras characterizes molecularly distinct sub-classes of colorectal tumours: B-Raf 
mutations occur in mainly proximal tumours with high levels of microsatellite 
instability and an intense methylation of multiple genes, the CpG island methylator 
phenotype (CIMP) 1 group (Shen et al. 2007). In contrast, K-Ras mutations are found 
in microsatellite-stable tumours with occasional gene methylation, the CIMP 2 group 
(Shen et al. 2007). The results thus characterize a molecular pathway sustaining 
cancer cell proliferation in a subtype of colorectal tumours that complements the 
previously identified CIMP1 subclassification (Matos et al. 2008). 
 Besides promoting cell proliferation and survival, a role for Rac1b in epithelial-
mesenchymal transition (EMT) and malignant transformation of mouse mammary 
epithelial cells has been reported. When these cells were exposed to stromelysin-
1/matrix metalloproteinase-3 (MMP-3), a stromal protease upregulated in many 
breast tumours, Rac1b expression was induced and promoted increased ROS 
production. ROS promoted both genomic instability and expression of the 
transcription factor Snail, which represses E-cadherin transcription leading to cell 
scattering and EMT (Radisky et al. 2005). Interestingly, two pathways known to be 
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activated by Rac1b, namely AKT and p50/RelA NF!B, have been described to 
upregulate Snail expression and promote subsequent EMT (Barbera et al. 2004). The 
extracellular matrix composition may further modulate the extent and duration of 
Rac1b activation, similar to what has been described for Rac1 (Sander et al. 1998). 
When HT29 cells were seeded on laminin-5 a transient increase in Rac1b activation 
was observed that correlated with adherens junction assembly (Chartier et al. 2006).  
 Rac1b has also been described to facilitate tumour progression of colorectal 
cancer cells by enhancing Dishevelled-3-mediated Wnt pathway signalling (Esufali et 
al. 2007), leading to increased "-catenin/Tcf-dependent transcription of target genes 
important for tumorigenesis (Korinek et al. 1997). In addition, it was found that Rac1b 
decreases membrane E-cadherin expression and reduces adhesion of these cells, 
likely via upregulation of Slug (Esufali et al. 2007), the E-cadherin-specific 
transcriptional repressor that has been reported to be a Wnt target gene (Vallin et al. 
2001). 
 A further contribution of Rac1b to cell transformation may result from its 
selective activation of the NF!B pathway. The p50/RelA NF!B pathway has recently 
been shown to require a second IKK$-dependent pathway to ensure termination of 
the gene activation response during inflammation. Only Rac1 activates this second 
RelB-mediated pathway but not Rac1b. If a similar regulatory network operates in 
colorectal and breast tissues, expression of Rac1b would continuously stimulate the 
p50/RelA NF!B-mediated transcription without inducing the RelB-mediated negative 
feedback mechanism. 
 In summary, experiments in tumour cell models have demonstrated that 
Rac1b can contribute to NF!B-mediated cell proliferation and survival, and to 
malignant progression by promoting EMT and ROS-induced DNA damage. Indeed, 
Rac1b was found to be overexpressed in breast (Schnelzer et al. 2000) and a 
subgroup of colon cancer (in colorectal tumours, the highest levels of Rac1b 
expression were found in metastases) (Jordan et al. 1999). Recently it was also found 
that this splice variant is less susceptible than Rac1 to ubiquitination and degradation 
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(Visvikis et al. 2008), and this could also contribute to its increased expression in 
cancers. 
 It is important to remember that Rac1b is not exclusively detected in tumour 
cells but is also expressed in various epithelial tissues, albeit at lower levels (Jordan 
et al. 1999). This indicates a role for Rac1b in normal epithelial physiology. 
Considering the reported properties of Rac1b, one could speculate that it is 
expressed in proliferative progenitor cells that are involved in the renewal of epithelial 
cell layers, for example in colon crypts (Radtke and Clevers 2005). These progenitor 
cells derive from tissue stem cells and have a high proliferative activity with little 
epithelial differentiation. In addition, the EMT-promoting activity of Rac1b may 
indicate a role during embryonic development.  
 
 
Objectives 
 
 On the basis of the described evidence and considering the absence of 
oncogenic Rac1 mutations in tumours, it is tempting to speculate that changes in 
alternative splicing of Rac1 may represent an alternative mechanism to deregulate 
Rac signalling during tumour progression. The published data on the properties of 
Rac1b in cell lines indeed support this idea: Rac1b stimulates G1/S progression, cell 
survival, cell transformation and ROS-mediated genomic instability.  
 Thus, an alternative splicing event may represent a specific therapeutic target 
for some tumours and this raises the question on how changes in alternative splicing 
of Rac1 can be caused. The molecular analysis of this alternative splicing event was 
the aim of the work presented in this thesis and the following objectives were 
established: 
! Determine the regulatory sequence elements that influence the alternative 
exon3b inclusion/exclusion. 
! Ascertain which splicing factors could be involved in the recognition of these 
regulatory sequence elements. 
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! Identify whether oncogenic signalling pathways act upon the expression 
and/or activity of these splicing factors. 
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Summary 
 
 The small GTPase Rac1 regulates signalling pathways controlling actin-
dependent cell motility as well as gene transcription. An alternative splicing variant 
Rac1b is overexpressed in a subset of colorectal tumours and is required to sustain 
tumour cell viability. Thus, it is of therapeutic interest to understand the molecular 
mechanism behind the overexpression of Rac1b through alternative splicing. Here 
we describe that ASF/SF2 and SRp20 are two antagonistic splicing factors regulating 
Rac1b expression in colorectal tumour cells. Using a Rac1 minigene we identified 
that SRp20 increased skipping of alternative exon 3b in HT29 colorectal cells, while 
ASF/SF2 increased its inclusion. Depletion of the endogenous expression of these 
splicing factors by specific siRNAs confirmed that ASF/SF2 acts as an enhancer of 
endogenous Rac1b splicing whereas SRp20 acts as a silencer. Point mutations in 
exon 3b defined two adjacent regulatory regions required for skipping or inclusion of 
exon 3b, which are recognized in vitro by SRp20 and ASF/SF2, respectively. Both 
splicing factors were found to be regulated by upstream signalling pathways: 
inhibition of the PI3-kinase pathway increased protein levels of ASF/SF2 and 
promoted Rac1b, whereas activation of "-catenin/TCF4 increased expression of 
SRp20 and inhibited that of Rac1b. Together, these data reveal that signalling 
pathways act in concert to target independent splicing factors and achieve the 
correct combinatorial code to regulate alternative splicing of the small GTPase Rac1. 
 
 
Introduction 
 
 The expression of human genes involves their transcription into a pre-
messenger RNA that is further processed to splice out intron and join exon 
sequences. It is now well documented that the majority of human genes can produce 
more than one mature messenger RNA (mRNA) through alternative patterns of 
intron removal or exon skipping (Modrek and Lee 2002, Blencowe 2006, Ben-Dov et al. 
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2008). This allows the synthesis of multiple mRNAs from a single gene and these 
transcripts can differ in mRNA stability and translation or encode protein variants 
with altered functional properties. In particular, alternative spliced exons frequently 
code for unstructured peptide regions and thus may modify function or regulation of a 
protein without affecting its structural integrity (Romero et al. 2006). Hence, the 
process of alternative splicing increases the functional complexity of gene 
expression from a genome. At present no simple structure/function prediction exists 
to provide evidence of biological relevance for a given alternative spliced variant, but 
many examples have been described of individual variants with novel protein 
properties (e.g. reviewed in Schwerk and Schulze-Osthoff 2005, Venables 2006, Srebrow 
and Kornblihtt 2006).  
 One striking example is alternative splicing of the small GTPase Rac1, a 
member of the Rho family controlling signalling pathways that regulate the actin 
cytoskeleton and gene transcription (Wennerberg and Der 2004, Jaffe and Hall 2005). 
When in the active GTP-bound conformation, Rac1 interacts with downstream 
effector proteins and activates signalling cascades. In tumours, Rac1 activation is 
known to become deregulated (Sahai and Marshall 2002) and one recently unravelled 
mechanism is through increased expression of alternative spliced Rac1b in 
colorectal or breast tumour samples (Jordan et al. 1999, Schnelzer et al. 2000). Rac1b 
differs in 57 nucleotides resulting from the in-frame inclusion of alternative exon 3b 
(Matos et al. 2000). The resulting Rac1b protein adopts predominantly the active GTP-
bound conformation in cells. This reflects altered regulatory properties due to an 
increased intrinsic nucleotide exchange activity, a decreased rate of GTP hydrolysis, 
and a failure to interact with Rho-GDI, a major downregulating factor in vivo 
(Schnelzer et al., 2000; Matos et al., 2003; Fiegen et al., 2004; Singh et al., 2004; Radisky et 
al., 2005). Furthermore, the variant Rac1b displays unique signalling properties. It 
does not stimulate several classical Rac signalling pathways, including lamellipodia 
formation or the activation of protein kinases PAK1 or JNK. However, Rac1b retains 
the ability to stimulate the NF!B pathway (Matos and Jordan 2005, Matos and Jordan 
2006), which initiates an anti-apoptotic transcriptional response and also promotes 
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cell cycle progression by an increase in cyclin D1 expression (Hinz et al. 1999, 
Guttridge et al. 1999, Perona et al. 1997, Joyce et al. 1999).  
 These different functional properties are apparently selected for in some 
tumour cell types. For example, Rac1b promoted epithelial-mesenchymal transition 
(EMT) of mouse mammary epithelial cells (Radisky et al. 2005) and contributed to 
further activate Wnt signalling in HCT116 colorectal cells (Esufali et al. 2007). In 
addition, some colon tumours that carry the oncogenic B-RafV600E mutation depend 
on increased Rac1b expression to sustain tumour cell survival (Matos and Jordan 
2008, Matos et al. 2008). However, the molecular details of how changes in alternative 
splicing lead to Rac1b overexpression remain unclear. 
 Alternative splicing events can be modulated by changes in the protein levels 
of individual splicing factors. For example, the relative concentrations of SR proteins 
and hnRNP factors expressed in a given cell will affect splice site choices in those 
pre-mRNAs containing respective regulatory elements (Eperon et al. 2000, Smith and 
Valcárcel 2000, Singh and Valcárcel 2005). Altered expression of splicing factors was 
also described in various tumour types (Ghigna et al. 1998, Stickeler et al. 1999, 
Venables 2004). In addition, splicing factors can be regulated through post-
translational modification in response to cellular signalling pathways. For example, 
activation of the p38-MAPK pathway led to phosphorylation of hnRNP A1, resulting 
in its cytoplasmic sequestration and altered splicing of an adenovirus reporter gene 
(van der Houven van Oordt et al. 2000). Also, phosphorylation of SRp40 by AKT2 has 
been shown to regulate alternative splicing of protein kinase C "II (Patel et al. 2005, 
Jiang et al. 2008) and the phosphatidylinositol-3 (PI3)-kinase pathway mediates 
alternative splicing of fibronectin in response to growth factor stimulation (Blaustein et 
al. 2004).  
 These examples provide a mechanistic framework for how alternative spliced 
variants can be generated in response to signalling pathways, however, our limited 
understanding about these events derives from a careful analysis of candidate gene 
examples. In this manuscript, we present a further concept for the signalling-splicing 
connection in which the combination of two oncogenic signalling pathways acts on 
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antagonistic SR proteins. We dissected the molecular regulation of Rac1 alternative 
splicing in colorectal cancer cells and found that ASF/SF2 and SRp20 exhibit 
antagonistic effects on alternative spliced exon 3b, both in the context of a minigene 
and the endogenous transcript. The data lead us to propose a model for the genetic 
tumour context in which overexpression of Rac1b can be selected for to promote 
colon tumorigenesis. 
 
 
Experimental procedures 
 
Cell culture and transfection 
 DLD-1 and SW480 colorectal cells were maintained in DMEM supplemented 
with 10% (v/v) fetal calf serum (FCS) (Invitrogen) whereas HT29 cells were grown in 
RPMI. Cell lines were regularly checked for absence of mycoplasm infection. Cells 
were grown in 35-mm dishes to 60-80% confluence, transfected using 
LipofectAMINE 2000 (Invitrogen), according to the manufacturer!s instructions, and 
analyzed 16-20 h later. Total amounts of transfected DNA were 2 µg of DNA per dish 
for DLD-1 and SW480 cells or 4 µg for HT29 cells. If required, the amount of DNA 
was adjusted with empty vector. Plasmid transfection efficiencies were judged 
microscopically by expression of 2 µg of GFP and reached 60-80% in DLD-1 and 
SW480 cells or 40-60% in HT29 cells. For RNA interference experiments, HT29 cells 
at 30-40% confluence were transfected in 35-mm dishes with 400 pmol of the 
indicated siRNAs using LipofectAMINE 2000 and analyzed after 48 h. The siRNA 
oligos were ordered from MWG Biotech (Ebersberg, Germany) with the following 
sequences: control siGFP: 5!-GGC UAC GUC CAG GAG CGC ACC TT; siSRp55A: 
5&-GCA GAU CUA AGG AUG AGU A; siSRp55B: 5&-GCA GGU GAA GUA ACC UAU 
G; siSRp20A: 5!-GAG UGG AAC UGU CGA AUG G; siSRp20B: 5!-GAG CUA GAU 
GGA AGA ACA C; siSF2A: 5!-AGA AGA UAU GAC CUA UGC A; siSF2B: 5!-GCA 
GGU GAU GUA UGU UAU G; si9G8A: 5!-AGA UCA AGA UCC AGG UCU A; 
si9G8B: 5!-ACA CUC CAU GUA GCU AAU A. For inhibition of signalling pathways, 
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cells were treated for 24 h with 2 µM U0126, 1 µM SB203580 or 10 µM LY294002 
(all from Sigma and dissolved in DMSO). 
 
DNA constructs 
 The following previously published constructs were used: HA-tagged TBP 
(Jordan et al. 1996); HA-tagged U2AF65 (Gama-Carvalho et al. 1997), and U2AF35 
(Pacheco et al. 2006); Myc-tagged hnRNPA1 (Matter et al. 2000); T7-tagged constructs 
of SC35, SRp55, SRp40, SRp30, SRp20, ASF/SF2 and 9G8 (Cáceres et al. 1997); 
dominant negative TCF4 (TCF-DN) and constitutively active  "-catenin ("Cat-CA) 
(Gonçalves et al. 2008); pCMV-PTEN (Huang et al. 2001); kinase-dead AKT mutant HA-
PKB-K179A (Burgering and Coffer 1995; recloned as a BglIII/EcoRI fragment into 
pEGFP); kinase-dead Flag-p38 mutant K53M (Ludwig et al. 1998); Myc-JNK 
(Rennefahrt et al. 2002; recloned as BamHI/XbaI fragment from pRev-TRE 
SAPKbeta/MKK7 following site-directed mutagenesis into kinase-dead mutant 
K56R/K57R); splicing reporter minigenes PTB-pG11 (Spellman et al. 2005) and FAS 
(Förch et al. 2000); All constructs were confirmed by automated DNA sequencing.  
 For the RAC1 minigene construct, a previously described 4.3 kb fragment 
containing intron 3 and the adjacent ends of exons 3 and 3b (Matos et al. 2000) was 
first subcloned into pCR-XL-TOPO (Invitrogen). Exon 3 was then complemented by 
exchanging a BamHI/BsmI fragment amplified from BAC clone RP11-425P05 with 
primers RACBAMEX3-F (5!-GGA TCC TTT GAC AAT TAT ACT TCT GCC AAT G) 
and RACINT3-BSMR (5!-CAG ACA CTG GTA TCT GAG CAT CTG T). Intron 3b and 
exon 4 were added to this construct as an NsiI fragment amplified from BAC clone 
RP11-425P05 with primers Not-Int3-F (5'-GCG GCC GCC GAT AAG AGG TTA TAT 
TGA) and RACEX4NOT-R (5!-GCG GCC GCT TTG CAC GGA CAT TTT CAA ATG). 
The assembled genomic region between exon 3 and exon 4 of the human RAC1 
gene was then cloned as a BamHI/NotI fragment into a pcDNA3-HA vector to 
generate the RAC1 minigene. Conserved nucleotides in exon 3b of RAC1 minigene 
were mutated using the QuickChange site-directed mutagenesis kit (Stratagene) 
following the manufacturers instructions. 
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Nucleic acid amplifications, semi-quantitative and Real-Time RT-PCR 
 Genomic DNA was extracted from SW480, DLD-1 and HT29 cells using the 
Wizard DNA Extraction Kit (Promega) and a RAC1 gene fragment encompassing 
286 bp upstream and 224 bp downstream of exon 3b was amplified with primers 
Int3KSP-F1 (5'-GCG GCC GCT TAC CCA CCG GCT TGA ATT A) and RacInt3b-R2 
(5'-GCT GCC TGT CAC AGC TCC CA). 
 Total RNA was extracted from cell lysates with the RNAeasy kit (Qiagen) and 
1 µg reverse transcribed using random primers (Invitrogen) and Ready-to-Go You-
Prime Beads (GE Healthcare, Buckinghamshire, UK). Transcript expression was 
analysed by RT-PCR with the following specific primers: for endogenous 
Rac1/Rac1b: Ex3F (5! GGA TCC TTT GAC AAT TAT TCT GCC AAT G) and Ex4R 
(5! CGG ACA TTT TCA AAT GAT GCA GG); for RAC1 minigene transcripts: 
HABamF (5! CAT GAT CGA CTA CGA CGT TCC TGA TTA TGC GG) combined with 
either reverse primer Jun3/4R (5! ACA AGC AAA TTG AGA ACA CAT CTG TT)) for 
exon 3+4 transcripts, or with Ex3bR (5! ATA TCC TTA CCG TAC GTT TCT CCA A) 
for exon 3+3b+4 transcripts, or with Ex4NotR (5! GCG GCC GCT TTG CAC GGA 
CAT TTT CAA ATG) for both transcripts; for PTB-derived pG11 minigene: pG-F (5! 
GGC AAA GAA TTC GCC ACC A) and FP-R (5! GAA CTT CAG GGT CAG CTT 
GC); for FAS minigene: PT1 (5' GTC GAC GAC ACT TGC TCA AC) and PT2 (5' 
AAG CTT GCA TCG AAT CAG TAG); for 9G8: 9G8F (5! TGC AGT ACG AGG ACT 
GGA TG) and 9G8R (5! CCG TGA CCT GCT TCT TCT TC); for ASF/SF2: ASF/SF2F 
(5! GCG ACG GCT ATG ATT ACG AT) and ASF/SF2R (5! ATC CTG CCA ACT TCC 
ACT TG); for SRp20: SRp20-F (5' AAC AAG ACG GAA TTG GAA CG) and SRp20-R 
(5' TGG GCC ACG ATT TCT ACT TC); and for RNA polymerase II (Pol II): Pol II-F 
(5!-GAG CGG GAA TTT GAG CGG ATG C) and Pol II-R (5!-GAA GGC GTG GGT 
TGA TGT GGA AGA). Amplification reactions were performed using AmpliTaq 
polymerase (Perkin-Elmer, Wellesley, MA, USA) at 60ºC for 30 cycles for 
endogenous Rac1/Rac1b, minigene (RAC1, pG11, or FAS)-derived transcripts, 9G8, 
ASF/SF2 and SRp20, and at 66ºC for 28 cycles for Pol II. All reactions included an 
initial denaturation of 5 min at 94ºC and a final extension of 10 min at 72ºC, and 
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each cycle contained 30 sec of denaturation and extension. Semi-quantitative 
analyses of transcript levels were established by using serial dilutions of control 
cDNAs in order to determine the linear amplification phase for each PCR reaction. 
Products were separated on 2% agarose gels stained with ethidium bromide, images 
recorded digitally and band intensity quantified using ImageJ software followed by 
normalization to Pol II expression levels. Real-time PCR quantification was 
performed on an ABI Prism 7000 Sequence Detection System. Primers were 
designed using the ABI Primer Express software that amplified amplicons specific for 
endogenous Rac1b (78 bp) (5!-GGG CAA AGA CAA GCC GAT TG and 5!-CGG ACA 
TTT TCA AAT GAT GCA GG) or total Rac1 transcripts (i.e., Rac1+Rac1b; 75 bp)) 
(5!-CCT GCA TCA TTT GAA AAT GTC CG and 5!-CCC ACT AGG ATG ATG GGA 
GTG T) as well as for RAC1 minigene transcript ex3+3b+4 (5! CAT GAT CGA CTA 
CGA CGT TCC TGA TTA TGC GG and 5! ATA TCC TTA CCG TAC GTT TCT CCA 
A) or minigene transcript ex3+4 (5! CAT GAT CGA CTA CGA CGT TCC TGA TTA 
TGC GG and 5! ACA AGC AAA TTG AGA ACA CAT CTG TT). Each cDNA sample 
was diluted 5-fold to guarantee accurate pipetting and 5 µL added to 300 nmol/L 
primers and SYBR Green Master Mix (Applied Biosystems, Foster City, CA). The 
cycling conditions comprised 10 min polymerase activation at 95ºC and 40 cycles at 
95ºC for 15 sec and 60ºC for 30 sec. For standardization, all samples were analyzed 
against HT29 cDNA as a reference sample using the 7000 SDS 1.1 RQ Software 
(%%CT method; Applied Biosystems) (Matos et al. 2008). Each amplification was 
performed in duplicate reactions and repeated in at least 3 independent experiments. 
No amplification was obtained when RNA was mock reverse transcribed without 
adding reverse transcriptase. 
 
SDS-PAGE, Western blotting and PAK-CRIB domain pull down assay 
 Samples were prepared and detected as described (Matos and Jordan 2006). 
The antibodies used for Western blots were custom rabbit polyclonal anti-Rac1b 
serum (Matos et al. 2003); mouse anti-Rac (clone 23A8) from Upstate 
Biotechnologies; rabbit anti-c-Myc (A-14) from Santa Cruz Biotechnology; mouse 
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anti-SR proteins (clone 1H4), mouse anti-ASF/SF2 and mouse anti-SRp20 from 
Zymed-Invitrogen; rabbit anti-PTEN from Cell Signalling; mouse anti-Flag (M2), 
mouse anti-HA and mouse anti-$-tubulin (clone B-5-1-2, as loading control) from 
Sigma; rabbit anti-GFP (ab290) from Abcam; and T7-Tag Antibody from 
Novagen/VWR. For densitometric analysis films from at least three independent 
experiments were digitalized and analyzed using ImageJ software (NIH). PAK-CRIB 
domain pull down assay was as described (Matos et al. 2003). 
 
Electrophoretic mobility shit assays (EMSA) 
 Nuclear extracts for EMSA were prepared in 20 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 420 mM NaCl, 0.2 mM EDTA, 25% v/v glycerol with protease inhibitors, as 
described (Wadman et al. 1997), diluted to adjust the salt concentration to the EMSA 
binding buffer and purified in Microcon spin columns (YM-10, Millipore) according to 
the manufacturer's instructions. Plasmid DNAs encoding the tested RNA probes 
were linearised at a Bam HI site, transcribed in vitro in the presence of $[32P]CTP 
(400 Ci/mmol, 10mCi/ml; Amersham Pharmacia Biotech) using a Maxiscript SP6 kit 
(Ambion), and purified with Microspin G-25 columns (GE Healthcare) according to 
the manufacturer's instructions. Either 0.5 or 1 µg of the indicated nuclear extracts or 
50-150 ng of recombinant ASF/SF2 (ProteinOne, Bethesda), or 100-500 ng of 
SRp20 (N-terminal fragment 1-86 aa, Abnova) were incubated for 5 min at 30 ºC in 
20 µL reaction volumes containing EMSA binding buffer (12 mM HEPES, pH 7.9, 
72.5 mM KCl, 3.2 mM MgCl2, 20 mM creatine phosphate, 20% glycerol, 1 mM DTT, 
1 mM ATP, 40 U RNAsin, 125 ng of E. coli tRNA and 0.5 mg BSA). Labelled RNA 
probes (8000 cpm, 5-10 fmol) were denatured at 95 ºC for 5 min, immediately chilled 
on ice and then added to the assay volume for 20 min at 30 ºC followed by chilling 
on ice. Protein-RNA complexes were resolved in 8% non-denaturing polyacrylamide 
gels (acrylamide/bisacrylamide ratio of 29/1) in 0.5x TBE buffer, which was then 
dried and autoradiographed. 
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Results 
 
A Rac1 minigene approach identifies candidate regulatory splicing factors 
 Previously we reported that the mammalian RAC1 gene contains 7 coding 
exons (Fig. 2.1A), which give rise to two alternative transcripts, Rac1 and Rac1b 
(Jordan et al. 1999, Matos et al. 2000). Typically, exon 3b is skipped and Rac1 is the 
predominant transcript produced. However, exon 3b-containing variant Rac1b has 
been found overexpressed in a subset of colorectal tumours and this promoted 
tumour cell survival (Matos et al. 2008). In order to study the molecular regulation of 
this splicing event in tumour cells, we first selected colorectal cell lines with different 
levels of Rac1 and Rac1b expression. As shown in Fig. 2.1B, SW480 cells express 
only Rac1 transcript and protein whereas DLD-1 and HT29 cells express Rac1 as 
well as different levels of the alternative Rac1b transcript and protein. In these cell 
lines we also compared the activated GTP-loaded Rac1 and Rac1b protein pools 
using a PAK-CRIB domain pull-down assay. In HT29 cells a predominant activation 
of Rac1b over Rac1 was observed although quantification of Rac1b transcripts by 
Real-time PCR indicated that only about 10% of the Rac1 pre-mRNA was spliced 
into Rac1b transcripts (not shown). Thus, the structural differences resulting from 
exon 3b inclusion lead to hyperactivation of Rac1b and this is in agreement with 
previously published data (Matos et al. 2003, Singh et al. 2004, Fiegen et al. 2004, 
Radisky et al. 2005). These results demonstrate that small changes in alternative 
Rac1 splicing are sufficient to generate Rac1b protein levels that have a profound 
effect on the activated, GTP-loaded Rac1 pool in colorectal cells.  
 In order to determine how the alternative splicing event of the RAC1 pre-
mRNA is controlled, we first checked for the presence of genomic mutations in the 
three cell lines. A genomic RAC1 fragment ranging from 286 bp upstream to 224 bp 
downstream of exon 3b was amplified and sequenced. The three fragments were 
wild type without any mutation that could account for the observed splicing 
differences. To study how this splicing event is regulated, we constructed a minigene 
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Figure 2.1: Alternative splicing of the small GTPase Rac1 in colorectal cells. (A) Schematic 
representation of the human RAC1 gene with its 7 coding exons, including the alternative exon 3b, 
and of the two alternative transcripts Rac1 and Rac1b. (B) Expression analysis of endogenous Rac1b 
in three colorectal cell lines; Top panel: RT-PCR detection of Rac1b, Middle panel: Western blot 
analysis using an anti-Rac1 antibody, Bottom panel: CRIB-domain pull-down assay followed by 
Western blot demonstrates the amount of active GTP-bound Rac1 and Rac1b in the indicated cell 
lines. Note that Rac1b protein is expressed in low amounts compared to Rac1 but adopts 
predominantly the active GTP-bound conformation. 
 
and cloned the genomic region between exon 3 and exon 4 of the RAC1 gene into a 
pcDNA3 vector backbone (Fig. 2.2A). The minigene was transfected into SW480 and 
HT29 cells and the minigene-derived transcripts were found to recapitulate the 
endogenous Rac1 and Rac1b expression patterns of these cell lines (Fig. 2.2A). 
With this RAC1 minigene tool we analysed the effect of a panel of known splicing 
factors on exon 3b inclusion. HT29 cells were co-transfected with the minigene and 
the indicated factors and transcript ratios were quantified by Real-time PCR (Fig. 
2.2B). We found that overexpression of two splicing factors had the most significant 
effect: SRp20 led to strong exon 3b skipping whereas ASF/SF2 promoted inclusion 
of exon 3b by over 2-fold. We then tested whether SRp20 and ASF/SF2 affected the  
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Figure 2.2: Analysis of exon 3b inclusion using a RAC1 minigene approach. (A) Schematic 
representation of the constructed RAC1 minigene, containing the genomic region between exon 3 and 
exon 4 of the human RAC1 gene. The panels below compare the RT-PCR amplification of 
endogenous Rac1 and Rac1b in HT29 and SW480 cells (left) with the transcripts derived from the 
RAC1 minigene after its transfection into these two cell lines (right). (B) Effect of co-transfected 
candidate splicing factors on RAC1 minigene alternative splicing in HT29 cells; Bottom panel: 
Western blot detection of the indicated splicing factors transfected, as well as of the TATA-binding 
protein (TBP) as negative control, Middle panel: RT-PCR amplification of the minigene-derived 
transcripts, Top graph: Real-time PCR quantification displayed on a logarithmic scale for proportional 
visualisation of positive and negative changes. 
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Figure 2.3: Comparison of the effect of splicing factor overexpression on different minigene 
constructs. (A) Schematic representation of the RAC1 minigene, the PTB-derived minigene pG11 
(Spellman et al., 2005) and the FAS minigene (Förch et al, 2000), all containing an alternative skipped 
exon. (B) The three minigene constructs were co-transfected with the indicated splicing factors and 20 
h later the respective alternative transcripts amplified by semi-quantitative RT-PCR. The 
electrophoretic staining and a graphical display of the transcript ratios are shown. Note that ASF/SF2 
and SRp20 differed in their effects on each minigene, indicating the observed role in Rac1 alternative 
splicing to be a specific event. 
 
RAC1 exon 3b specifically or exerted a general effect on splicing. For this, both 
factors were co-expressed with two different minigene constructs that also contain 
alternative skipped exons, the PTB-derived minigene pG11 (Spellman et al. 2005) and 
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the FAS minigene (Förch et al. 2000) (Fig. 2.3A). As shown in Fig. 2.3B, ASF/SF2 and 
SRp20 had different effects on the splicing decisions from each minigene. SRp55 
and 9G8 were included as additional control factors. We concluded that ASF/SF2 
and SRp20 were two candidate splicing factors regulating alternative splicing of 
Rac1 exon 3b. 
 
Depletion of ASF/SF2 or SRp20 affects endogenous Rac1/Rac1b splicing 
ratios 
 In order to test the relevance of the observed splicing effects for endogenous 
Rac1b levels, we first established the experimental conditions to deplete expression 
of ASF/SF2 and SRp20 using small interfering RNA oligonucleotides (siRNA). 
Transfection of the siRNAs indicated in Fig. 2.4A into HT29 cells led to efficient 
depletion by more than 80% for each factor. In these tests depletion of SRp55 was 
included as a negative control and of 9G8, because it shares some binding motifs 
with SRp20 (Cavaloc et al. 1999, Huang and Steitz 2001). Under the described 
experimental conditions, the relative changes in endogenous Rac1b expression were 
quantified by Real-time PCR in HT29 cells following depletion of each of the four 
splicing factors (Fig. 2.4B). The depletion of ASF/SF2 strongly inhibited endogenous 
Rac1b generation. In contrast, the suppression of SRp20 and 9G8 increased 
endogenous Rac1b compared to cells transfected with control or SRp55-specific 
siRNAs. The opposite effects were observed when these four splicing factors were 
overexpressed in HT29 cells, although transfection was less than with siRNAs. In 
particular, overexpression of ASF/SF2 promoted whereas SRp20 and 9G8 inhibited 
generation of endogenous Rac1b compared to control or SRp55-transfected cells. 
These data confirm the results obtained in the minigene approach and substantiate 
the identification of ASF/SF2 and SRp20 as candidate regulators of Rac1 alternative 
splicing. 
 We next asked whether the relative expression of ASF/SF2 and SRp20 in the 
colorectal cell lines would correlate with the level of endogenous Rac1b. When 
compared to SW480 cells, which do not express endogenous Rac1b, we found that  
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Figure 2.4: Depletion of endogenous ASF/SF2 and SRp20 confirm their role in regulating 
Rac1b expression. (A) Documentation of the degree of siRNA-mediated depletion of the indicated 
splicing factors. Two different oligos, A and B, were used for each target and their effect analysed 48 
h after transfection by Western blot, or by RT-PCR in case of 9G8, where no suitable commercial 
antibodies were available. (B) The expression of endogenous Rac1b in HT29 cells was determined by 
Real-time PCR following either overexpression of the indicated splicing factors (as described in Fig. 
2.2B) or depletion of their endogenous levels by siRNAs. The graphical display of RNAi data 
represents the mean values of the A- and B-oligos obtained in three independent transfection 
experiments. Note that ASF/SF2 depletion inhibited generation of endogenous Rac1b whereas SRp20 
depletion promoted it. (C) Comparison of the endogenous expression levels of ASF/SF2 and SRp20 
in HT29 and SW480 cells. Note that in HT29 cells the expression of endogenous Rac1b correlates 
with increased ASF/SF2 and decreased SRp20 transcript and protein levels when compared to 
SW480 cells. Detection of $-tubulin served as loading control. (D) Experimental manipulation of 
ASF/SF2 and SRp20 levels triggers forced exon 3b inclusion in SW480 cells. Cells were co-
transfected with the RAC1 minigene and either control vector, or T7-tagged ASF/SF2, or T7-tagged 
ASF/SF2 plus siSRp20 oligos. The Western blot (lower panel) shows the three different experimental 
conditions of ASF/SF2 and SRp20 levels while the black bars in the graph represent the 
corresponding minigene-derived transcript analyses (top panel). Note the progressive increase in 
exon 3b-containing transcripts upon overexpression of enhancer ASF/SF2 and depletion of silencer 
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SRp20, approximating splicing ratios to that normally observed in untransfected DLD-1 or HT29 cells 
(grey bars). 
 
HT29 cells clearly expressed more ASF/SF2 and less SRp20, both at transcript and 
protein level by RT-PCR or Western blot, respectively (Fig. 2.4C). We therefore 
reasoned that the experimental manipulation of ASF/SF2 and SRp20 levels in 
SW480 cells should provoke increased expression of Rac1b. We observed that 
overexpression of ASF/SF2 in SW480 cells led to some increase in Rac1b and this 
could further be raised upon simultaneous depletion of SRp20, now reaching Rac1b 
levels normally detected in DLD-1 cells (Fig. 2.4D). These results provide a proof of 
principle that ASF/SF2 acts as an enhancer for exon 3b inclusion whereas SRp20 is 
a silencer promoting exon 3b skipping. 
 
The Rac1 exon 3b sequence contains binding sites for ASF/SF2 and SRp20 
 The observed effects of ASF/SF2 and SRp20 on alternative splicing of Rac1b 
suggested that these factors could bind directly to exon 3b in the Rac1 pre-mRNA. 
For the identification of such binding sites we first aligned exon 3b sequences from 
various species and identified conserved nucleotide positions (Fig. 2.5A). A series of 
conserved or control nucleotides were then mutated in the RAC1 minigene (Fig. 
2.5B) and the resulting constructs transfected into HT29 cells (Fig. 2.5C). Mutant 
minigene-derived transcripts were amplified by RT-PCR and the ratios of exon 3b-
containing transcripts quantified. This systematic analysis identified that nucleotide 
changes at exon positions +7 and +11 strongly inhibited exon 3b inclusion (exonic 
mutants E1.0 and E1.2) whereas changes at positions +18 and +19 promoted 
constitutive inclusion of exon 3b (mutants E2.0 and E2.1) (Fig. 2.5C). Together, 
these data indicated that exon 3b contains an exonic splice enhancer element 
followed by a silencer element. From the experiments described above, we 
postulated that these elements would be recognised by ASF/SF2 and SRp20, 
respectively.  
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Figure 2.5: Identification of regulatory sequence elements in exon 3b. (A) Genomic sequence 
alignment of the exon 3b sequences from eight vertebrate species; Hs: Homo sapiens, Mm: Mus 
musculus, Cf: Canis familiaris, Rn: Rattus norvegicus, Bt: Bos Taurus, Gg: Gallus gallus, Pt: Pan 
troglodytes, Ma: Macaca mulatta. Conserved nucleotide positions are boxed in grey and highlighted 
below the alignment. (B) Indication of the conserved nucleotides in the exon 3b sequence that were 
point mutated in the RAC1 minigene (boxed in black), including two non-conserved positions as 
controls (E1.C and E2.C). (C) Effect of mutations on inclusion of exon 3b into the minigene-derived 
transcripts. Shown is the electrophoretic gel image of the semi-quantitative RT-PCR assay and the 
graphic display of its band intensities (given in logarithmic scale for proportional visualisation of 
positive and negative changes). Note the intense skipping due to mutation E1.0 and the preferential 
exon 3b inclusion due to mutation E2.0. (D) Electrophoretic mobility shift assay (EMSA). Mutation 
E1.0 disrupts a predicted ASF/SF2 binding site. This was experimentally tested by incubating 
recombinant ASF/SF2 protein with probes generated by in vitro transcription from the wild type exon 
3b sequence as well as from mutant E1.0 and E2.0 sequences. Left: Western blot following non-
denaturing EMSA acrylamide gel conditions to detect the migration of 15, 50 or 150 ng ASF/SF2 in 
complex with exon 3b wt probe. Right: Autoradiographs showing mobility shifts of the indicated 
probes in the presence of 50 or 150 ng recombinant ASF/SF2. Note the severe loss of affinity of 
ASF/SF2 to the mutant probe E1.0. 
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 We further evaluated the exon 3b sequence and its mutants using 
bioinformatics softwares to recognize exonic splicing regulatory elements. The 
ESEfinder program (Cartegni et al. 2003, available at http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home) as well as the Splicing Rainbow 
software (Stamm et al. 2006, available at http://www.ebi.ac.uk/asd-
srv/wb.cgi?method=8) predicted that mutants E1.0 and E1.2 would interrupt an 
ASF/SF2 binding site, and the Fairbrother and Wang algorithm at the ESR search 
(Goren et al. 2006, available at http://ast.bioinfo.tau.ac.il/ESR.htm) predicted 
generically the loss of an exonic splice enhancer. With regard to positions +18 and 
+19 of exon 3b, the algorithms from the C. Burge lab (Fairbrother and Wang (Goren 
et al. 2006) as well as the FAS-ESS (Wang et al, 2004); available at 
http://genes.mit.edu/fas-ess/) identified a putative exonic splice silencer at this 
position, which became interrupted by mutants E2.0 and E2.1. A similar mutational 
approach was applied to conserved nucleotides near the 5'-end of the downstream 
intron 3b; however, no clear results were obtained (see Supplemental data, Fig. 
S2.2). 
 For direct experimental demonstration that ASF/SF2 binds the predicted motif 
around nucleotides +7 and +11, the wild type exon 3b sequence as well as mutant 
E1.0 and E2.0 sequences were in vitro transcribed and radiolabelled, then incubated 
in the presence of recombinant ASF/SF2 and analysed in electrophoretic mobility 
shift assays (EMSA). We found that increasing amounts of recombinant ASF/SF2 led 
to a clear shift in electrophoretic mobility of the wild type and the E2.0 probe and this 
shift was abolished by excess unlabelled probe (Fig. 2.5D). In contrast, mutant probe 
E1.0 revealed a strongly reduced affinity for ASF/SF2, confirming the bioinformatics 
predictions. 
 Because in eukaryotic cells splicing factors can be post-translationally 
modified and differ from recombinant protein in binding affinity or subcellular 
localization, we wished to confirm the EMSA data with nuclear extracts. ASF/SF2 
and SRp20 were overexpressed in DLD-1 cells, nuclear proteins extracted and 
incubated with the radiolabelled exon 3b and mutant probes. Confirming the result  
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Figure 2.6: Electrophoretic mobility shift 
assays with nuclear extracts from colorectal 
cells. (A) Nuclear extracts were prepared from 
DLD-1 cells transfected with ASF/SF2, then 0.5 or 
1 µg incubated with the indicated probes and 
complexes separated in non-denaturing 
acrylamide gels. To verify the specificity of the 
observed complexes, additional aliquots were 
incubated with an excess of unlabeled probe, or 
with an anti-ASF/SF2 antibody or a control 
antibody. Note the super-shifted band (*) in the 
presence of anti-ASF/SF2 and also that mutant 
probe E1.0 has a strongly reduced affinity to 
ASF/SF2. (B) As described for (A) except that 
nuclear extracts were prepared from DLD-1 cells 
transfected with SRp20. Note the super-shifted 
band (*) in the presence of anti-SRp20 and that 
mutant probe E2.0 has a strongly reduced affinity 
to SRp20. (C) Restoration of normal splicing 
patterns from mutants E1.0 and E2.0. The 
significantly reduced binding affinities of ASF/SF2 
to mutant probe E1.0 as well as of SRp20 to 
probe E2.0 were compensated by co-expressing 
the respective mutant minigenes with the 
corresponding ASF/SF2 or SRp20 constructs into 
HT29 cells. Lower panel: Western blot shows 
increasing expression levels of ASF/SF2 or 
SRp20 levels. Middle panel: Minigene-derived 
transcripts were amplified by RT-PCR and stained 
following gel electrophoresis. Top graph: Relative 
band intensities were quantified and displayed on 
a logarithmic scale for proportional visualisation of 
positive and negative changes. Note that 
overexpression of these factors restored exon 3b 
inclusion almost to wild type levels.  
 
 
with recombinant protein, we observed that the presence of increasing ASF/SF2-
containing nuclear extracts caused a mobility shift of wild type exon 3b and mutant 
E2.0 probes (Fig. 2.6A). The shifted complex was diminished by adding an excess 
unlabelled probe and was super-shifted in the presence of an ASF/SF2 antibody, but 
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not a control antibody. As observed before, mutant E1.0 with a disrupted ASF/SF2 
recognition motif was hardly recognised by nuclear extracts and no super-shift was 
observed (Fig. 2.6A). When the same set of experiments was repeated with nuclear 
extracts expressing SRp20, we obtained a comparable mobility shift of wild type 
exon 3b but now mutant probe E1.0 exhibited the shift whereas probe E2.0 was 
inefficiently recognized (Fig. 2.6B). The exon 3b and mutant probes were also 
incubated with a recombinant N-terminal SRp20 fragment, however, this fragment 
apparently did not bind to RNA (not shown). 
 The EMSA data revealed that point mutations E1.0 and E2.0 significantly 
decreased the binding affinities for ASF/SF2 or SRp20, respectively, but did not fully 
ablate protein binding. We therefore assumed that overexpression of ASF/SF2 
should be able to compensate the reduction in affinity towards the exon 3b mutant 
E1.0, and overexpression of SRp20 should compensate mutant E2.0. We tested this 
by co-transfecting the mutant minigenes E1.0 and E2.0 with increasing amounts of 
either ASF/SF2 or SRp20 and analysed the minigene-derived transcripts. As shown 
in Fig. 2.6C, increasing amounts of ASF/SF2 partially restored exon 3b inclusion 
from mutant E1.0 and overexpression of SRp20 restored skipping of exon 3b from 
mutant E2.0 to near wild type minigene levels. 
 Together, these data show that alternative spliced exon 3b contains positive 
and negative splicing regulatory elements that are recognized by splicing factor 
complexes containing either ASF/SF2 or SRp20, respectively.  
 
PI3-kinase and "-catenin signalling pathways affect Rac1b expression 
 Our data so far identified ASF/SF2 and SRp20 as key splicing factors 
regulating Rac1b expression in colorectal cells. Because Rac1b is overexpressed in 
a group of colorectal tumours, we asked which upstream oncogenic signalling 
pathways would act on these SR proteins and trigger the Rac1 exon 3b splicing 
event. 
 One hallmark oncogenic pathway activated in many colorectal tumours is Wnt 
signalling, which recruits cytosolic "-catenin as a transcriptional co-activator (Clevers 
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2006). Very recently, we found that the SFSR3 gene encoding SRp20 is a 
transcriptional target for activated "-catenin/TCF4 complexes, leading to increased 
SRp20 protein levels (Gonçalves et al. 2008; see chapter III). We therefore tested in 
colorectal cells the expression of Rac1b following either pathway stimulation with an 
activated "-catenin mutant or pathway inhibition with a dominant negative TCF4 
mutant. Endogenous Rac1b levels were found to clearly respond to "-catenin/TCF4-
induced changes in SRp20 protein levels. In particular, we observed that the 
inhibition of Wnt signalling decreased SRp20 and increased Rac1b levels (Fig. 2.7A). 
This is in agreement with the data in Figures 2.4B and 2.6B that revealed SRp20 as 
a silencer of exon 3b inclusion. This finding suggested that tumours with low Wnt 
pathway activation are permissive to overexpression of Rac1b. 
 Furthermore, we suspected the existence of signals that directly promote 
Rac1b overexpression via ASF/SF2. We tested the effect of three MAP kinase and 
the PI3-kinase pathways. The inhibition of ERK, JNK or p38 MAP kinase activities by 
the respective specific inhibitors U0126, SP600125 or SB203580 had no significant 
effect on endogenous Rac1b levels within 24 h (Fig. 2.7B and data not shown). 
Similarly, no effect was observed following transfection of kinase-dead JNK or p38 
mutants (Fig. 2.7B and data not shown). In contrast, interfering with the PI3-kinase 
signalling by cell treatment with 10 µM inhibitor LY294002 revealed a 1.5-fold 
increase in Rac1b within 24 h. Similarly, overexpression of the counteracting 
phosphatase PTEN or of a kinase-dead mutant of the downstream effector kinase 
AKT significantly induced Rac1b expression within 24 h. Under the same 
experimental conditions we found that PI3-kinase inhibition (by LY294002 treatment 
or following overexpression of PTEN) led to increased expression of endogenous 
ASF/SF2, both at the transcript and the protein levels (Fig. 2.7C). In control 
experiments, these conditions of PI3-kinase inhibition did not affect endogenous 
expression of another splicing factor, hnRNP A1 (data not shown). We observed no 
change in ASF/SF2 expression when the p38 MAP kinase activity was inhibited (Fig. 
2.7C). 
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Figure 2.7: Different signalling pathways act in concert to modulate Rac1b expression. (A) 
Effect of "-catenin/TCF4 transcriptional activity on alternative splicing of Rac1b. HT29 cells were 
transfected as indicated with either empty pEGFP vector, or a dominant negative GFP-TCF4 mutant 
(TCF-DN), or a non-degradable GFP-"-catenin mutant ("Cat-CA). Top panel: Real-time PCR 
quantification of the expression of endogenous Rac1b. Lower panel: Western showing the indicated 
expression levels of the transfected GFP-tagged constructs, the resulting changes in endogenous 
SRp20 protein levels and $-tubulin levels as loading controls. Note that pathway activation by 
transfection of "Cat-CA promoted an increase in SRp20 but a decrease in Rac1b expression. (B) 
Effect of PI3-kinase and p38 MAP kinase pathway inhibition on alternative splicing of Rac1b. HT29 
cells were treated with inhibitors LY294002 (10 'M) or SB203580 (1 'M), or transfected with 
constructs encoding control vector, PTEN, or kinase-dead mutants of either AKT or p38. RNA was 
extracted after 24 h, endogenous Rac1b quantified by Real-time PCR and data graphically displayed. 
(C) Effect of PI3-kinase and p38 MAP kinase pathway inhibition on ASF/SF2 expression levels. Cells 
were treated as described above and whole cell lysates analysed by Western blot for changes in 
ASF/SF2 protein levels (tubulin levels served as loading control). Note that in the presence of the 
PI3K inhibitor or upon overexpression of PTEN an increase in ASF/SF2 was observed that correlated 
with increased Rac1b expression. 
 
 Together, these data provide evidence that the PI3-kinase and "-catenin 
signalling pathways affect the expression of ASF/SF2 and SRp20, respectively, and 
consequently modify the generation of Rac1b.  
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Discussion 
 
 A major contribution of the present work is the demonstration that different 
cellular signalling pathways act in concert to regulate a specific alternative splicing 
event. By synchronizing the expression of two SR proteins with antagonistic roles, 
the pathways regulate inclusion or skipping of an alternative exon. The example 
studied is alternative splicing of exon 3b of the signalling small GTPase Rac1. 
 Experimental data from cell lines and normal tissues have revealed that exon 
3b is usually either skipped or included into only a small transcript fraction (Jordan et 
al. 1999, Radisky et al. 2005). It has typical features of alternative exons such as its 
small size of 57 bp and a poorly conserved polypyrimidine tract. The polypyrimidine 
tract is an important splicing regulatory element at the splice acceptor site and its 
length usually correlates with the efficiency of exon inclusion. Calculating the 
consensus values (CV) that reflect the “strength” of a polypyrimidine signal (Carmel et 
al. 2004, online tool at http://ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm), a weak tract 
becomes evident for exon 3b (CV= 75.08) when compared to the CVs of the 
surrounding exons 3 (83.41) and 4 (92.25). In agreement, we observed that single 
point mutations, which strengthen the exon 3b polypyrimidine tract in the RAC1 
minigene, were sufficient to promote nearly constitutive inclusion of exon 3b (data 
not shown). This data and the absence of genomic mutations in the analysed cell 
lines suggested that differences in Rac1b expression are based on a regulated 
alternative splicing event. 
 In this work we demonstrate that Rac1 alternative splicing is regulated by the 
SR proteins ASF/SF2 and SRp20 in colorectal cells. In order to dissect the 
mechanisms regulating the alternative Rac1b splicing event, we first constructed a 
RAC1 minigene that recapitulates the endogenous splicing decisions in colon cell 
lines. We then tested a panel of candidate splicing factors for their effect on the 
minigene and were fortunate to identify one Rac1b promoting and another silencing 
factor. Their physiological roles in Rac1 alternative splicing in colorectal tumour cells 
were then confirmed at the endogenous level by RNA interference experiments. 
Chapter II
 
  91 
Moreover, these factors recognized probes transcribed in vitro from exon 3b. 
Altogether, our data lead us to propose that exon 3b contains an exonic splice 
enhancer recognized by ASF/SF2 adjacent to an exonic silencer bound by SRp20. In 
our experimental system of colorectal cell lines, we observed that the relative protein 
concentrations of ASF/SF2 versus SRp20 determined the alternative splicing rate. 
Not only did the endogenous protein levels of both factors correlate with the amount 
of Rac1b expressed in different cell lines, but also the experimental manipulation of 
ASF/SF2 and SRp20 expression levels by RNAi or splicing factor overexpression 
changed alternative splicing of exon 3b.  
 As upstream events regulating the relative protein concentrations of ASF/SF2 
versus SRp20, we identified two signalling pathways that affected their expression 
and promoted a corresponding increase or decrease in Rac1b. The Wnt pathway 
activates the "-catenin/TCF4 transcriptional complex, for which the SFSR3 gene 
encoding SRp20 is a direct target (Gonçalves et al. 2008; see chapter III). Pathway 
stimulation increased SRp20 levels that we found to act as a silencer on exon 3b, 
leading to decreased Rac1b generation. The PI3-kinase pathway was found involved 
in regulating the antagonistic factor ASF/SF2. Inhibition of this pathway increased 
expression of both the transcript and protein levels of ASF/SF2, which acts as an 
enhancer of exon 3b inclusion. Consequently, an increased Rac1b expression was 
observed. Together, this shows that different signalling pathways concurrently target 
independent splicing factors in order to exert control over alternative splicing of 
Rac1b. 
 Numerous studies have documented that the relative abundance of 
antagonistic splicing factors, including ASF/SF2 and SRp20, can affect splicing 
decisions (e.g. Jumaa and Nielsen 1997, Mayeda et al. 1993, Galiana-Arnoux et al. 2003). 
It is therefore well accepted that splicing factor expression levels are a major 
mechanism to trigger differences in alternative splicing patterns. According to current 
knowledge, antagonistic splicing factors regulate alternative splicing through a 
combinatorial mode of action with a subset of individual genes responding to a given 
factor combination or activation (Smith and Valcárcel 2000, Singh and Valcárcel 2005). 
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The novelty of our findings resides in the demonstration that a concerted signalling 
level of apparently independent pathways is essential to promote a specific 
alternative splicing event. This adds further complexity to the regulation of alternative 
splicing and implies that certain splice site choices require a balanced stimulation of 
multiple pathways. 
 It is possible that Rac1b alternative splicing is further modulated through 
protein phosphorylation of ASF/SF2 or SRp20. For example, our observation is 
suggestive that overexpression of PTEN promoted an increase in ASF/SF2 
expression whereas that of a kinase-dead AKT mutant did not. However, the kinase-
dead AKT mutant still induced some increase in Rac1b, albeit less pronounced than 
following PTEN expression. This suggests that post-translational modification of 
ASF/SF2 also contributes to the regulation of exon 3b inclusion. Indeed, nuclear and 
cytoplasmic functions for ASF/SF2 are known to be modulated by phosphorylation 
(Xiao and Manley 1997, Sanford et al. 2005) and AKT has been recently described to 
phosphorylate ASF/SF2 in vitro (Blaustein et al. 2005). The inhibition of PI3-kinase 
pathway has previously been implicated in the regulation of other alternative splicing 
events such as of the fibronectin and PKC "II genes (Blaustein et al. 2004, Pelisch et 
al. 2005, Patel et al. 2001), but mechanistic details remained uncharacterized. Further 
experiments will be required to clarify whether and how the PI3-kinase pathway 
affects ASF/SF2 expression at the transcriptional or the post-transcriptional level, 
and what role of phosphorylation by one of the AKT kinases is playing. It is possible 
that the PI3K pathway regulates other SR protein regulators besides AKT, such as 
the SRPK and Clk/Sty family of protein kinases. These operate in the cytosol (Gui et 
al. 1994) and may antagonize the effect of AKT on SR proteins (Blaustein et al. 2005). 
 Our observation that PI3-kinase signalling inhibited expression of Rac1b (Fig. 
2.7B) helps to clarify genetic pathways leading to colorectal tumorigenesis. One 
group of tumour shows oncogenic KRAS mutations and these increase cell 
proliferation via ERK signalling and provide pro-survival stimuli via the PI3-
kinase/Rac1 pathway (Qiu et al. 1995). This group is represented by SW480 cells, 
which do not express endogenous Rac1b (see Fig. 2.4C) and this is compatible with 
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mutant K-Ras strongly activating PI3-kinase, thus leading to decreased ASF/SF2 
expression.  
 In contrast, HT29 cells have a wild type KRAS gene but carry the alternative 
oncogenic BRAF mutation (Matos et al. 2008). B-Raf operates downstream of K-Ras 
in the ERK pathway and thus cannot stimulate PI3-kinase directly. In agreement, 
HT29 cells express more ASF/SF2 and more Rac1b. HT29 cells represent another 
group of colorectal tumours in which the oncogenic B-RafV600E mutation occurs 
associated with overexpressed Rac1b (Matos et al. 2008). Whereas B-RafV600E 
primarily stimulates cell proliferation, Rac1b signalling sustains tumour cell survival 
(Matos et al. 2008). However, the molecular details of how Rac1b becomes 
overexpressed remained unclear. The data presented in this manuscript now allow 
us to propose a mechanism for Rac1b overexpression: genetic lesions that initiate 
colorectal tumorigenesis without enhancing PI3-kinase and "-catenin signalling, 
promote the selection of cellular backgrounds with increased ASF/SF2 levels relative 
to SRp20. These cellular settings would favour Rac1b overexpression leading to 
increased tumour cell survival and subsequent tumour progression. 
 In conclusion, cellular signals are known to influence the outcome of 
alternative splicing but most knowledge in this field has provided evidence for a "one 
signalling pathway, one gene"-type of regulation. In this manuscript we revealed that 
different signalling pathways need to act in concert so that the targeting of 
independent splicing factors can provide the correct combinatorial code to regulate 
alternative splicing of the small GTPase Rac1. 
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Supplemental data 
 
 The observed effects of ASF/SF2 and SRp20 on alternative splicing of Rac1b 
suggested that these factors could bind directly to exon 3b in the Rac1 pre-mRNA, 
however, additional regulatory elements in the intronic regions located upstream or 
downstream of this exon may exist. In order to determine if the intronic regions 
surrounding the alternative exon participated in the regulation of this event, we 
screened for deletion mutants of the RAC1 minigene, transfected them into HT29 
cells (Fig. S2.1B) and amplified mutant minigene-derived transcripts by RT-PCR. 
Two mutants were identified that affected exon 3b inclusion (Fig. S2.1A). I3-del, 
which has a 2.3 kb deletion in intron 3 of the minigene, led to an increase in exon 3b 
inclusion. In contrast, I3b-del that has a 78 nt deletion in intron 3b, led to a complete 
skipping of the alternative exon 3b. 
 Knowing that splice site recogniton is more efficient when introns or exons are 
small (Sterner et al. 1996), we wanted to discard the possibility that the changes 
observed in the inclusion level of exon 3b resulted only from the reduction of intron 
length. For this purpose, we filled in the deleted regions in I3-del and I3b-del with 
heterologous sequences belonging to intron 1 of WNK2 and BRCA1 genes (Fig. 
S2.1A). As shown in figure S2.1B, the increase in exon 3b inclusion caused by I3-del 
construct was no longer observed when the deleted region in exon 3 was filled with 
either one of the heterologous sequences used. In contrast, the complete skipping of  
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the alternative exon caused by I3b-del was maintained for both constructs with 
heterologous 78 bp sequences in intron 3b (Fig. S2.1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.1: Analysis of exon 3b inclusion by manipulating the adjacent intronic regions of 
RAC1 minigene. (A) Schematic representation of the RAC1 minigene-derived constructs, containing 
different deletions in both introns 3 and 3b, and the corresponding constructs with heterologous 
sequences filling in those deletions. Thin black lines represent the intronic deletions and the patterned 
boxes represent different heterologous sequences (B) Effect of the transfected constructs on RAC1 
minigene alternative splicing in HT29 cells, analysed by RT-PCR. 
 
 From these results we can conclude that the 78 bp region identified in intron 
3b is important for the inclusion of alternative exon 3b, and therefore, this region 
could contain sequence elements that promote exon 3b inclusion, known as intronic 
splicing enhancers (ISEs). For the identification of such elements we first aligned the 
78 bp intron 3b sequences from various species and identified conserved nucleotide 
positions (Fig. S2.2A). A series of conserved or control nucleotides were then 
mutated in the RAC1 minigene (Fig. S2.2B) and the resulting constructs transfected 
into HT29 cells (Fig. S2.2C). Mutant minigene-derived transcripts were amplified by 
RT-PCR and the inclusion of the alternative exon 3b analysed. As shown in figure 
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S2.2C all the constructs with mutations in the conserved nucleotides decreased exon 
3b inclusion approximately to the same extent, indicating that they are all important 
for the regulation of this alternative splicing event. If this effect is a result of 
disrupting/creating several binding sequences for splicing factors or, alternatively, in 
disrupting/creating RNA secondary structures involved in the alternative splicing of 
exon 3b, remains to be determined.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.2: Analysis of regulatory sequence elements in intron 3b. (A) Genomic sequence 
alignment of the 78 bp intron 3b sequences from seven vertebrate species; Hs: Homo sapiens, Mm: 
Mus musculus, Cf: Canis familiaris, Rn: Rattus norvegicus, Bt: Bos Taurus, Pt: Pan troglodytes, Ma: 
Macaca mulatta. Conserved nucleotide positions are boxed in grey and highlighted below the 
alignment. (B) Indication of the conserved nucleotides in the intron 3b sequence that were point 
mutated in the RAC1 minigene (boxed in black), including two non-conserved positions as controls 
(I2.C and I3.C). (C) Effect of mutations on inclusion of exon 3b into the minigene-derived transcripts. 
Shown is the electrophoretic gel image of the semi-quantitative RT-PCR assay. Note the 
approximately same level of skipping in all mutated constructs except for the controls I2.C and I3.C 
(which have non-conserved nucleotides mutated). 
 
 We additionally evaluated this intron 3b sequence and its mutants using 
bioinformatic softwares to recognize intronic splicing regulatory elements. The only 
program that was not specific for exonic regions was the Splicing Rainbow software 
(Stamm et al. 2006, available at http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8), 
which predicted that mutants I1.0 and I2.0 would create an ASF/SF2 binding site, 
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and mutants I3.0 and I4.0 would disrupt an hnRNPK and an hnRNPU binding sites, 
respectively. In future work, it should be investigated whether the candidate splicing 
factors identified by the Splicing Rainbow software have in fact a role in the 
regulation of Rac1 alternative splicing by performing, for example, the same kind of 
experiments we did for the exon 3b (EMSA and overexpression/knockout of the 
splicing factors). 
 However, the fact that all four mutants had roughly the same effect on the 
skipping of alternative exon 3b, and no common splicing factor is predicted to be 
involved, indicate that this intronic region may affect Rac1 alternative splicing due to 
changes in a secondary structure element of the pre-mRNA. 
 To further assess the competence of this region to act as an enhancer of 
alternative exon inclusion, we studied its effect in a different genomic context. For 
this, we cloned the corresponding 78 bp of RAC1 intron 3b into the downstream 
intron of exon 11 of the PTB-derived pG11 minigene, and named it pG11-RacI3b 
(Fig. S2.3A). The reason for choosing pG11 minigene was the similar exon/intron 
architecture compared to the RAC1 minigene (see Fig. 2.3A) and the similar ratio of 
alternative exon inclusion. HT29 cells were then transfected with pG11-RacI3b and 
also the original pG11 minigene as control. From the analysis of the pG11 minigene 
specific RT-PCR (Fig. S2.3B) we concluded that the intronic region of RAC1 
minigene we inserted in the pG11 minigene did not enhance the inclusion of 
alternative exon 11, as it did with exon 3b of the RAC1 minigene. Thus, this region 
does not act as a sequence-independent enhancer of splicing in a different genomic 
context but its importance in the inclusion of alternative exon 3b cannot be 
completely discarded. This is in agreement with the notion that every exon has its 
specific set of identity elements (splice site signals, splicing enhancers, silencers and 
secondary structures) that permit its recognition by the spliceosome. The sum of 
contributions from each of these identity elements then defines the overall 
recognition potential of an exon or the overall binding affinity for the spliceosome. 
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Figure S2.3: Effect of the 78 bp region in intron 3b on a different genomic context. (A) 
Schematic representation of the pG11 minigene-derived construct, containing 78 bp of the intron 3b of 
RAC1 minigene in the downstream intron of exon 11. (B) Effect of the transfected constructs on pG11 
minigene alternative splicing in HT29 cells, analysed by RT-PCR. 
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Summary 
 
 Gene expression programs can become activated in response to extracellular 
signals. One evolutionarily conserved example is binding of Wnt glycoproteins to 
their receptor, which triggers a signal transduction cascade that stabilizes 
cytoplasmic "-catenin protein allowing it to translocate into the nucleus. There, "-
catenin binds to TCF/LEF family transcription factors and promotes the expression of 
target genes. Mutations in either the "-catenin gene itself or its partner protein APC 
are responsible for the oncogenic activation of this pathway in colorectal tumours. 
Here we report the splicing factor SRp20 as a novel target gene of "-catenin/TCF4 
signalling. Transfection of activated "-catenin mutants into colorectal cells increased 
expression of endogenous SRp20 transcript and protein and also stimulated a 
luciferase reporter construct containing the SRp20 gene promoter. In contrast, 
inhibition of endogenous "-catenin signalling by a dominant negative TCF4 construct 
downregulated both luciferase reporter and SRp20 expression. We further 
demonstrate that the "-catenin/TCF4 mediated increase in SRp20 protein levels is 
sufficient to modulate alternative splicing decisions in the cells. In particular, we 
observed a change in the alternative splicing pattern in a control minigene reporter 
as well as in the endogenous SRp20-regulated CD44 cell adhesion protein. These 
results demonstrate that the "-catenin/TCF4 pathway not only stimulates gene 
transcription but also promotes the generation of transcript variants through 
alternative splicing. Our data support the recent notion that transcription and 
alternative splicing represent two different layers of gene expression and that 
signalling pathways act upon a coordinated network of transcripts in each layer. 
 
 
Introduction 
 
 The genetic information encoded in genomes is expressed in a differentiated 
and dynamic manner in order to generate specialized cellular phenotypes or the 
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coordinated succession of developmental stages. Such gene expression programs 
are controlled by various mechanisms including the activation of specific 
transcription factors in response to extracellular signals. Examples of important and 
evolutionarily conserved extracellular signals are the secreted Wnt glycoproteins. 
They play a fundamental role during embryonic development for the formation of 
germ layers and body axis (Cadigan and Nusse 1997, Yamaguchi 2001, Marikawa 2006) 
but also regulate stem cell renewal in colon crypts, hair follicles and bone marrow 
(Reya and Clevers 2005). Some target genes have been identified including the cell 
cycle-promoting cyclin D1 and c-myc genes as well as the tissue remodelling 
metalloproteinase matrilysin (Clevers 2006). When activated inappropriately, this 
pathway promotes malignant transformation, especially in colorectal cancer. 
 The Wnt1 class glycoproteins stimulate a canonical Wnt signalling pathway 
(reviewed in Bienz and Clevers 2000, Clevers 2006), which employs the transcriptional 
coactivator "-catenin as a central effector. In unstimulated cells, free cytoplasmic "-
catenin is constitutively marked for ubiquitination and subsequently degraded by the 
proteasome. The molecular mark recognized by the SCF complex is provided 
through phosphorylation of "-catenin at critical N-terminal serine and threonine 
residues by glycogen synthase kinase 3" (GSK3) and controlled by a multiprotein 
complex containing Axin and the APC tumour suppressor protein. Upon Wnt-ligand 
binding to its plasma membrane receptor, GSK3 is inhibited, and in consequence, 
unphosphorylated "-catenin accumulates in the cell. Improper activation of this 
pathway can be due to mutations in the "-catenin gene that inactivate the GSK3 
phosphorylation sites, as observed in various sporadic tumours of, for instance, 
colon (Ilyas et al. 1997, Morin et al. 1997), ovary (Sagae et al. 1999, Wright et al. 1999), 
liver (Koch et al. 1999, Legoix et al. 1999) and skin (Rubinfeld et al. 1997). In addition, 
loss of the adenomatous polyposis coli (APC) tumour suppressor gene activates the 
pathway and is a hallmark of hereditary and sporadic colorectal cancer (Fodde et al. 
2001). Free cytoplasmic "-catenin translocates into the nucleus, where it binds to 
transcription factors of the TCF/LEF family and acts as a co-activator to promote the 
transcription of Wnt target genes. 
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 Besides the activation of target gene transcription, recent genome-wide 
studies have revealed that tissues also differ in their gene expression profiles at the 
post-transcriptional level of alternative splicing. Current bioinformatics studies 
estimate that >70% of human genes can produce alternatively spliced variants (Ben-
Dov et al. 2008) and numerous examples were characterized demonstrating a 
functional diversity between proteins encoded as splice variants from the same gene 
(reviewed in Venables 2004, Srebrow and Kornblihtt 2006). In addition, splice variants 
can differ with respect to transcript stability or translation efficiency. Alternative splice 
variants thus expand transcriptome diversity and provide an important contribution to 
the functional diversity in gene expression programs. Another recent breakthrough 
from genome-wide gene expression analyses is that the majority of genes regulated 
by a given stimulus at the transcriptional level differ from those regulated at the 
alternative splicing level (Le et al. 2004, Pan et al. 2004, Blencowe 2006). This indicates 
that activation of signalling pathways can affect parallel layers of gene expression. It 
has been proposed that layers of alternative splicing are composed of specific 
groups of alternative spliced exons that are regulated together and thus constitute a 
coordinated physiological program in which specific splicing variants are generated 
to fulfil specific cellular functions (Blencowe 2006).  
 How are different splice variants turned on and off? Similar to the control of 
transcription through transcription factors that bind promoter, enhancer or silencer 
elements, splicing decisions involve recognition of transcript-specific sequence 
elements by splice regulating proteins. A cell-type-specific splicing pattern is the 
results of a complex combination of constitutive splicing components, of modulating 
splicing factors and of their cooperative assembly on exon-specific regulatory 
sequence elements. For example, the highly conserved SR protein family of RNA-
binding proteins (Cáceres et al. 1997) is essential for constitutive splicing and also 
influences the selection of alternative splice sites. Members of the hnRNP family of 
proteins antagonize their activity, and alterations in the expression ratio of these 
antagonistic factors cause drastic changes in splice-site selection. These factors 
establish RNA-protein and protein-protein interactions that define splice sites for the 
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spliceosome. For each transcript, a specific combination of these factors regulates 
the recognition of alternative exons (Smith and Valcárcel 2000, Singh and Valcárcel 
2005) and can involve their tissue-specific expression profiles or their 
phosphorylation and intracellular localization. Thus, the regulation of alternative 
splicing, much like that of transcription, is based on a combinatorial mode and 
responds to extracellular signals. Here we describe that the "-catenin/TCF signalling 
pathway not only affects gene transcription but also modulates alternative splicing 
decisions. We show that this pathway can directly activate transcription of the 
SFSR3 gene, encoding splicing factor SRp20. The subsequent increase in SRp20 
protein levels propagates the signal to another layer of regulation and results in the 
generation of alternative splice variants on a subset of SRp20-target transcripts. 
 
 
Experimental procedures 
 
Cell culture and transfection 
 DLD-1 and SW480 colorectal cells were maintained in DMEM supplemented 
with 10% (v/v) fetal calf serum (FCS) (Invitrogen) whereas HT29 cells were grown in 
RPMI. Cell lines were regularly checked for absence of mycoplasm infection. Cells 
were grown in 35-mm dishes to 60-80% confluence, transfected using 
LipofectAMINE 2000 (Invitrogen) according to the manufacturer!s instructions, and 
analyzed 16-20 h later. Total amounts of transfected DNA were 2 µg of DNA per dish 
for DLD-1 and SW480 cells or 4 µg for HT29 cells. For immunoprecipitation, DLD-1 
cells were transfected with 4 µg of DNA per 60-mm dish. If required, the amount of 
DNA was adjusted with empty vector. Plasmid transfection efficiencies were judged 
microscopically by expression of 2 µg of GFP and reached 60-80% in DLD-1 and 
SW480 cells or 30-40% in HT29 cells. For RNA interference experiments, cells at 30-
40% confluence were transfected with 200 pmol of the indicated siRNAs using 
LipofectAMINE 2000 (Invitrogen) and analyzed after 48 h. The siRNA oligos were 
ordered from MWG Biotech with the following sequences: siSRp20(1): 5!-GAG UGG 
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AAC UGU CGA AUG G; siSRp20(2): 5!-GAG CUA GAU GGA AGA ACA C; control 
siGFP: 5!-GGC UAC GUC CAG GAG CGC ACC TT. 
 
DNA plasmids and constructs 
 The following published constructs were received as gifts: TCF-DN (encoding 
a dominant negative TCF4 containing just the "-catenin binding domain of TCF4 
fused to a nuclear localization signal (N-TCF4); van de Wetering et al. 2002); "Cat-CA 
(encoding a constitutively active nondegradable "-catenin mutant lacking the first 47 
amino acids, Kolligs et al. 1999); splicing reporter minigenes pG11 (Spellman et al. 
2005) and FAS (Förch et al. 2000); and T7-tagged SRp20, SRp30, SRp40, and SRp55 
(Cáceres et al. 1997). The TOPglow/FOPglow TCF Reporter Kit and the pCDNA3-HA-
(31TCF4 construct (encoding a TCF4 mutant with intact DNA binding but lacking the 
N-terminal "-catenin binding domain, thus avoiding interference with endogenous 
complexes in DNA/protein co-precipitation assays; see below) were purchased form 
Upstate (Millipore). The (31TCF4 mutant was subcloned into pEGFPc1 using EcoRI 
and KpnI restriction sites. The SFSR3 promoter-driven luciferase reporter constructs 
were amplified by PCR from genomic DNA and subcloned into pGL2-Enhancer 
Vector (Promega): pRep5 with primers pGL2SRp20_KpnF (5! GGT ACC TGA CTG 
CTG TAT CGT TTC CAA) and pGL2SRp20_MluR (5! ACG CGT CCG ATG AGT 
CTT CC), and pRep3 with primers pGL2SRp20_Kpn802 (5! GGT ACC TTG CGG 
CTC TGT CTT CGT AA) and pGL2SRp20_MluR. pRep4, pRep2 and pRep1 were 
derived from pRep5 by deleting restrictions fragments using SmaI, SmaI and PvuII, 
or SmaI and StuI restriction enzymes, respectively. All constructs were confirmed by 
automated DNA sequencing.  
 
Analysis of transcript expression and semi-quantitative RT-PCR 
 Total RNA was extracted from cell lysates with the RNAeasy kit (Qiagen) and 
1 µg reverse transcribed using random primers (Invitrogen) and Ready-to-Go You-
Prime Beads (GE Healthcare). Primers for specific amplification were as follows: for 
SRp20: SRp20-F (5' AAC AAG ACG GAA TTG GAA CG) and SRp20-R (5' TGG 
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GCC ACG ATT TCT ACT TC); for CD44: CD44H-F (5! CAT CTA CCC CAG CAA 
CCC TA) and CD44H-R (5! GGT TGT GTT TGC TCC ACC TT); for CD44E: CD44v8-
F (5! TTT GGA CAG GAC AGG ACC TC) and CD44H-R; for pG11 minigene: pG-F 
(5! GGC AAA GAA TTC GCC ACC A) or 11/FP-F (5! ATT CTT TTC GGA GCA AGG 
GC) and FP-R (5! GAA CTT CAG GGT CAG CTT GC); for FAS minigene: PT1 (5' 
GTC GAC GAC ACT TGC TCA AC) and PT2 (5' AAG CTT GCA TCG AAT CAG 
TAG); and for RNA polymerase II (Pol II): Pol II-F (5!-GAG CGG GAA TTT GAG 
CGG ATG C) and Pol II-R (5!-GAA GGC GTG GGT TGA TGT GGA AGA). 
Amplification reactions were performed using AmpliTaq polymerase (Perkin-Elmer) 
at 60ºC for 30 cycles for SRp20, pG11, FAS and CD44E, at 58ºC and 30 cycles for 
CD44 and at 66ºC for 28 cycles for Pol II. All reactions included an initial 
denaturation of 5 min at 94ºC and a final extension of 10 min at 72ºC and each cycle 
contained 30 sec of denaturation and extension. Semi-quantitative analysis of 
transcript levels were previously established using serial dilutions of control cDNAs 
in order to determine the linear amplification phase for each PCR reaction. Products 
were separated on 2% agarose gels stained with ethidium bromide, images recorded 
digitally and band intensity quantified using ImageJ software followed by 
normalization to Pol II expression levels. No amplification was obtained when RNA 
was mock reverse transcribed without adding reverse transcriptase. 
 
DNA/protein co-immunoprecipitation  
 For immunoprecipitation (IP), 2x106 DLD-1 cells were seeded in 60 mm 
dishes and transfected with either pEGFP-empty vector or pEGFP-(31TCF4. 
Following 16-20 h, cells were washed in cold PBS and lysed on ice in 250 µl of lysis 
buffer [50 mM Tris-HCl at pH 7.5, 0.5% (v/v) NP-40, 150 mM NaCl, 10% (v/v) 
glycerol, 2.5 mM MgCl2 and a protease inhibitor cocktail (Sigma)]. Lysates were 
prepared from 4 parallel dishes, then pooled, cleared by centrifugation at 2500g for 5 
min, and an aliquot of 0.1 vol. was transferred to 2x Laemmli buffer (Pre-IP). The 
remaining supernatant from either GFP or GFP-TCF4 containing lysates were split 
into four aliquots of 200 µl and each added to 50 µl of protein G-agarose beads 
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(Roche) slurry (1:1 in lysis buffer), pre-coupled with 2 µg/ml-1 of mouse monoclonal 
anti-GFP antibody (ab1218, Abcam). After an incubation of 2 hours at 4 ºC, beads 
were collected and an 0.1 vol. aliquot of the supernatant (Post-IP) was added to 2x 
Laemmli buffer before the beads were washed 6 times with 1 ml of lysis buffer. Pre- 
and Post-IP aliquots as well as one of each precipitates were analyzed by Western 
blot to assess transgene expression levels and immunoprecipitation efficiency. The 
remaining three precipitates from each transfection were incubated with one of the 
following DNA probes: the TOPglow (TCF Reporter Plasmid, Upstate) digested with 
PvuI and XhoI restriction enzymes, to generate a 1042 bp fragment, containing the 4 
canonical TCF binding sites (Probe 1, used as positive control); the pRep5 SRp20 
promoter reporter construct digested with SalI (nucleotide -263) and EcoRI 
(nucleotide +590), to generate a 950 bp fragment with no transcriptional response 
(Probe 2, used as negative control); or the pRep5 SRp20 promoter construct 
digested with SmaI (nucleotide -1282) and Sal I (nucleotide -263) to generate a 1019 
bp fragment containing all the putative TCF binding sites from the SRp20 promoter 
(Probe 3, used as test probe). All Probes were labelled by 5'-end labelling with [)-
32P] ATP using T4 polynucleotide kinase (kit, GE Healthcare) and unincorporated 
label was removed by gel-filtration chromatography on Sephadex G-25 spin columns 
(GE Healthcare). DNA/Protein co-immunoprecipitation assays were adapted 
according to previously described methodologies (Aiyar and Sugden 1998, Kaldalu et al. 
2000). Briefly, the DNA concentration of the probes was adjusted to 2 ng/µl and 10 
ng of each was added in parallel to the above described GFP or GFP-(31TCF4 
immunoprecipitates, in 40 µl of binding buffer [10 mM HEPES at pH 7.9, 20 mM 
MgCl2, 50 mM NaCl, 50 mM KCl, 10% (v/v) glycerol, 0.05% (v/v) Triton X-100] and 
incubated for 1 h at room temperature with gentle rotation. Beads were then washed 
6 times with 1 ml of wash buffer [50mM HEPES at pH 7.9, 100 mM KCl, 50 mM 
NaCl, 2.5 mM MgCl2, 0.1% (v/v) Triton X-100] and resuspended in 20 µl of 2x 
Laemmli buffer to separate bound probes from TCF4. Probes were denatured for 5 
min at 65º C and resolved for 2 h at 100 V in a 5% polyacrylamide (29:1)-TBE gel, 
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 pre-runned for 1 h at 100 V. The gel was then dried and exposed to X-ray film for 
48-96 h. All results were confirmed in at least three independent experiments. 
 
SDS-PAGE and Western blotting 
 Samples were prepared and detected as described (Matos and Jordan 2006). 
The antibodies used for Western blots were mouse anti-SR Proteins 1H4 and mouse 
anti-SRp20 (Neugebauer and Roth 1997) from Zymed-Invitrogen, mouse anti-"-catenin 
from BD Transduction Laboratories, monoclonal anti-$-tubulin clone B-5-1-2 (as 
loading control) from Sigma, rabbit anti-GFP ab290 from Abcam UK, and T7-Tag 
Antibody from Novagen (MERCK). For densitometric analysis, films from at least 
three independent experiments were digitalized and analyzed using ImageJ software 
(NIH). 
 
Cell fractionation 
 Nuclear proteins were separated into a soluble pool not retained in the 
nucleus and into a chromatin-bound insoluble pool according to modification of 
previously described procedures (Solan et al. 2002). Briefly, cells washed in cold PBS 
were scraped and lysed on ice for 10 min in 200 µl of fractionation buffer [50mM Tris 
at pH 7.9, 0.1% (v/v) NP40; 1.5 mM MgCl2, 10 mM KCl and a protease inhibitor 
cocktail (Sigma)]. The soluble fraction was collected by centrifuging the lysate at 
3500g for 5 min and adding the supernatant to 50 µl of 5x Laemmli SDS sample 
buffer. The pellet containing the insoluble nuclear fraction was washed once in 
fractionation buffer and then resuspended in 250 µl of 1x Laemmli sample buffer 
supplemented with 5 mM MgCl2 and 50 U endonuclease (Benzonase, Sigma) for 
cleavage of nucleic acids. Equal volumes of both fractions were analyzed side by 
side on Western Blots. Results were confirmed in at least three independent 
experiments. 
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Confocal immunofluorescence microscopy 
 Cells were grown on 10x10 mm glass coverslips, transfected and incubated 
as indicated above, then washed twice in PBS, immediately fixed with 4% (v/v) 
formaldehyde in PBS for 30 min at room temperature, and subsequently 
permeabilized with 0.2% (v/v) Triton X-100 in PBS for 10 min at room temperature. 
Cells were then labelled for 30 min with a 1:200 dilution of phalloidin-TRITC (Sigma) 
washed 3 times in PBS, briefly stained with 0.5 ng/ml DAPI (Sigma), washed again 
and the coverslips were mounted in VectaShield (Vector Laboratories) and sealed 
with nail polish. Images were recorded with the 405 nm, 488 nm and 532 nm laser 
lines of a Leica TCS confocal microscope and processed with Adobe Photoshop 
software. 
 
Luciferase Reporter Assay 
 Approximately 5x105 DLD-1 cells were seeded in 35 mm dishes, transfected 
with 100 ng of the pRL-TK luciferase reporter (for constitutive expression of Renilla 
luciferase as internal control, Promega), 1 µg of each specific luciferase reporter 
(pReps or TOPglow) and 1 µg of "Cat-CA, TCF-DN, or pEGFP control vector. After 
16-20 h, transfected cells were lysed, assayed with the Dual Luciferase Reporter 
Assay (Promega) following the manufacturer's instructions and measured in an 
Anthos Lucy-2 Luminometer. Lysates were assayed in duplicates and additional 
aliquots analyzed by Western Blot to document protein expression levels. All Firefly 
luciferase values were normalized by the control values obtained for Renilla 
luciferase and, when indicated, plotted as fold-increase over the value of vector 
control. Displayed values correspond to at least three independent transfection 
assays. 
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Results 
 
SRp20 protein levels correlate in colorectal cell lines with the extent of 
endogenous "-catenin/TCF4 signalling 
 Colorectal cell lines are widely used to study "-catenin/TCF4-driven gene 
transcription, but this activity can differ significantly between cell lines depending on 
which genetic alteration occurred in the pathway. In order to characterize pathway 
activation in three colorectal cell lines - SW480, HT29 and DLD-1 - cells were 
transiently transfected with either the TOPglow luciferase reporter gene, which 
reflects the activity of "-catenin/TCF-mediated transcription, or the corresponding 
mutant reporter FOPglow (Korinek et al. 1997). A constitutively expressed Renilla 
luciferase reporter was also co-transfected in order to correct for the differences in 
transfection efficiencies between the cell lines. Analysis of luciferase activity in the 
three transfected cell types revealed that they varied up to 5-fold in their endogenous 
"-catenin-driven transcriptional activity, which was highest in SW480 and lowest in 
HT29 cells (Fig. 3.1A). As further experimental support for the observed differences, 
we compared the amount of nuclear "-catenin in these cells by using a detergent-
based cell fractionation methodology (see Experimental procedures) in which 
chromatin-associated "-catenin remains in the insoluble fraction. Figure 3.1B shows 
that the amount of insoluble nuclear "-catenin correlated well with the corresponding 
TOPglow activity in each cell line.  
 Because preliminary experiments on alternative splicing in our lab (V. 
Gonçalves, P. Matos and P. Jordan, unpubl.) indicated significant differences between 
these cell lines, we asked whether pathway activation would correlate with the 
expression levels of different SR proteins. Lysates from all cell lines were analyzed 
by Western blot using monoclonal antibody 1H4, which simultaneously detects a 
variety of endogenous SR proteins (Neugebauer and Roth 1997). As shown in Figure 
3.1C, the immunoblot revealed that the three cell lines presented a similar band 
pattern, with most prominent expression of SRp55, SRp40, SRp30 and SRp20. 
Interestingly, the SRp20 levels varied between the cell lines: expression was lowest 
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in HT29, increased in DLD-1 and highest in SW480 cells. Thus, SRp20 levels 
apparently correlated with the different activities of "-catenin-driven transcription in 
these cell lines. 
 
 
Figure 3.1: Activation of  "-catenin/TCF signalling in colorectal cells lines. (A) Diagram showing 
the activity of TOPglow, a "-catenin/TCF-regulated transcriptional luciferase reporter construct (TOP) 
or a mutant control construct (FOP) after transfection into the three indicated colorectal cell lines. 
Results were normalized to the activity of a co-transfected, constitutively active Renilla luciferase 
construct. (B) Western blot showing the comparison of the nuclear chromatin-associated "-catenin 
pool in the three cell lines. A detergent-based cell fractionation methodology separated "-catenin into 
a soluble (S) and a non-soluble, chromatin-bound (NS) pool. Note that the amount of non-soluble 
nuclear "-catenin correlated well with the corresponding TOPglow activity in each cell line. (C) 
Western blot analysis of the pattern of SR protein expression in the three cell lines. The pan-SR 
protein antibody 1H4 was used to detect the indicated endogenous SR proteins. Levels of "-catenin 
and $-tubulin were detected as loading controls. 
 
"-catenin/TCF4 signalling modulates SRp20 expression  
 In order to study whether the differences in SRp20 expression levels occurred 
as a direct consequence of "-catenin signalling, we analyzed DLD-1 cells in more 
detail. These cells exhibited an intermediate level of endogenous "-catenin/TCF4 
activation and are therefore a suitable cellular system to induce either an increase or 
a decrease of pathway activity. For this, two previously reported mutant constructs 
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were GFP-tagged and expressed in DLD-1 cells: a constitutively active mutant ("Cat-
CA) that increases "-catenin signalling is encoded by a non-degradable "-catenin 
lacking the first 47 amino acids (Kolligs et al. 1999), whereas a TCF4 mutant encoding 
just the N-terminal "-catenin binding domain of TCF4 fused to a nuclear localization 
signal (TCF-DN), has a dominant negative effect on "-catenin signalling (van de 
Wetering et al. 2002). Figure 2.2A shows experimental verification of the subcellular 
localization of these transfected mutants. In agreement with previously published 
data,  "Cat-CA localized to the nucleus as well as to the plasma membrane (Fig. 
3.2A, left panels), while TCF-DN localized predominantly to the nucleus (Fig. 3.2A, 
right panels). When "Cat-CA was coexpressed with the "-catenin/TCF-specific 
TOPglow reporter (Fig. 3.2B), an over 2-fold increase in luciferase activity was 
observed. In contrast, TCF-DN coexpression significantly inhibited the endogenous 
"-catenin/TCF4 activity measured in DLD-1 cells. These data show that it was 
possible to increase or inhibit the "-catenin/TCF activity in DLD-1 cells, yielding 
levels comparable to those observed in SW480 or HT29 cells, respectively. Under 
these experimental conditions, the expression of SR proteins was again analyzed in 
transfected DLD-1 cells by Western blot (Fig. 3.3, upper panel). We found that the 
SRp20 band increased in the presence of  "Cat-CA but decreased in TCF-DN 
transfected cells, supporting the idea of a direct stimulation of SRp20 expression 
through "-catenin/TCF4 activity. In order to confirm the results obtained with the pan-
SR antiserum, a specific monoclonal antibody against SRp20 was used. 
Densitometric analysis of the Western blots, using $-tubulin as loading normalizer, 
revealed an over 2.5-fold increase in SRp20 protein levels upon  "Cat-CA 
expression in DLD-1 cells and a reduction to approximately one half in the presence 
of TCF-DN (Fig. 3.3, middle panel). 
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Figure 3.2: Characterization of GFP-tagged  "-catenin and TCF4 mutants and their effect on  "-
catenin/TCF transcriptional activity. (A) Subcellular localization of the mutants by confocal 
microscopy. Images show DLD-1 colorectal cells transfected with a non-degradable, constitutively 
active  "-catenin mutant ("Cat-CA, left column), the empty pEGFP control vector (Vector, middle 
column), or a dominant negative TCF4 mutant (TCF-DN, right column). Note the nuclear localization 
of "Cat-CA and TCF-DN. (B) Variation in the endogenous  "-catenin/TCF transcriptional activity of 
DLD-1 cells; Upper panel: Diagram of the TOPglow and FOPglow reporter activities upon co-
transfection with "Cat-CA, empty pEGFP vector or TCF-DN, Middle and lower panel: Western blot 
analyses of the GFP-"Cat-CA, pEGFP and GFP-TCF-DN expression levels as well as $-tubulin as 
loading control. Note the increased luciferase activity in the presence of GFP-"Cat-CA and the 
inhibition by TCF-DN.  
 
 
The SFSR3 promoter responds to "-catenin/TCF4 signalling 
 We next asked whether the observed increase in SRp20 protein involved 
increased transcription as a response to "-catenin/TCF4 activity. Indeed, the 
abundance of SRp20 mRNA increased when  "Cat-CA was expressed in DLD-1 
cells, whereas the presence of TCF-DN led to reduced transcript levels (Fig. 3.3, 
lower panel). A semi-quantitative RT-PCR methodology (see Experimental 
procedures) revealed that the observed changes mirrored the variations observed in 
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SRp20 protein levels (Fig. 3.3, lower panel). These data indicated that "-
catenin/TCF4 signalling might target the SRp20 promoter and regulate transcription 
of SRp20. We, therefore, cloned a 1982 bp genomic fragment containing the SRp20 
gene promoter into a pGL2 luciferase reporter vector. This reporter construct termed 
pRep5 was expressed in SW480, DLD-1 and HT29 cells and showed clear 
transcriptional activity when compared to the empty pGL2-vector (Supplemental Fig. 
S3.1B). In addition, the extent of pRep5 activation in these cell lines corresponded to 
their endogenous "-catenin-driven transcriptional activity, as determined in Fig. 3.1. 
 
 
Figure 3.3: Effect of  "-catenin/TCF 
transcriptional activity on the 
expression of SRp20 protein and 
transcript. DLD-1 cells were 
transfected with "Cat-CA, empty 
pEGFP vector or TCF-DN as 
indicated and then analyzed by 
Western blot for SR protein levels 
(upper panel), or SRp20 protein level 
(middle panel), and by RT-PCR for 
SRp20 transcript levels (lower panel). 
Images from three different SRp20 
Western blots as well as from RT-
PCR experiments were digitalized, the 
band intensities were quantified, and 
the mean fold-changes are displayed 
graphically beside the corresponding 
panels. 
 
 
 
 
 The pRep5 construct was then tested for its direct response to "-
catenin/TCF4 signalling by transfecting the above-described "-catenin and TCF4 
mutants into DLD-1 cells. The empty pEGFP control vector was transfected in 
parallel for normalization purposes so that background variations due to other 
transcription factors that may affect promoter activity could be eliminated. As shown 
in Figure 3.4, co-transfection of "Cat-CA increased reporter activation and the 
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observed fold-increase was comparable to that obtained with the TOPglow reporter 
in the presence of "Cat-CA (see Fig. 3.2). The pRep5 reporter also responded with 
inhibition to the presence of TCF-DN, while no such response was detected with the 
empty pGL2-vector (Fig. 3.4). Next, additional pGL2-based reporter constructs 
containing shorter fragments of the original 2 kb promoter region (Fig. 3.4, pRep1-4) 
were generated. When expressed in DLD-1 cells, these constructs allowed delimiting 
the responsive promoter region to the sequence between nucleotides -225 and -
1282 (Fig. 3.4, grey shaded rectangle). Within this region, the transcriptional 
response increased progressively with promoter fragment size. Surprisingly, 
sequence analysis of this region using the TRANSFAC® database (http://www.gene-
regulation.com/pub/databases.html) revealed no high score putative TCF/LEF family 
binding sites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Response of the SFSR3 gene promoter to "-catenin/TCF4 transcriptional activity. 
Drawing showing the 1982 bp genomic fragment containing the SRp20 gene promoter that was 
subcloned to yield the luciferase reporter construct pRep5 and derived deletion mutants (left side). 
Grey shaded area corresponds to the responsive promoter region between nucleotides -225 and -
1282. The reporters transcriptional activities in response to stimulation by "Cat-CA or to inhibition by 
TCF-DN are also shown as diagrams (right side) for each individual construct and are given as fold-
increase in luciferase activity compared to the control pEGFP vector. 
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 We therefore tested the binding of TCF4 to the responsive promoter region by 
DNA/protein co-immunoprecipitation. GFP-TCF4 was expressed in DLD-1 cells, 
immunoprecipitated (Fig. 3.5B) and then incubated with different radiolabelled 
promoter fragments (Fig. 3.5A). As shown in Figure 2.5C, the positive control 
fragment with four consensus TCF binding sites prepared from the TOPglow reporter 
vector (Fig. 3.5A, probe 1) was clearly pulled down by GFP-TCF4 whereas the 
negative control fragment prepared from the pREP5 construct did not bind (Fig. 3.5A. 
probe 2). Under these conditions, the transcriptionally activated SFSR3 promoter 
fragment between nucleotides -225 and -1282 (Fig. 3.5A, probe 3) was also pulled-
down by TCF4, albeit less efficiently than the TOPglow fragment. 
 Considering that the reporter transcriptional response increased progressively 
with promoter fragment size, these data suggest that the response of the SRp20 
promoter to "-catenin/TCF signalling is regulated through several binding sites of 
lower affinity, spread across the responsive promoter region, rather than a highly 
conserved TCF recognition motif. Consistently, bioinformatics analysis of the cloned 
promoter sequence revealed 19 potential sites with considerable homology with the 
degenerated TCF/LEF transcription factor binding motif, 13 of which within the most 
responsive region between nucleotides -225 and -1282 (see sequence in 
Supplemental Fig. S3.2). In contrast, considerably fewer potential binding sites were 
identified in the promoter of the SFSR6 gene encoding SRp55 (Fig. 3.5D), which 
revealed no expression changes in the presence of "Cat-CA (Fig. 3.3, upper panel).  
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Figure 3.5: Binding of the SFSR3 gene promoter to TCF4. (A) Drawing showing the three 
promoter fragments used as radioactive probes in DNA/protein co-immunoprecipitation assays. 
Probes 1 and 2 served as positive or negative controls, respectively, whereas probe 3 corresponds to 
the transcriptionally responsive promoter region (grey shaded area between nucleotides -225 and -
1282). (B) Anti-GFP-stained Western blot showing the expression of GFP (control) and GFP-
%31TCF4 in cell lysates before (Pre-IP) and after (Post-IP) immunoprecipitation with monoclonal anti-
GFP antibody ab1218, as well as the corresponding precipitated proteins (IP). (C) Autoradiograph of 
the polyacrylamide gel used to separate the radiolabelled DNA probes. The “free probe” lanes 
document comparable probe labelling efficiency whereas “captured probe” lanes show the amount of 
probe precipitated by either GFP (control) or GFP-%31TCF4. Inserted numbers indicate the band 
intensity quantification compared to the corresponding control bands. (D) Schematic comparison of 
the SFSR3 and SFSR6 gene promoters. Arrows indicate potential TCF4 binding sites. The grey box 
indicates the SFSR3 promoter region identified in Fig. 3.4 that was required to respond to "-
catenin/TCF4 signalling. 
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"-catenin signalling modifies alternative splicing decisions 
 Alternative splicing is regulated by a combinatorial code that involves 
regulatory RNA sequence elements and changes in either the expression or the 
nuclear prevalence of competing splicing factors, including the SR proteins (Smith 
and Valcárcel 2000, Singh and Valcárcel 2005). In agreement with this notion, the 
observed increase in SRp20 could lead to different alternative splicing decisions in 
DLD-1 cells in a specific subset of genes. To test this, we employed minigene 
reporter constructs that would respond to increasing SRp20 levels and co-
transfected T7-tagged SR proteins together with the different minigenes. As shown in 
Fig. 3.6A, the PTB-derived minigene pG11, which contains the alternatively spliced 
exon 11 of PTB fused between GFP exons (Fig. 3.6A, Spellman et al. 2005), 
underwent alternative splicing in the presence of SRp20. The effect was SRp20-
specific because co-transfected T7-tagged SRp30, SRp40 or SRp55 had no effect 
on the alternative splicing of this minigene in DLD-1 cells (Fig. 3.6B). In contrast, a 
FAS minigene (Förch et al. 2000) showed no response to co-transfected T7-tagged 
SRp20 (Supplemental Fig. S3.3).  
 We then wished to determine whether the increase in SRp20 that was 
observed in response to  "-catenin/TCF4 signalling was sufficient to modulate 
alternative splicing of the PTB-derived minigene pG11. In order to allow a more 
accurate estimation of variations in pG11 alternative splicing, it was necessary to 
avoid competition with the abundant pG-FP amplicon (see Fig. 3.6C). Therefore, a 
semi-quantitative RT-PCR assay was designed based on a primer that overlaps the 
junction between the PTB exon 11 and the second GPF exon (primer 11-FP-F), 
selectively amplifying the alternatively spliced form (amplicon 11-FP). Using this 
specific assay, we first validated the co-transfection of PTB-derived minigene pG11 
with the different T7-tagged SR proteins and calculated that SRp20 over-expression 
increased inclusion of the alternative exon by more than 3-fold (Fig. 3.6C). 
Subsequently, we tested the alternative splicing response of the PTB-pG11 construct 
in cells co-expressing the GFP-fused mutants of "-catenin and TCF4. Consistent 
with the described impact of "-catenin signalling on SRp20 expression (Fig. 3.3), the 
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co-transfection of "Cat-CA produced a roughly 2-fold increase in p11-FP mRNA 
levels, whereas TCF-DN reduced the inclusion of the alternative exon by ~50% (Fig. 
3.7). 
 
Figure 3.6: Effect of SRp20 on alternative splicing of the PTB-derived minigene pG11. (A) 
Drawing of the PTB-derived minigene pG11 showing the CMV promoter, the two constitutive GFP 
exons G and FP, and the alternative PTB exon 11. Diagonal lines represent splicing patterns. 
Amplified minigene-derived transcripts pG-11-FP, pG-FP and p11-FP are depicted below. Positions of 
primers used for RT-PCR analysis are indicated. (B) RT-PCR analysis of exon 11 inclusion following 
overexpression of various SR proteins. Using forward primer pG-F in the first GFP exon and reverse 
primer FP-R in the second GFP exon, the inclusion of exon 11 can be distinguished as amplicons pG-
FP of 155 bp and pG-11-FP of 189 bp, respectively. Note that in control DLD-1 cells, the pG11 
minigene originates small amounts of the alternatively spliced pG-11-FP isoform, whereas 
overexpression of SRp20 strongly promotes pG-11-FP generation. The expression levels of the 
transfected SR proteins as well as of $-tubulin as loading control are shown as Western blots below 
the RT-PCR image. (C) Specific amplification of the PTB exon 11-containing transcripts. Primer 
11/FP-F overlaps the splice junction between the PTB exon 11 and the second GPF exon, so that 
only exon 11-containing transcripts are amplified, allowing a more accurate semi-quantitative 
determination of exon 11 inclusion. The diagram shows the fold-increase following transfection of 
DLD-1 cells with different SR proteins, and the two RT-PCR gel images show amplicons 11-FP as 
well as Pol II as control amplification. 
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 In order to directly demonstrate that these changes in alternative splicing were 
the result of increased SRp20 levels following  "-catenin signalling, we used two 
specific siRNA oligos to knockdown endogenous SRp20 expression in DLD-1 cells 
co-transfected with  "Cat-CA and the minigene. Fig. 3.7 shows that two different 
SRp20 siRNAs reduced endogenous SRp20 protein levels to 20% and this clearly 
prevented the  "Cat-CA-induced changes in pG11 alternative splicing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Effect of  "-catenin/TCF4 transcriptional activity on alternative splicing of pG11. 
DLD-1 cells were co-transfected with the PTB-derived minigene pG11 and "Cat-CA, empty pEGFP 
vector or TCF-DN as indicated. The alternative exon 11-containing transcripts were specifically 
amplified by RT-PCR, and band intensities were quantified by densitometry using amplified Pol II 
levels as internal control. The stimulating effect of "Cat-CA on exon 11 inclusion was further analyzed 
in cells previously transfected with either control or one of two SRp20-specific small interfering RNAs. 
Below the RT-PCR gel, a Western blot shows the degree of depletion of the endogenous SRp20 
protein. Note that depletion of SRp20 prevented PTB exon 11 inclusion even in the presence of "Cat-
CA. 
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"-catenin signalling induces the tumour-associated splice variant CD44E  
 To investigate whether the observed effect of  "-catenin/TCF4 signalling on 
alternative splicing is physiologically relevant, we searched the literature for 
examples of reported SRp20 regulated genes. The most studied alternatively spliced 
gene in cancer is CD44, which encodes a transmembrane protein involved in cell-
cell adhesion (reviewed in Ponta et al. 2003). CD44 has over 20 experimentally 
observed isoforms due to variable incorporation of 10 alternative exons (v1-v10) in 
its proximal extracellular domain. Although the constitutionally expressed CD44 form 
(CD44H, which lacks all of the alternative exons) is always predominant, the 
increased expression of certain isoforms has been detected in several types of 
cancer (Naor et al. 2002). One such isoform, CD44E, contains the variable exons v8 
to v10 and its splicing was reported to be stimulated by SRp20 due to the presence 
of an exonic splice enhancer (ESE) sequence within exon v9 (Galiana-Arnoux et al. 
2003).  
 In order to determine whether "-catenin signalling promoted CD44E 
expression, we first amplified by RT-PCR all CD44 isoforms expressed in DLD-1 
cells, including CD44H and E (Fig. 3.8A). We then compared the basal expression of 
these isoforms in DLD-1 cells following either over-expression of T7-SRp20 or 
depletion of endogenous SRp20 by RNA interference. As shown in Figure 3.8B, the 
expression level of the CD44H isoform (~270 bp) was predominant, as reported, but 
amplification of CD44E (a 700 bp product, identity verified by direct sequencing) 
increased in the presence of T7-SRp20, but not of T7-SRp55, and completely 
disappeared upon depletion of endogenous SRp20 protein.  
 Next, we used an exon v8-specific forward primer for selective amplification 
(Fig. 3.8A,C) and estimated more accurately the amount of CD44E transcript. SRp20 
over-expression induced an over 2-fold increase in CD44E levels in these cells while 
SRp20 depletion reduced exons v8-10 inclusion to below 25% of that found in control 
cells (Fig. 3.8C, left and middle panels, respectively). Finally, we expressed 
constitutively active "-catenin in DLD-1 cells and observed increased endogenous  
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CD44E, whereas expression of dominant negative TCF4 mutants inhibited the 
endogenous level of exons v8-v10 inclusion (Fig. 3.8C, right panel). 
 
Figure 3.8: Effect of  "-catenin/TCF4 transcriptional activity and SRp20 protein levels on 
alternative splicing of endogenous CD44. (A) The drawing shows the variable exon region of the 
CD44 gene. Diagonal lines represent the two analyzed splicing patterns. Amplified minigene-derived 
transcripts CD44H and CD44E as well as the primers used for their amplification are depicted below. 
(B) RT-PCR analysis of endogenous CD44 transcripts with primers CD44H-F and CD44-R annealing 
to the constitutive exons that flank the variable exon region. CD44 transcripts were amplified from 
DLD-1 cells transfected with either T7-tagged SR proteins or siRNAs to deplete endogenous SRp20. 
Note the specific changes in CD44E, as indicated. (C) Quantitation of endogenous CD44E generation 
using an exon v8-specific forward primer. CD44E was amplified from DLD-1 cells transfected with 
SRp55 or SRp20 (left panel), with specific siRNAs to deplete endogenous SRp20 (middle panel), or 
with "Cat-CA, and TCF-DN to modulate "-catenin/TCF4 transcriptional activity (right panel). Below the 
RT-PCR images, the corresponding Western blot images are shown to document the expression 
levels of overexpressed SR proteins, of depleted SRp20, or of "Cat-CA, and TCF-DN, respectively. 
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Discussion 
 
 The main conclusion from the present work is that the "-catenin/TCF4 signal 
transduction pathway stimulates gene transcription of the splicing factor SRp20, and 
this eventually generates a subset of transcript variants through alternative splicing. 
 Several lines of evidence support this conclusion. First, we show that the 
endogenous levels of SRp20 transcript and protein correlate with the activity of "-
catenin-driven transcription in different colorectal cell lines. Furthermore, 
experimental stimulation or inhibition of "-catenin/TCF4 signalling affects SRp20 
levels. Then we demonstrate that the isolated SRp20 gene promoter responds to 
stimulation and inhibition of "-catenin/TCF4 signalling. In addition, the "-catenin-
stimulated increase of SRp20 protein levels is sufficient to promote alternative 
splicing decisions in colorectal cells, both in a minigene and in a selected 
endogenous gene, CD44. Finally, suppression of endogenous SRp20 by RNA 
interference prevents the "-catenin/TCF4-induced changes in alternative splicing. 
 Together, our data identify SFSR3 as a novel target gene for "-catenin/TCF4 
signalling. Although microarray data with Wnt signal-dependent gene expression 
profiles of colorectal cells have been published and collected at the Wnt homepage 
(http://www.stanford.edu/~rnusse/wntwindow.html, van de Wetering et al. 2002, van der 
Flier et al. 2007, Vlad et al. 2008), SFSR3 has not been included in these gene lists. 
We observed an about a twofold increase in SRp20 transcripts in our experiments, 
which is close to the threshold value set in most microarray experiments. Probably, 
SFSR3 values did not meet the stringent cut-off thresholds applied in order to filter 
significant changes in gene expression. However, the observed changes in SFSR3 
expression have apparent physiological impact, because we detected clear changes 
in alternative splicing as a consequence of increased SRp20 levels. Thus, in case of 
splicing factors, subtle changes in gene expression may be sufficient to modulate 
alternative splicing decisions. Bearing in mind that the regulation of alternative 
splicing is based on a combinatorial mode, one can appreciate that relative changes 
in concentration between individual SR proteins and antagonizing hnRNP factors can 
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affect splice site choice in specific pre-mRNAs that contain the respective regulatory 
sequence elements (Smith and Valcárcel 2000). 
 Our analysis further revealed that the SFSR3 promoter contains 13 putative 
TCF binding sites within the "-catenin-responsive region and that TCF4 co-
precipitates the corresponding promoter fragment. Consistently, the transcriptional 
activation of our reporter constructs to activated "-catenin increased proportionally 
with the length of the subcloned responsive promoter region, and therefore with the 
number of putative binding sites present (compare Fig. 3.4, pRep2-pRep4). Others 
have also found upregulated Wnt target genes with a variable number of TCF/LEF 
sites in the promoter region between nucleotides -2000 and -100 (Schwartz et al. 
2003, Ziegler et al. 2005). Although these data indicate that SFSR3 is a primary 
transcriptional TCF4 target, it cannot be excluded that other TCF-regulated 
transcription factors such as c-myc (He et al. 1998), c-jun or Fra-1 (Mann et al. 1999) 
also contribute to the regulation of SRp20 expression.  
 One endogenous target event in DLD-1 cells for the "-catenin-induced change 
in SRp20 levels is alternative splicing of CD44E. Suppression of endogenous SRp20 
reduced the amount of generated CD44E, while ectopic expression of SRp20 protein 
or stimulation of its expression by activated "-catenin led to elevated CD44E levels. 
The family of CD44 cell-surface glycoproteins is involved in cell-matrix adhesion and 
growth factor presentation and was shown to influence cell growth, survival and 
differentiation. Members of the CD44 family have been implicated in progression and 
metastasis of tumours (Ponta et al. 2003), including colorectal tumours (Wielenga et al. 
1993, Herrlich et al. 1995, Gotley et al. 1996, Ropponen et al. 1998, Wielenga et al. 1999). 
In particular, CD44E was found significantly elevated in metastatic colorectal 
carcinomas (Takeuchi et al. 1995) and serum levels of CD44E were shown to double 
in blood from colorectal cancer patients with liver metastases, correlating with its 
immunohistochemichal expression (Yamaguchi et al. 1988, 1998). One possible 
explanation for a role for CD44E in metastatic cancers is that isoforms containing 
exon v10 provide a site for modification with chondritine-4-sulphate chains that 
promote anchoring of tumour cells to endothelial cells and may facilitate metastasis 
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(Hayes et al. 2002). Our data therefore indicate that deregulated Wnt signalling in 
colorectal tumours may be one mechanism for promoting the expression of pro-
invasive CD44 variants. Indeed, deregulated CD44 expression patterns have been 
reported in early lesions of colorectal neoplasia (Wielenga et al. 1999). 
 A connection of the Wnt pathway with pre-mRNA splicing has previously been 
observed for an E1A reporter transcript, the estrogen receptor variant %5-6, and 
splice variants WISP1v and FGFR3 AT-II (Sato et al. 2005, Lee et al. 2006, 2007). In 
these cases, the "-catenin/TCF4 complex apparently regulated the expression level 
of another splicing factor, SF1, and thus affected a different set of splicing events 
(Shitashige et al. 2007). 
 Altered expression of splicing factors has been frequently observed in various 
tumour types (Ghigna et al. 1998, Stickeler et al. 1999, Venables 2004), and human 
cancers express a large number of alternatively spliced transcripts (Wang et al. 2003, 
Venables 2004, Kalnina et al. 2005, Srebrow and Kornblihtt 2006). Our data on the 
regulation of SRp20 by "-catenin/TCF4 signalling provide a mechanistic insight into 
some of these observations.  
 In conclusion, these results demonstrate that the "-catenin/TCF pathway 
stimulates not only gene transcription, but also the generation of a subset of 
transcript variants through alternative splicing. Thus, two levels of a cellular gene 
expression program are affected by "-catenin/TCF signalling, first the transcriptional 
activation of the SFSR3 gene encoding splicing factor SRp20, and second the 
generation of alternative splice variants as a downstream consequence of increased 
SRp20 protein levels. These data further support the recent notion that transcription 
and alternative splicing represent two different layers of gene expression and that 
signalling pathways act upon a coordinated network of transcripts in each layer. 
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Figure S3.1: Transcriptional activity 
of the subcloned SFSR3 promoter. 
(A) The human SFSR3 gene is 
localized on chromosome 6p21 
(Accession Nb: NC_000006) and its 
promoter region shown. Primers were 
designed to amplify the indicated 
1982 bp fragment upstream of the first 
non-coding exon of SRp20 followed 
by subcloning into a pGL2-luciferase 
reporter vector. (B) The empty pGL2-
vector or the pRep5 reporter construct 
containing the 1982 bp fragment were 
transfected into SW480, DLD-1 or 
HT29 colorectal cells. Luciferase 
activity was measured in the 
corresponding lysates and revealed a 
clear transcriptional activation of the 
pRep5 construct that corresponded to 
the endogenous "-catenin-driven 
transcriptional activity shown in Fig. 
3.1. 
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Figure S3.2: Potential TCF4 binding sites in the SFSR3 promoter. The subcloned promoter 
sequence was analysed in silico to identify putative TCF/LEF family binding sites using several on-line 
applications that combine pattern matching analysis with a library of mononucleotide weight matrices 
from the TRANSFAC® database (http://www.gene-regulation.com/pub/databases.html). No prefect 
match CCTTTGATC binding sites were found within this region, however, a total of 21 potential 
binding sites for the degenerated TCF/LEF transcription factor binding motif SCWTTGWDY (van de 
Wetering and Clevers 1992, Koh et al. 2000, Surendran and Simon 2003) were identified. Of these 21 
potential binding sites, 13 falls between nucleotides -225 and -1282, which was identified as the 
promoter region responsive to "-catenin-mediated increase and TCF-DN mediated repression. The 
promoter fragments covered by the reporter constructs pRep1-pRep5 is shown and at the right margin 
of the sequence the fold-increase observed upon co-transfection with "Cat-CA is indicated. Note that 
the transcriptional response increased progressively with promoter fragment size from pRep2-pRep4 
and correlated with the number of putative TCF/LEF binding sites. Grey shaded area corresponds to 
the responsive promoter region between nucleotides -225 and -1282. Red crosses mark the 
nucleotide boundaries between the subcloned promoter fragments in pRep1-5. TATA box is marked 
in blue and the first non-coding SRp20 exon is shaded in black background. 
"-catenin/TCF4 pathway regulates SRp20 expression
 
  128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.3: Alternative splicing of the FAS minigene does not respond to increased SRp20 
levels. The FAS minigene (Förch et al 2000) was co-transfected with different splicing factors into 
DLD-1 cells. After 24 h, RNA was isolated from the transfected cells and minigene-derived transcripts 
amplified by RT-PCR. Note that overexpression of T7-tagged SRp20 did not change the splicing 
pattern while SRp30 promoted skipping of exon 6. 
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 The work presented in this thesis elucidates mechanisms that regulate 
alternative splicing of Rac1. The main conclusion is that differences in expression of 
splice variant Rac1b are based on a regulated alternative splicing event, which is 
controlled by the PI3-kinase and Wnt signalling pathways. These synchronize the 
expression of two SR proteins with antagonistic roles, ASF/SF2 and SRp20, that 
regulate inclusion or skipping of the alternative exon 3b of Rac1 pre-mRNA (Fig. 
4.1). 
 
Figure 4.1: Proposed model for Rac1 alternative splicing regulation. The schematic 
representation depicts signalling-controlled alternative splicing of the splice variant Rac1b according 
to our results. Red arrows illustrate the pathway leading to alternative exon 3b skipping, while green 
arrows illustrate the pathway leading to alternative exon 3b inclusion. ESE: exonic splice enhancer. 
ESS: exonic splice silencer. !cat: "-catenin.  
 
Alternative splicing of Rac1 is a regulated event  
 
 The fact that Rac1b is not exclusively detected in tumour cells but is also 
expressed in various epithelial tissues, albeit at lower levels (Jordan et al. 1999), 
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indicates a role for Rac1b in normal epithelial physiology. Even at lower levels, 
Rac1b is a constitutively active isoform and that could bring serious consequences to 
the normal signalling in cells. In this way, it is not surprising that this splice variant 
has a tightly controlled splicing regulation, only allowing it to be expressed in the 
correct cellular context. Accordingly, the alternative exon 3b is very small (57 bp), 
has a week polypyrimidine tract and a long upstream intron, all factors that favour its 
skipping. Consequently, when single point mutations, which strengthen the exon 3b 
polypyrimidine tract, were experimentally introduced in the RAC1 minigene, the 
inclusion of exon 3b became nearly constitutive (data not shown). 
 These observations together with the absence of genomic mutations in the 
analysed cell lines (see Chapter II) suggested that differences in Rac1b expression 
are based on a regulated alternative splicing event, as seen in many examples of 
changes in the extent of alternative splicing described in development, between 
different tissues and also in certain tumour types. Indeed, this work found that two 
SR proteins with antagonistic roles, ASF/SF2 and SRp20, regulate inclusion or 
skipping of the alternative exon 3b of Rac1 pre-mRNA. 
 
Molecular and bioinformatic approaches to elucidate alternative splicing 
 
 To dissect the mechanisms regulating the alternative Rac1b splicing event, 
we constructed a RAC1 minigene that recapitulates the endogenous splicing 
decisions in colon cell lines (see Chapter II; Fig. 2.2A). This approach was particularly 
important for the identification of the binding sites in the alternative exon 3b for the 
splicing factors found. Only in a minigene context could we mutate the genomic 
sequence of the alternative exon allowing us to determine the correct localization of 
the regulatory sequence elements for the binding of ASF/SF2 and SRp20, in 
colorectal cancer cells. One important lesson from this work was that given the 
divergent sequence and architecture of genes, every exon has its specific set of 
identity elements that permit its recognition by the spliceosome. First, for example, 
we cloned the alternative exon 3b, along with 306 bp of the upstream intron and 244 
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bp of the downstream intron, in the intronic region between two constitutive exons of 
the PTB splicing reporter minigene. After transfection in SW480 and HT29 cells, we 
completely lost the regulation of the alternative exon 3b observed for the 
endogenous Rac1b and for our RAC1 minigene. Although others have found 
minigene splicing reporters that maintained the regulation of the studied alternative 
splicing event of interest, it is preferable to use a minigene that contains the original 
genomic context because this preserves the natural splicing regulation environment. 
Second, intron 3b deletions showed that a 78 bp region identified in intron 3b is 
important for the inclusion of alternative exon 3b (see Chapter II - Supplemental data). 
However, when we studied its effect in a different genomic context by cloning this 
region into the downstream intron of exon 11 of the PTB-derived pG11 minigene, we 
also concluded that this intronic region did not enhance the inclusion of an alternative 
exon from a different genomic background. Third, efforts to characterize RAC1 intron 
3 contribution to alternative Rac1b splicing employed large deletion mutants, which 
revealed significant effects on alternative splicing rates, rendering a considerable 
increase in exon 3b inclusion. This shows that the spacing between the upstream 
and alternative exons in the original genomic environment contributes to splicing 
regulation and this is lost in reporter minigenes without this context. 
 In this work we demonstrate that the SR proteins ASF/SF2 and SRp20 
regulate Rac1 alternative splicing in colorectal cells. As shown in Chapter II, our data 
lead us to propose that exon 3b contains an exonic splice enhancer recognized by 
ASF/SF2 adjacent to an exonic silencer recognized by SRp20. Accordingly, some 
bioinformatic softwares indeed predicted such exonic splicing regulatory elements, 
which serve as binding sites for those splicing factors. In fact, only ESEfinder and 
Splicing Rainbow softwares specifically identified an ASF/SF2 binding site at the 
assumed correct position, and only ESR search and FAS-ESS identified a putative 
exonic splice silencer at the binding site position for SRp20. Currently, the short and 
degenerate nature of the splicing regulatory sequences complicate their accurate 
determination even with the most updated softwares. In the case of alternative 
splicing regulation, these bioinformatic tools certainly help to find several hypotheses 
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on what splicing factor(s) to study or also to obtain confirmation that a specific 
mutation is indeed disrupting/creating a binding site for a particular splicing factor, as 
observed by us (see Chapter II - The Rac1 exon 3b sequence contains binding sites for 
ASF/SF2 and SRp20). In contrast, when the biological impact of a specific mutation in 
one of these regions is analysed, we still have to confirm experimentally the 
predictions made by the bioinformatic softwares. For example, in our lab a novel 
missense mutation in the APC tumour suppressor gene was identified in a familial 
adenomatous polyposis (FAP) patient, leading to increased skipping of exon 14 and 
generation of a truncated and dysfunctional protein. Based on the know-how 
acquired during this thesis, we performed a bioinformatic analysis, which predicted 
the mutation to change SRp55, hnRNPA1 or ASF/SF2 splicing factor binding sites. 
Using RNA interference methodology and a reporter minigene approach these 
predictions were experimentally validated and revealed that only ASF/SF2 was 
required for exon 14 inclusion. These results identified APC mutation c.1918C>G 
(pR640G) as pathogenic and indicated a mechanism involving disruption of an 
ASF/SF2 exonic splicing enhancer element (Gonçalves et al. 2009). 
 Besides our molecular and bioinformatic identification of an enhancer and 
silencer elements in alternative exon 3b, we also did a similar study for the 
surrounding intronic regions and identified a 78 bp region in intron 3b important for 
the inclusion of alternative exon 3b (see Chapter II - Supplemental data). The fact that 
all minigene-derived constructs with conserved nucleotides mutated in that 78 bp 
region had roughly the same effect on the skipping of alternative exon 3b and no 
common splicing factor is predicted to be involved (by bioinformatic analysis), 
indicate that this intronic region may affect Rac1 alternative splicing due to changes 
in a secondary structure element of the pre-mRNA. In principle, these local 
structures can be inhibiting or activating spliceosomal assembly by concealing splice 
sites or enhancer-binding sites or masking repressor-binding sites, respectively 
(Hertel 2008). Therefore, it should be investigated whether the candidate splicing 
factors identified by the Splicing Rainbow software have in fact a role in the 
regulation of Rac1 alternative splicing. 
Chapter IV
 
  135 
 Finally, we cannot exclude the possibility that other regulatory elements exist 
in the alternative exon and/or the upstream intron, as well as the influence of RNA 
transcription by the recruitment of splicing factors and the elongation rate of RNA 
polymerase II (see Chapter I - Pre-mRNA synthesis by RNA polymerase II). 
 
Alternative splicing regulation through changes in splicing factor expression  
 
 In our experimental system of colorectal cell lines, we observed that the 
relative protein concentrations of ASF/SF2 versus SRp20 determined the alternative 
splicing rate (see Chapter II; Fig. 2.4), performing ASF/SF2 as an enhancer while 
SRp20 acted as a silencer of exon 3b inclusion. Numerous studies have documented 
that the relative abundance of antagonistic splicing factors, including ASF/SF2 and 
SRp20, can affect splicing decisions (e.g. Jumaa and Nielsen 1997, Mayeda et al. 1993, 
Galiana-Arnoux et al. 2003). Thus, our findings illustrate a further example of such 
regulation. It is therefore well accepted that splicing factor expression levels are a 
major mechanism to trigger differences in alternative splicing patterns (Smith and 
Valcarcel 2000, Singh and Valcarcel 2005). Recently, Sanford et al. identified 180 
mRNA targets that could be cross-linked to ASF/SF2 and intriguingly Rac1b was not 
on this list. The explanation for this fact is simply that in their experiments they used 
HEK293T cells, which in our hands do not express the alternative splice variant 
Rac1b. 
 Specific regulation requires the selected targeting of splicing 
activator/repressor combinations unique to particular exons. This is often mediated 
through changes in post-translational modifications that are essential for optimal 
activity of many splicing regulatory factors, such as alterations in the phosphorylation 
state of specific SR proteins (Stamm 2008). It is possible that Rac1b alternative 
splicing is further modulated through protein phosphorylation of ASF/SF2 or SRp20. 
For example, our observation is suggestive that overexpression of PTEN promoted 
an increase in ASF/SF2 expression whereas that of a kinase-dead AKT mutant did 
not. However, the kinase-dead AKT mutant still induced some increase in Rac1b, 
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albeit less pronounced than following PTEN expression. This suggests that post-
translational modification of ASF/SF2 also contributes to the regulation of exon 3b 
inclusion. Indeed, nuclear and cytoplasmic functions for ASF/SF2 are known to be 
modulated by phosphorylation (Xiao and Manley 1997, Sanford et al. 2005) and AKT 
has been recently described to phosphorylate ASF/SF2 in vitro (Blaustein et al. 2005). 
Further experiments will be required to clarify whether and how the PI3-kinase 
pathway affects ASF/SF2 expression at the transcriptional or the post-transcriptional 
level, and what role of phosphorylation by one of the AKT kinases is playing. It is 
possible that the PI3K pathway regulates other SR protein regulators besides AKT, 
such as the SRPK and Clk/Sty family of protein kinases. In addition the expression of 
SRp20 in colorectal cell lines correlated best with Rac1b levels when clone 1H4 of 
the SR proteins antibody was used, which preferentially detects a phosphorylated 
epitope in the serine/arginine-rich domain. This indicates that SRp20 
phosphorylation may also be involved in Rac1b alternative splicing regulation. The 
development of new specific anti-phosphoSRp20 tools would be required to confirm 
this hypothesis. 
 Recent bioinformatic studies revealed that changes in splicing factor expression 
might have a key role in the splicing abnormalities identified in many cancers (Kim et 
al. 2008, Ritchie et al. 2008). Increased expression of SR proteins usually correlates 
with cancer progression. ASF/SF2 was found to be upregulated in several human 
tumours, including lung, colon, kidney, liver, pancreas and breast tumours (Karni et al. 
2007). Accordingly, gene amplification of SFRS1, which codes for ASF/SF2, is 
commonly found in breast cancers (Sinclair et al. 2003). Furthermore, increased 
expression of ASF/SF2 transforms immortal rodent fibroblasts and leads to the 
formation of sarcomas in nude mice, whereas downregulation of ASF/SF2 reverses 
these phenotypes. Other SR proteins, such as SC35 and SRp55, did not have 
transforming activity, indicating a highly specific role of ASF/SF2 in cancer 
development. Altogether, these results support the notion that SFRS1 is a proto-
oncogene (Karni et al. 2007). The oncogenic action of increased ASF/SF2 levels is 
expected to elicit concentration-dependent changes in the alternative splicing of 
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certain key target genes. Our data identify Rac1 as another RNA target for ASF/SF2 
that can explain its transforming activity. We found that ASF/SF2 regulates the 
alternative splicing of Rac1 pre-mRNA by binding to an ESE in exon 3b and 
promoting the inclusion of this alternative exon (see Chapter II). This results in 
production of Rac1b, a constitutively active isoform, which confers increased NF!B-
mediated cell proliferation and survival, and malignant progression by promoting 
EMT and ROS-induced DNA damage. Importantly, Rac1b was found to be 
overexpressed in breast (Schnelzer et al. 2000) and colon tumours (Jordan et al. 1999) 
and the levels of ASF/SF2 mirror those of Rac1b in the analyzed colorectal cancer 
cell lines (see Chapter II; Fig. 2.4C). Therefore, our data characterise one particular 
event underlying the induction of malignant transformation by splicing factor 
overexpression, which is still a fairly unclear issue. The alternative splice variant 
Rac1b can contribute to the transforming activity of this splicing factor in cell types 
such as breast or colon.  
 The changes in the extent of alternative splicing that were observed in many 
tumours are most likely the consequence of primary genetic changes in other genes 
(Venables 2004, Grosso et al. 2008). These genes may either directly change the 
expression level of splicing factors or affect signalling pathways, which in turn 
promote changes in the concentration, localization and/or activity of splicing factors, 
leading to altered splicing. Several signalling pathways and numerous splicing 
regulatory factors have now been implicated in the modulation of pre-mRNA splicing 
(Stamm 2002, Shin and Manley 2004). This work further contributes to our 
understanding of the mechanisms behind the altered expression of splicing factors in 
various tumour types (Stickeler et al 1999, Venables 2004) by relating oncogenic 
signalling pathways to known splicing factors. In particular, we found that in 
colorectal cancer cells the changes in the expression of the splicing factor ASF/SF2 
were due to alterations in the PI3K signalling pathway. Inhibition of this pathway 
increased expression of both the transcript and protein levels of ASF/SF2, which 
acts as an enhancer of exon 3b inclusion, leading to an increased Rac1b expression. 
In addition, we also demonstrate that changing directly the transcription of individual 
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splicing factors can modulate alternative splicing. The Wnt pathway, which activates 
the "-catenin/TCF4 transcriptional complex, has the SFSR3 gene, encoding SRp20, 
as a direct target (Gonçalves et al. 2008; see chapter III). Pathway stimulation increased 
SRp20 levels that act as a silencer on exon 3b, leading to decreased Rac1b 
generation. Current literature has primarily recognised signal-mediated splicing 
regulation as operated through activation of intricate networks of signal transduction 
pathway (see Chapter I - Signal-mediated alternative splicing control; Fig. 1.5; Tarn 2007). 
However, the mechanistic details of the pathways involved, from cellular signals to 
alternative splicing events, still lack comprehensive description. Our data on the 
direct regulation of SRp20 expression by "-catenin/TCF4 signalling provide a novel 
mechanistic insight into how cellular signals regulate alternative splicing: a 
transcription factor is activated, which directly regulates the transcription level of 
splicing factors in response to changes in  the  respective  signalling  pathways  (Fig.  
Figure 4.2: Alternative splicing regulation by cellular signals. Simplified model of the different 
mechanisms by which signalling pathways control alternative splicing. Our results on the regulation of 
SRp20 by "-catenin/TCF4 signalling provide a new mechanistic pathway (on the right) linking 
extracellular signals to alternative splicing events, by affecting a transcription factor that regulates the 
expression levels of splicing factors in response to changes in the respective signalling pathways. SF: 
splicing factor. TF: transcription factor. !cat: "-catenin. (adapted from Tarn 2007) 
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4.2). These changes in the expression levels of splicing factors ultimately lead to 
alterations in the normal splicing pattern of a gene. These data further support the 
recent notion that transcription and alternative splicing represent two different layers 
of gene expression and that signalling pathways act upon a coordinated network of 
transcripts in each layer.  
 
Implications for colorectal tumorigenesis 
 
 Numerous reports have shown that alternative splicing patterns are changed 
in tumours (reviewed in Venables 2006). The genes yielding alternative or even 
tumour-specific splice variants operate in many cellular events critical for cancer 
biology (Skotheim and Nees 2007), However, to what extent they functionally 
contribute to the initiation and progression of cancers is largely uncharacterised. In 
case of splice variant Rac1b the evidence for its contribution to colorectal 
tumorigenesis is quite strong. Recently it was found that Rac1b and B-RafV600E (an 
activating mutation of B-Raf present in some colon tumours) functionally cooperate 
to sustain colorectal cancer cell survival, suggesting they constitute an alternative 
survival pathway to oncogenic K-Ras. This may characterize a molecular pathway 
sustaining cancer cell proliferation in a subtype of colorectal tumours that 
complements the previously identified subclassification (Matos et al. 2008). However, 
the molecular details of how Rac1b becomes overexpressed remained 
indeterminate. The data presented in this thesis now allow us to propose a 
mechanism for Rac1b overexpression: genetic lesions that initiate colorectal 
tumorigenesis without enhancing PI3-kinase and "-catenin signalling, promote the 
selection of cellular backgrounds with increased ASF/SF2 levels relative to SRp20. 
These cellular settings would favour Rac1b overexpression leading to increased 
tumour cell survival and subsequent tumour progression. Such mechanism could 
define an important alternative pathway to the well known cases of colorectal 
tumours with oncogenic mutations in either "-catenin gene itself or its partner protein 
APC, or to human tumours with genetic inactivation of PTEN (resulting in constitutive 
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upregulation of PI3K signalling) or gain of function mutations in either PI3K or its 
upstream activator Ras. Therefore, cells without any of these classic mutations might 
still be able to gain a tumorigenic phenotype by overexpressing Rac1b. 
 Intriguingly, splice variant Rac1b has also been described to facilitate tumour 
progression of colorectal cancer cells by enhancing Dishevelled-3-mediated Wnt 
pathway signalling (Esufali et al. 2007), leading to increased "-catenin/Tcf-dependent 
transcription of target genes important for tumorigenesis (Korinek et al. 1997). This is 
an apparent contradiction to the data reported in this thesis. It is tempting to 
speculate that a negative feedback loop exist, in which Rac1b promotes canonical 
Wnt signalling which in turn, increases SRp20 expression leading to a decreased 
Rac1b generation, as our data suggest. This feedback regulation could allow the cell 
to manage Rac1b levels in certain physiological situations or during the different 
stages of tumour progression. In agreement, clinical evidence suggests that Wnt 
signalling acts differently at different stages of tumour progression (Behrens 2005). 
 Can the changes in alternative splicing in tumours be of any therapeutical 
relevance? An increasing number of examples describing the control of alternative 
splicing by signal transduction pathways support the notion that the loss of the 
accurate control of alternative splicing may lead to preferential expression of cancer-
prone protein isoforms without any alteration in their genetic information (Kalnina et al. 
2005). Here we describe a new example of alternative splicing control by signal 
transduction pathways (see Fig. 4.1), which act in concert to regulate the expression 
levels of Rac1b, already described as a cancer-prone protein isoform and likely 
representing an evolutionary advantage for cancer development (Esufali et al. 2007).  
 The ability to efficiently and specifically rescue defective splicing would 
represent an extremely valuable therapeutic tool (Cartegni and Krainer 2003). Several 
approaches are being explored for the correction of cancer-associated splicing 
abnormalities (reviewed in van Alphen et al. 2009). One strategy uses synthetically 
modified antisense oligonucleotides, which can have the addition of 
phosphorothioate linkages or substitution of the 2! ribose at certain positions by 2! 
fluoropyrimidines or a 2!-O-methyl that do not compromise siRNA activity and 
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concomitantly increases resistance to ribonucleases (Morrissey et al. 2005). Fluoro-"-
d-arabinonucleic acid (FANA (Dowler et al. 2006) or as 4!-S-FANA (Watts et al. 2007)) 
or arabinonucleic acid (ANA (Fisher et al. 2007)) modifications can increase both the 
serum stability and the potency of siRNAs. Other modifications, such as the addition 
of lauric acid, lithocholic acids and cholesterol derivatives, can be made to increase 
cellular uptake (Lorenz et al. 2004), which is currently one of the main hurdles of RNAi 
therapy. These kinds of oligos are able to block spliceosome assembly at specific 
sites, thereby preventing the recognition of specific exons and the generation of 
cancer-associated splice variants. However, the application of siRNAs to 
therapeutics has raised a number of concerns about their safety. The saturation of 
the RNAi machinery (Grimm et al. 2006, Castanotto et al. 2007), the off-target effects 
(Birmingham et al. 2006) and the stimulation of cellular immune responses by inducing 
interferons and inflammatory cytokines (Hornung et al. 2005, Judge et al. 2005), are all 
potential drawbacks to this promising technology. Despite the technique!s youth, the 
list of human diseases for which RNAi is being tested in clinical trials as a 
therapeutic agent is extensive, and includes HIV infection, wet age-related macular 
degeneration, hypercholesterolemia, respiratory diseases and cancers. These kinds 
of studies are mainly done in non-human primates (Li et al. 2005, Zimmermann et al. 
2006) and murine model systems (Shishkina et al. 2004, Soutschek et al. 2004, Bitko et 
al. 2005, Song et al. 2005, McNamara et al. 2006, Palliser et al. 2006, Kumar et al. 2007, 
Pardridge 2007, Doré-Savard et al. 2008, Sato et al. 2008,). For example, in spinal 
muscular atrophy (SMA), the leading genetic cause of early childhood death, the 
survival motor neuron 1 gene (SMN1) is deleted or inactivated. The nearly identical 
SMN2 gene has a silent mutation that impairs the utilization of exon 7 and the 
production of functional protein. Exon 7 inclusion can be stimulated in cell culture by 
oligonucleotides or intracellularly expressed RNAs, but evidence for an in vivo 
improvement of SMA symptoms is lacking. Recently, it was demonstrated that a 
bifunctional U7 snRNA that stimulates exon 7 inclusion (by targeting the 3! part of 
exon 7 and carrying an ESE sequence that can attract stimulatory splicing factors 
(Marquis et al. 2007)), when introduced by germline transgenesis, can efficiently 
complement the most severe mouse SMA model (Meyer et al. 2009). A different RNAi 
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approach has also been successfully used for Duchenne!s muscular dystrophy 
(DMD), which is a neuromuscular disease caused by deletions/duplications or point 
mutations in the DMD gene, encoding dystrophin, causing disruption of the open 
reading frame (ORF). The induction of exon skipping, circumventing the mutated 
exon through intramuscular injection of carefully designed antisense 
oligonucleotides, corrects the ORF of dystrophin in in vitro cell lines, animal models 
and humans (van Deutekom et al. 2007). Thus, similar approaches could be 
developed, aiming at the skipping of alternative exon 3b of RAC1 pre-mRNA, in 
order to abolish/reduce the expression of this tumour-specific splice variant, Rac1b. 
The work presented here has a fundamental importance for such an approach 
because we identify key target sequences in exon 3b that regulate the alternative 
splicing event, allowing their use as binding sites for a specific antisense 
oligonucleotide or even in a bifunctional snRNP approach as described above for 
SMN2. Without this identification it would be very difficult, if not impossible, to predict 
with certainty which sequences to use in the snRNP or for targeting the antisense 
oligonucleotide specifically to skip the alternative exon 3b.  
 Other strategies were described, aimed at targeting components of the 
splicing machinery that are abnormally expressed in cancer (Grosso et al. 2008). 
These are expected to be less specific because they are likely to impinge on splicing 
regulation in normal cells. Nevertheless, many approaches have been attempted 
with encouraging results (Sampath et al. 2003, He et al. 2004, Hayes et al. 2006, 2007). 
Our data identify ASF/SF2 overexpression as a target factor for such strategies to 
prevent Rac1b generation, although this would not only influence a multitude of 
splicing targets but also interfere with the role of ASF/SF2 in constitutive splicing. 
 Another therapeutic strategy against tumour-related splice variants that is 
being explored consists of raising antibodies against epitopes that are uniquely 
present in the cancer-associated protein isoforms and conjugating the antibodies to 
tumour-cell toxins. This can also be a possible approach since the protein Rac1b has 
19 additional amino acids that could serve as a specific epitope, which has already 
been used for the successful production of a Rac1b-specific antibody.  
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 As already shown, the switch in splicing from Rac1 to Rac1b represents an 
important step towards tumorigenesis. Several studies have identified the 
mechanisms downstream of Rac1b that contribute to its increased proliferation and 
survival, and malignant progression. However, the mechanism that stimulates this 
alternative splicing event remained still unclear. This work demonstrates, for the first 
time, that mechanism, in which different cellular signalling pathways act in concert to 
regulate Rac1b specific alternative splicing event, by targeting independent splicing 
factors: the PI3-kinase and Wnt pathways, by synchronizing the expression of 
ASF/SF2 and SRp20, respectively, regulate inclusion or skipping of the alternative 
exon 3b of Rac1 pre-mRNA (Fig. 4.1). The Wnt pathway activates "-catenin/TCF4 
that directly promotes SRp20 expression, which act as a silencer leading to exon 3b 
skipping (Rac1b decrease). The inhibition of PI3K signalling promotes ASF/SF2 
expression and/or activation, which act as an enhancer leading to exon 3b inclusion 
(Rac1b increase). The precise mechanism underlying the expression and/or 
activation of ASF/SF2 by PI3-kinase still remains to be revealed and should be 
object of further studies in order to completely dissect the regulation of the alternative 
splicing of the small GTPase Rac1. 
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